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Growth hormone (GH) is an important regulator of body growth and metabolism.  
GH binding to its receptor activates the receptor-associated tyrosine kinase, JAK2, which 
in turn, initiates multiple signaling cascades, including activation of Stats 1, 3, 5a, and 5b.  
JAK2 is an important signaling molecule activated by GH.  However, very few proteins 
have been identified as binding partners for active JAK2.  We identified steroid-sensitive 
gene-1 (SSG1) as a JAK2 binding protein that binds to the active form of JAK2 in a yeast 
two-hybrid screen of a rat adipocyte cDNA library.  Full-length SSG1 binds to the 
kinase-active form of JAK2 and its kinase (JH1) domain, but not kinase-inactive JAK2 
(K882E) or JH1 (K882E).  Full-length SSG1 binds JAK2 better than the JH1 domain 
suggesting that there are at least two sites of interaction for SSG1 in JAK2.  SSG1 
contains three SRPX5 (sushi-repeat-containing protein, X-linked, domain 5) domains.  
All three of these SRPX5 domains interact preferentially with the kinase-active form of 
JAK2.  Our results suggest that the SRPX5 domain is a novel protein-protein interaction 
domain, most likely a phosphotyrosine binding domain.  To determine the physiological 
consequences of the interaction between SSG1 and JAK2, we show that SSG1 does not 
alter JAK2 kinase activity and only modestly increases GH-dependent phosphorylation of 
Stat5b on Tyr694.  In contrast, SSG1 enhances phosphorylation of Stat3 on Tyr705 in the 
presence and absence of GH.  Phosphatase experiments suggest that SSG1 enhances GH-
independent phosphorylation of a different, currently unidentified amino acid in Stat3, 
and negatively regulates the GH-responsive c-fos promoter construct.  SSG1 co-localizes 
with markers for both the endoplasmic reticulum and Golgi.  By confocal microscopy, I 
show that a portion of JAK2 co-localizes with SSG1 in these subcellular compartments.  
SSG1, which contains a signal peptide, is a secreted protein.  Secretion is blocked by 
Brefeldin A.  JAK2 enhances both the secretion and cleavage of SSG1, assessed by TCA 
precipitation of medium and immunofluorescence.  Together, my results show that SSG1 
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interacts with JAK2 and regulates downstream signaling of JAK2.  JAK2 enhances the 





Ligand-stimulated kinase signal transduction 
Polypeptide ligand binding to extracellular cell surface receptors initiates 
intracellular signaling cascades.  In many cases, this intracellular signaling cascade is a 
relay of reversible phosphorylation events.  Kinases play a critical role in signaling events 
by phosphorylating other components in the cascade.  Phosphorylation oftentimes, but 
not always, leads to activation of the target protein.  There are three classes of kinases: 
serine/threonine kinases, tyrosine kinases, and dual specificity kinases which 
phosphorylate substrates on serine, threonine, and tyrosine residues.  Sequencing has 
revealed that serine/threonine kinases make up the majority of protein kinases, with 
tyrosine kinases accounting for roughly 2% of all kinases (1).  Once a protein has been 
phosphorylated by a kinase, it can then trigger other downstream events including 
binding to other proteins, including adaptor proteins; phosphorylating other proteins, 
including proteins with and without enzymatic activity; binding DNA and initiating gene 
transcription. 
 
JAK family of kinases 
 The kinase family implicated in signaling events for the cytokine family of 
receptors is the JAK family of tyrosine kinases.  There are four members of the 
mammalian Janus kinase (JAK) family of non-receptor tyrosine kinases: JAK1, JAK2, 
JAK3, and Tyrosine kinase 2 (Tyk2) (2-6).  JAK1, JAK2, and Tyk2 have ubiquitous 
tissue expression; however, JAK3 expression is limited to myeloid and lymphoid cells (7,  
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8).  The JAK proteins contain seven JAK homology domains, termed JH domains (Fig. 
1.1).  The JH1 domain is at the C-terminus of the protein and encodes the kinase.  Each 
JAK family member contains a pair of conserved tyrosine residues in the activation loop.  
Phosphorylation on one or both of these activating tyrosines causes a conformational 
change, which allows substrate binding.  Immediately N-terminal to the JH1 domain is 
the JH2 domain which resembles the kinase domain except it lacks kinase activity and is 
referred to as a pseudokinase domain.  Evidence suggests that the pseudokinase domain 
regulates the activity of the kinase since deletion of this region in JAK2 results in kinase 
hyperactivity.  JAKs also contains a region (JH3 and a part of JH4 domain) that 
resembles an SH2 domain; however, this region fails to bind phospho-tyrosine containing 
proteins (9).  The JH4-JH7 domains compose a FERM (four point one, ezrin, radixin and 
moesin) domain and are necessary for the association with cell surface receptors (10-15).  
This amino terminal region is the least conserved among the JAK family; however, the 
differences lend to receptor binding specificity. 
 
Cytokine superfamily of receptors 
 The cytokine/hematopoietin superfamily of receptors is a large family of receptors 
consisting of receptors for growth hormone (GH), prolactin (PRL), leptin, erythropoietin 
(EPO), most interleukins (ILs), and the interferons (IFNs).  While these receptors share 
low amino acid identity, they share several conserved motifs (Fig. 1.2).  Two fibronectin-
type III domains are located in the extracellular region of these receptors (16, 17).  
Within this fibronectin domain is a WSXWS motif, which has been implicated in ligand 
binding to the receptor (18-21).  The GH receptor contains a WSXWS-like motif, which 
has conservative substitutions: Y/F-G/S-E-F-S.  The cytoplasmic region of these 
receptors contains a proline-rich region, termed Box 1 (22).  Box1 is positioned adjacent 
to the plasma membrane and is required for interaction with the JAK tyrosine kinase 
family (13, 22-26).  The cytoplasmic region of these receptors also contains a 
hydrophobic stretch of amino acids termed Box2.  Mutational analyses of both of these 
regions in the receptors are consistent with these regions being critical for ligand-















Figure 1.1  Schematic representation of JAK domain structure. 
JAK family members are composed of seven JAK homology (JH) regions.  JH1 is the kinase domain.  JH2 
is the pseudokinase domain.  JH3 and part of JH4 resemble an SH2 domain.  The rest of JH4-JH7 compose 












Figure 1.2  The cytokine/hematopoietin receptor superfamily. 
Schematic representation of receptors of the cytokine superfamily including receptors for growth hormone 
(GH), prolactin (PRL), leptin, granulocyte colony-stimulating factor (G-CSF), erythropoietin (EPO), ciliary 
neurotrophic factor (CNTF), leukemia inhibitor factor (LIF), oncostatin M (OSM), thrombopoietin, 
granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukins (ILs), and interferon (IFN)-γ 
and –α.  The extracellular portion of these receptors contain conserved cysteine residues (four thin lines) as 
well as the WSXWS motif implicated in ligand binding (black box).  The cytoplasmic tail of these 
receptors contain the proline-rich Box 1 important for interaction with JAK kinases and hydrophobic rich 




The GH receptor, along with several other receptors in this family (e.g. prolactin, 
erythropoietin, and granulocyte colony stimulating factor receptors), consist of 
homodimers of identical subunits.  Other receptors are heterodimers/trimer/tetramers 
composed of shared subunits (e.g. gp130, leukemia inhibitory factor (LIF) receptor-β, IL-
3β chain, IL-2γ chain receptors) and ligand-specific subunits (e.g. ciliary neurotrophic 
factor (CNTF) and oncostatin M (OSM) receptors). 
Members of the cytokine superfamily of receptors lack intrinsic kinase activity; 
therefore, they rely on intracellular tyrosine kinases to transmit extracellular signals to the 
internal cellular environment.  The Janus family tyrosine kinases are activated upon 
cytokine binding to its receptor.  JAKs are associated with the cytoplasmic region of the 
cell surface receptors.  Ligand binding to what is thought to be pre-formed multimerized 
receptors induces a conformational change in the cytoplasmic portion of the receptor 
which brings two associated JAK molecules into close proximity of each other (33-38).  
Once the two JAK molecules are in close proximity and in the right conformation, they 
are able to trans-phosphorylate each other (37).  The activated JAKs then phosphorylate 
tyrosines in their associated receptors as well as in the JAKs themselves.  These 
phosphorylated tyrosine residues serve as docking sites for downstream signaling 
molecules, including the signal transducers and activators of transcription (Stat) proteins, 
which will be discussed below. 
 
Physiological role for JAKs revealed by knockout animals 
 JAKs have important physiological roles since they mediate the response of a 
wide variety of cytokine receptors including IFNs, most ILs, GH, PRL, and EPO.  JAKs 
mediate immune responses, growth, differentiation, lactation, and blood cell development 
and genetic loss of any of the JAK family members elicts an unique physiological 
outcome. 
 Tyk2 has been demonstrated to play a role in signaling in response to IFN-α, IL-
6, IL-10, and IL-12.  Mice lacking Tyk2 have a modest reaction to viral infection, and 
macrophages lacking Tyk2 have an impaired response to LPS (39, 40).  JAK3 expression 
is limited to hematopoietic tissues (7, 8).  JAK3 is important for lymphoid development; 
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however, mice lacking JAK3 (and lymphocytes) can survive normally in a pathogen-free 
environment (41-43). Consistent with defects in the development of lymphoid cells, mice 
lacking JAK3 have impaired responses to IL2-, IL-4, and IL-7 (43).  JAK3 deficient mice 
have a phenotype similar to severe combined immunodeficiency (SCID) seen in humans 
suggesting that JAK3 plays a critical role in the immune response. 
JAK1 and JAK2 have ubiquitous tissue expression; therefore, loss of either of 
these JAK family members results in a more severe phenotype than Tyk2 or JAK3 
deficient mice.  JAK1 signaling is important for many of the ILs and IFNs.  JAK1 
deficient mice die post-natally (44) which was attributed to a neurological defect 
resulting in a failure to suckle.  Additionally, JAK1 deficient mice have impaired 
thymocyte and B cell production and diminished responses to a number of cytokines 
including LIF, IL-6, IL-7, IL-10 and IFNs (45).  JAK2 deficient mice are embryonic 
lethal with death attributed to a failure of blood cell development demonstrating that 
JAK2 plays an essential role in EPO signaling (46).  JAK2 deficient cells fail to respond 
to EPO, Tpo, IL-3, granulocyte/macrophage colony-stimulating factor, IFN-γ, PRL and 
GH (47, 48); however, JAK2 deficient cells are able to respond to granulocyte specific 
colony-stimulating factor, IFN-α, IFN-β, and IL-6 (47). 
 
Dysregulation of JAK signaling 
In the absence of ligand, JAKs are thought to be kept in an inactive state in close 
proximity to the receptors.  Constitutive activation of JAK signaling results in 
constitutive activation of the Stat transcription factors.  Dysregulation of JAK-Stat 
signaling in these cells and tissues has been associated with immune disorders and a 
variety of cancers. 
 The homolog for JAK in Drosophila melanogaster, Hopscotch (Hop), has been 
studied, and mutations in Hop lead to developmental abnormalities (49).  In Drosophila, 
Tum-l was shown to be an overactive mutation of Hop (50).  This mutant displayed 
genetically determined characteristics of leukemia in the fly (51).  Hyperactivation of the 
JAK-Stat (Hop-Stat) pathway results in an alteration of the chromatin structure such that 
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more genes may be activated (52).  Conversely, a loss-of-function mutation in Hop 
results in a condensation of chromatin thereby inactivating gene transcription. 
Several JAK mutations have been discovered in human cancers.  These mutant, 
constitutively active JAK proteins result in aberrant Stat signaling promoting oncogenesis 
in myeloproliferative disorders.  The most studied of these JAK2 mutants is JAK2 V617F 
(53-56).  The JAK2 V617F mutation is related to polycythemia vera (PV) as 
demonstrated in mouse studies where the JAK2 V617F induced a PV phenotype.  Indeed, 
greater than 80% of patients with PV have the JAK2 V617F mutation.  JAK2 V617F was 
also identified in 50% of patients with thrombocythemia (ET) and idiopathic 
myelofibrosis (IMF), two other myleoproliferative diseases.  JAK2 V617F is 
constitutively phosphorylated on the activating tyrosine, tyrosine 1007, with downstream 
signaling comparable to cytokine-induced signaling.  This elevated downstream signaling 
is confirmed in patients with PV who demonstrated elevated Stat5 and Stat3 activation.  
Recently, other human mutations in JAK2 have been identified: K539L (PV), T875N 
(acute megakaryoblastic myeloid leukemia), and deletion of 682-686 (acute 
lymphoblastic leukemia) (reviewed in (57)).  The role they play in oncogenesis is not 
fully elucidated. 
As mentioned above, JAK3 deficiency results in SCID consistent with JAK3 
playing a key role in the immune response.  Mutations in JAK3 have also been identified 
with patients presenting of a wide variety of immunodeficiency. 
 
JAK2 
 JAK2 is activated by nearly two-thirds of the cytokine receptors including the 
receptors for GH, PRL, EPO, leptin, many of the ILs and IFNs (32, 58) (Fig. 1.2).  
Consistent with JAK2 playing a significant physiological role, JAK2 knockout mice were 
embryonic lethal. 
 Murine JAK2 consists of 1132 amino acids and has a molecular weight of 
~120,000.  Murine JAK2 contains 49 tyrosine residues.  Ligand binding to receptor 
causes a conformational change (35), allowing the associated JAK2 molecules to auto-
activate (59, 60).  At least ten sites of autophosphorylation have been identified in JAK2: 
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tyrosines 119, 221, 570, 637, 813, 868, 913, 966, 972, 1007, and 1008 (59-67).  
Phosphorylation of tyrosines 1007/1008, 221, and 570 regulate JAK2 kinase activity.  
Tyrosine 1007 is the activating tyrosine in JAK2, and phosphorylation of this tyrosine is 
thought to stabilize JAK2 in an active conformation (62, 68).  Mutation of Tyr1007 to 
phenylalanine almost completely abolishes the kinase activity of JAK2 (62). 
When either Tyr221 or Tyr570 was mutated to phenylalanine, JAK2 kinase 
activity was altered, suggesting that these sites regulate JAK2 kinase activity (59, 61).  
Argestinger et al. (59) propose that pTyr221 increases the kinase activity of JAK2.  In 
contrast, phosphorylation of Tyr570 appears to decrease the kinase activity of JAK2 (59, 
61).  Additionally, the Y570F mutant prolonged JAK2 activation by EPO binding to an 
EPO-leptin chimeric receptor (EPO ligand binding and transmembrane domains fused to 
the intracellular leptin receptor) (61).  Phosphorylated Tyr813 interacts with SH2B1, 
which dramatically enhances JAK2 kinase activity (60).  2D peptide mapping combined 
with LC-MS/MS revealed that tyrosines 868, 966, and 972 within the kinase domain of 
JAK2 are sites for autophosphorylation and are required for JAK2 kinase activity (69).  
Argetsinger et al. (69) proposes that phosphorylation of tyrosines 868, 966, and 972 in 
JAK2 may result in a conformational change which would open up the ATP and substrate 
binding sites and increase catalytic activity.  Mass spectrometry (70), X-ray 
crystallography (68), 2D phosphopeptide mapping, and/or high pressure liquid 
chromatography (62, 65) indicate that tyrosines 918, 931, 934, 940, 956, 966, 972, and 
1008 may also be phosphorylated. 
In addition to phosphorylated tyrosine residues, JAK2 also contains 
phosphorylated serines.  The MAPK pathway is thought to phosphorylate Ser523 of 
JAK2 since phosphorylation is blocked with a MEK inhibitor.  Phosphorylated Ser523 
inhibits JAK2 kinase activity (71, 72).  Ishida-Takahashi et al. (72) demonstrates that a 
Ser523 to Ala mutant has prolonged JAK2 signaling consistent with phosphorylation of 
this serine playing an inhibitory role.  Further, Ser523 of JAK2 may regulate the duration 
of kinase activity. 
 Phosphorylated tyrosine residues play other important roles in addition to 
regulating JAK2 kinase activity.  Some phosphorylated tyrosines serve as docking sites 
for downstream signaling molecules after ligand stimulation.  Proteins containing Src 
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homology 2 (SH2) or phosphotyrosine binding (PTB) domains are recruited to the 
phosphorylated GH receptor-JAK2 complex.  Surprisingly, only a few proteins have been 
identified as proteins directly interacting with phosphorylated tyrosines within JAK2.  
Negative regulators of JAK2 signaling, suppressor of cytokine signaling (SOCS)-1 (73) 
and SOCS-3 (74), and protein tyrosine phosphatase (PTP)-1B (75) all have been reported 
to interact with the phosphorylated form of the activating tyrosine, tyrosine 1007, of 
JAK2.  Several signaling proteins interact with a peptide containing phosphorylated 
tyrosine 966 including signal transducers and activators of transcription (Stat) 5a and 5b, 
phospholipase C (PLC)-γ1, PLC-γ2, SHC, and the p85α, p85β and p110δ subunits of 
phosphatidylinositol (PI) 3-kinase, and Sts-1 (76-78).  However, it is unclear whether any 
of these proteins are recruited to pTyr966 of JAK2.  Only the interaction with Sts-1 has 
been verified for binding pTyr966.  Sts-1 is a tyrosine phosphatase, which regulates Zap-
70 activity (76-78).  Phosphorylated tyrosine 813 binds SH2B1 (60, 79) and its family 
member, SH2B2 (79).  Interaction with SH2B1 and SH2B2 enhances JAK2 kinase 
activity, potentially by stabilizing the active JAK2 dimer (79) as discussed in more detail 
below.  Finally, previous work by our lab (80) demonstrated that a C-terminal fragment 
of steroid-sensitive gene-1 (SSG1) interacts preferentially with kinase-active JAK2. 
 
Positive regulation of JAK2 
Two proteins, SH2B1 and SH2B2, have been shown to positively regulate JAK2 
(79, 81).  SH2B1 was first identified as an adaptor protein, which interacts with tyrosine, 
phosphorylated JAK2 in a yeast two-hybrid assay screening a rat adipocyte cDNA library 
with JAK2 as bait (82).  Subsequent work showed that SH2B can also interact with JAK2 
in a non-phosphotyrosine dependent manner (83) and is phosphorylated by JAK2 (82).  
Phosphorylated Tyr813 in JAK2 has been shown to bind SH2B1 (60).  SH2B1 binding to 
pTyr813 enhances JAK2 kinase activity.  One group proposes SH2B1 and SH2B2 
enhances JAK2 activity by forming homodimers and inducing JAK2 dimer formation 
(84) while others provide evidence that SH2B1 and SH2B2 stabilize active JAK2 (79).  
SH2B2 also binds to pTyr813 and enhances JAK2 kinase activity (79). 
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Negative regulation of JAK2 
Negative regulatory pathways are important mechanisms used by the cell to 
terminate cytokine-induced signals.  Termination of these signals is critical as 
exemplified by the observation that mutations that cause JAK2 to be constitutively active 
can lead to cancer ((53-56, 85-88) and reviewed in (57)).  JAK2-Stat signaling is thought 
to be negatively regulated by at least two mechanisms, including SOCS proteins via a 
classical negative feedback loop and phosphatases which dephosphorylate tyrosines in 
JAK2 as well as GH receptor and Stat proteins. 
Suppressor of cytokine signaling (SOCS) proteins play a critical role in the 
negative feedback loop induced by cytokine stimulation.  SOCS gene transcription is 
induced by cytokine binding to cytokine receptor, activating JAKs and is mediated, at 
least in part, by the Stat family of transcription factors (see below) which are activated by 
JAKs.  As in all negative feedback loops, SOCS proteins act to inhibit further signaling 
initiated by the receptor-JAK complex and activated Stats (89-91).  GH induces the 
expression of the negative regulators SOCS-1, -2, -3 and CIS (92-94).  SOCS-2 protein 
expression increases with time, but the expression of the other SOCS family members is 
more transient (95, 96).  The SH2 domain within SOCS-1 interacts with phosphorylated 
Tyr1007, the activating tyrosine in the kinase domain of JAK2 (73).  SOCS-1 binding to 
JAK2 inhibits JAK2 kinase activity, resulting in decreased phosphorylation of Stat5b and 
decreased transcription of Stat5b target genes (92, 93, 97).  SOCS-3 can also bind the 
activating tyrosine in JAK2 and inhibit tyrosine kinase activity via the N-terminal kinase 
inhibitory region of SOC-3 (74, 98).  However, inhibition by SOCS-3 of GH-stimulated 
Stat signaling (97) is thought to be dependent on SOCS-3 binding to GH receptor and 
inhibiting JAK2 kinase activity. 
SOCS-2 plays a role in JAK2-Stat signaling as suggested by gigantism in SOCS-2 
null mice, as a consequence of upregulated GH-Stat5b signaling (99).  Intriguingly, 
SOCS-2 overexpression results in a slight increase in growth (100).  SOCS-2 has been 
shown to interact with Tyr487 and Tyr595 (100-102) in the GH receptor which are 
different than the phosphotyrosines that Stat5b is recruited to (pY534, pY566, and pY627 
in rabbit GH receptor; pY577, pY606, and pY639 in mouse GH receptor) (101).  Thus, 
SOCS-2 does not appear to inhibit GH receptor-JAK2-Stat signaling by competing for 
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Stat5 binding sites within the activated receptor (101).  Rather, SOCS-2 may 
downregulate GH signaling by binding to the activated GH receptor, recruiting an E3 
ubiquitin ligase complex thus targeting the receptor for degradation (93, 102-105).  
SOCS-2 may also target SOCS-1 and SOCS-3 for degradation, prolonging GH signals 
(106).  Recently, it was shown that CIS also binds the GH receptor at Tyr487 and Tyr595 
suggesting that CIS binding to the GH receptor does not block Stat5 signaling by 
blocking recruitment to the GH receptor (101). 
Phosphatases also play an essential role in shutting off GH signals.  Several 
protein tyrosine phosphatases (PTP) have been implicated in the downregulation of GH 
receptor-JAK2 signaling including PTP-1B, PTP-H1, TC-PTP, and SHP-1, and SHP-2 
(reviewed in (107)).  SHP-1 and SHP-2 are SH2 domain-containing phosphatases (108).  
GH induces the expression of SHP-1 (109).  In addition, GH induces the nuclear 
translocation of SHP-1, which is then able to dephosphorylate Stat5b, thus terminating 
Stat5b-mediated gene transcription (109, 110).  In support of this, hepatic cells from mice 
deficient of SHP-1 have prolonged GH-dependent tyrosyl phosphorylation of JAK2 and 
Stat5b activation (111).  SHP-2 has also been reported to dephosphorylate Stat5b in the 
cytosol (110).  SHP-2 can also bind pTyr595 and pTyr487 in the GH receptor with 
pTyr595 being the major site for interaction (112).  Stofega et al. (113) demonstrated that 
GH stimulates the tyrosine phosphorylation of SIRP-α (signal regulatory protein alpha).  
These pTyr in SIRP-α recruit SHP-2.  Mutating the SHP-2 binding sites in SIRPα 
enhances GH receptor-JAK2 signaling (113).  Mutations in GH receptor, which prevent 
SHP-2 from binding to GH receptor, result in prolonged activation of JAK2 and Stat5b 
(112). 
Several PTPs have been identified as phosphatases that dephosphorylate tyrosines 
within the GH receptor including PTP-H1, PTP1, TC-PTP, and PTP-1B (114).  Evidence 
that PTP-1B is important for GH signaling is provided by PTP-1B knockout mice, which 
exhibit increased GH-stimulated phosphorylation of JAK2, Stat5, and Stat3 (115).  
Additionally, PLCγ1 has been shown to form a complex with PTP-1B and JAK2.  This 
complex is able to attenuate GH-induced phosphorylation of both JAK2 and Stat5, which 
suggests that this complex is a negative regulator of GH signaling (116).  Finally, JAK2 
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has also been shown to interact with a substrate-trapping mutant of PTP-1B and to be a 
substrate of PTP-1B (75). 
 The GH-induced JAK2 signal may also be terminated by receptor-mediated 
endocytosis.  By decreasing the number of receptors available on the cell surface, fewer 
JAK molecules are activated, thus lessening overall GH signal transduction.  Govers et al. 
(117) reported a motif in the cytosolic portion of the GH receptor that recruits the 
ubiquitin conjugation machinery to the GH receptor.  Their data suggest that GH receptor 
may be internalized and degraded in an ubiquitin-dependent manner (118, 119).  Finally, 
in addition to degradation of the receptor, degradation of JAK2 or the Stat proteins may 
also play a critical role in silencing GH-induced JAK-Stat signaling.  To support this 
hypothesis, Wang et al. (120) identified a region in Stat5b, which mediates proteosome-
targeted degradation. 
 
Signal transducers and activators of transcription 
Signal transducers and activators of transcription (Stat) proteins were initially 
identified as components of interferon (IFN) signaling (121, 122).  Subsequently, other 
Stat family members were identified as transcription factors induced by other 
polypeptides resulting in distinct and important physiological outcomes. 
The Stat family consists of seven proteins: Stat1, Stat2, Stat3, Stat4, Stat5a, 
Stat5b, and Stat6.  The Stat family genes are localized to three chromosomal regions: 
murine chromosomes 1, 10, and 11; human chromosomes 2q12-33, 12q13-14.1 and 
17q11.2-22.  An invertebrate Stat protein was identified in Drosophila, Stat92E (123, 
124).  A Stat protein was also identified in Dictyostelium discoideum (125) suggesting 
that Stat proteins have an important evolutionary role.  The Stat proteins are remarkably 
similar in most of their protein composition; however they contain unique C-termini, 
which contain critical and conserved residues and elements for activation and function.  
Stat proteins contain a conserved structural arrangement of their conserved motifs, 
including an N-terminus that is important in the formation of Stat dimers, a coiled-coil 
















Figure 1.3  Schematic representation of the domain structure of Stat proteins. 
Stat proteins contain an N-terminal coiled-coiled (CC) domain, a DNA binding domain (DBD) and a Src 
Homology 2 (SH2) domain as well as a conserved tyrosine (Y) which is phosphorylated in response to 





The C-terminus contains the tyrosine critical for the interaction with other Stat proteins 
(126-128).  Further, the unique C-terminus of the Stat proteins contains the transcription 
activation domain (TAD).  Stat proteins lacking the TAD can form dimers with activated 
Stats and serve as dominant negative proteins (129). 
Stats are latent cytoplasmic transcription factors that are transiently activated 
upon ligand stimulation and serve as messengers inside the cell.  Stat proteins are tyrosyl 
phosphorylated, often by a receptor associated JAK kinase.  This phosphorylation leads 
to homo- or heterodimerization by reciprocal SH2 domain-phosphotyrosine binding of 
the Stat proteins.  The Stat dimers translocate to the nucleus where they bind to DNA 
(130) and serve as transcription factors for target genes.  Because the C-termini of the 
Stat proteins differ, the Stats have different DNA binding specificities.  This binding 
specificity combined with the ability of different cytokines to stimulate different Stats 
and form homo- or heterodimers upon ligand stimulation provides specificity in this 
signal transduction cascade. 
This model of cytosolic Stat activation, dimerization, and nuclear translocation 
leading to Stat-mediated transcription is widely accepted.  However, others have shown 
that Stat dimers exist in the absence of ligand stimulation (126, 131-137).  Novak et al. 
(131) showed that Stat3 homodimer formation was independent of tyrosine 
phosphorylation but dependent on the presence of divalent cations.  Kretzschmar et al. 
(133) showed by FRET analysis that Stat3 homodimers exist prior to cytokine 
stimulation.  Dimer formation was dependent on an intact SH2 domain; however, ligand 
activation increased the FRET signal indicating a ligand-dependent increase in dimer 
formation or conformational change of the preformed dimer yielding a higher FRET 
efficiency (133).  Ndubuisi et al. (132) reported that only a small percentage of Stat3 
monomers are present in the cytosol.  The majority of Stat3 was found in a high 
molecular weight complex that the authors termed a “statosome” (132).   
Stat nuclear localization can be constitutive (ligand-independent) or conditional 
(ligand-dependent). Nuclear accumulation of tyrosine phosphorylated Stat1 is in part due 
to the interaction of Stat1 with the proteins in the nuclear pore complex, specifically 
importin-α5 (138, 139).  Tyrosine phosphorylation of Stat1 was found to be essential for 
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nuclear import as was the GTP-ase, Ran, as demonstrated by the failure of mutant 
proteins to translocate to the nucleus after IFN-γ stimulation (139). 
Additionally, it has been shown that Stat proteins are present in the nucleus 
independent of ligand stimulation (133, 137, 140-146).  This is not entirely surprising 
since Stat proteins contain both a nuclear localization signal (NLS) and a nuclear export 
signal (NES).  Consistent with this, using fluorescence localization after photobleaching, 
Pranada et al. (146) demonstrated that Stat3 constitutively shuttles between the cytoplasm 
and nucleus independent of ligand stimulation or tyrosine phosphorylation.  Liu et al. 
(140) reported that Stat3 nuclear import by importin-α3 was independent of tyrosine 
phosphorylation.  Stat1 also shuttles between the nucleus and the cytoplasm independent 
of ligand-stimulated tyrosine phosphorylation (142, 143).  Unphosphorylated Stat5b also 
shuttles into and out of the nucleus (144).  However, tyrosyl phosphorylated Stat5b 
accumulates to a greater extent in the nucleus than non-tyrosyl phosphorylated Stat5b in 
response to GH (147).  Non-phosphorylated nuclear Stats can regulate gene expression in 
unstimulated cells (reviewed in (148)); however, the genes that are regulated by 
unphosphorylated Stat are different from those regulated by phosphorylated Stat dimers 
(reviewed in (148)). 
Nuclear import of Stat proteins is balanced by nuclear export.  Stat proteins also 
contain a nuclear export sequence, which facilitates their exit from the nucleus.  Nuclear 
export of Stat proteins helps maintain the cytoplasmic pool of Stats for ligand activation 
as well as contributes to silencing of the target genes activated by these transcription 
factors.  McBride et al. (149) suggest that nuclear tyrosine dephosphorylation of Stat1 is 
necessary for Stat1 to disassociate from DNA, thus unmasking the NES and allowing for 
CRM1-mediated nuclear export.  Bhattacharya & Schindler (141) reported that two of 
three Stat3 NES were important regulators of basal Stat3 nuclear export.  According to 
Pranada et al. (146), a Stat3 Y705F mutant was able to cycle between the cytoplasm and 
nucleus suggesting that tyrosine phosphorylation/dephosphorylation is not necessary for 
import or export of Stat3.  Nuclear export of Stat5b is also CRM-1 dependent (144).  The 
same may be true for other Stat proteins, which undergo nucleo-cytoplasmic shuttling.  
Taken together, the shuttling of Stats into and out of the nucleus suggests that a pool of 
cytosolic Stats must be maintained for ligand-dependent signaling. 
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Stat proteins can interact with other transcription factors or coactivators to 
regulate gene expression (reviewed in (148)).  Both unphosphorylated (150, 151) and 
phosphorylated (152-154) Stat3 protein form dimers with NF-κB and regulate NF-κB 
responsive genes.  Unphosphorylated Stat3 interacts with the unphosphorylated p65 
subunit of NF-κB to regulate RANTES gene expression (150).  Hagihara et al. (153) 
demonstrated that IL-1 stimulates a complex formation of Stat3, NF-κB, and p300 on the 
serum amyloid promoter, resulting in enhanced transcription of serum amyloid A.  Yu et 
al. (154) demonstrated a complex between Stat3 and the p65 subunit of NF-κB, which 
inhibits the transcription of iNOS.  Stat1 interacting with NF-κB p65 alters p65 DNA 
binding, ultimately decreasing the expression of NF-κB anti-apoptotic target genes (155).  
Unphosphorylated Stat6 has been shown to interact with the coactivator, p300, resulting 
in constitutive expression of the COX-2 gene in non-small cell lung cancer (156). 
 
Physiological relevance of Stat3 
Stat3 was first identified as acute phase response factor (APRF) in response to IL-
6, a transcription factor important in the acute phase inflammatory response (157).  Stat3 
is expressed in most tissues.  Subsequent work has shown that a number of cytokines and 
growth factors, including multiple ILs, GH, CNTF, OSM, LIF, leptin, EGF, and PDGF, 
activate Stat3.  Stat3 regulates expression of a subset of genes important in the cell cycle 
progression, including cyclinD1, p21, and c-myc, as well as genes important in apoptosis, 
including Bcl-xL. 
 Consistent with Stat3 being expressed in most tissues, the lack of Stat3 results in 
embryonic lethality (158).  Therefore, to gain a better understanding of the cellular 
function of Stat3, tissue-specific targeting of Stat3 has been done in various cell lineages.  
When Stat3 is conditionally knocked out of T cells, mice exhibit a marked reduction in 
IL-6 responsiveness and T-cell proliferation (159).  This result supports a role for Stat3 in 
regulating anti-apoptotic gene expression.  Genetic deletion of Stat3 in macrophages 
highlighted the role Stat3 plays in anti-inflammation and the immune response.  Mice 
lacking Stat3 in macrophages have elevated production of inflammatory cytokines 
resulting in enterocolitis in adult mice (160).  Stat3 deletion in the mammary gland 
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resulted in a decrease in apoptosis of mammary epithelial cells and a delay of involution 
(161).  Stat3-deficient hepatocytes fail to induce acute phase response genes in response 
to IL-6 (162).  Stat3 has also been deleted in the skin resulting in delayed wound healing 
as a result of impaired growth factor-dependent (EGF, HGF, TGF-α, and IL-6) migration 
of epidermal cells (163).  Mice lacking Stat3 in the skin also exhibited impairment in the 
hair cycle, including sparse hair with age, development of ulcers with age, and 
hyperplasia of the epidermis (163).  In total, these tissue-specific Stat3 deficient mice 
reveal that Stat3 plays a variety of physiological roles including both pro- and anti-
apoptotic roles, inflammation, roles in the immune response, cell growth and motility. 
 In humans, some patients with idiopathic short stature exhibit defective activation 
of Stat3 (164).  Fibroblasts from these patients revealed impaired GH-induced Stat3 
activation.  Concomitant with these findings, Stat3 regulated gene expression of cyclins 
was reduced while p21 was increased (164).  This phenotype was reversed with 
administration of exogenous GH (164).  It remains unclear whether impaired Stat3 
activation and/or elevated p21 levels play a role in short stature. 
 
Dysregulation of Stat3  
 Several lines of evidence suggest that Stat3 participates in oncogenesis.  Several 
studies have shown that Stat3 is constitutively activated in a number of tumors and tumor 
models, promoting cell proliferation and cell survival ((165), reviewed in (166, 167)).  
Stat3 is constitutively phosphorylated on both Tyr705 and Ser727 in anaplastic 
lymphoma kinase (ALK) positive tumor cells (165).  Constitutively phosphorylated Stat3 
enhances Bcl-xL gene transcription and promoted cell survival of human U266 myeloma 
cells (165).  Others have shown that dominant negative forms of Stat3 can suppress 
features of a transformed phenotype.  In one such example, Bowman et al. (129) 
demonstrated that Stat3β, which lacks the C-terminal transactivation domain, acts as a 
dominant negative by suppressing expression of c-myc.  Further, c-myc expression is 
required for v-Src transformation, and Stat3β was able to inhibit Src transformation 
(129). 
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Bromberg et al. (168) showed that a dominant active form of Stat3 was capable of 
transforming fibroblasts, suggesting that Stat3 is oncogenic.  A gain of function mutation 
in which Stat3 is constitutively dimerized is able to bind DNA and constitutively drive 
gene transcription, resulting in a transformed cell phenotype (168).  Bromberg et al. (168) 
also demonstrated that this constitutively dimerized Stat3 was tumorigenic in nude mice, 
apparent after 2 weeks of injection.  It should be noted, however, that thus far, 
constitutively activated Stats in cancer are usually a result of hyperactive kinase activity.  
It will be interesting to determine if constitutive dimers are found in vivo with the same 
oncogenic phenotype described by Bromberg et al. (168). 
 Several reports have established that constitutively seryl phosphorylated Stat3 is 
present in a number of tumors, consistent with serine phosphorylation promoting 
tumorigensis (169-171).  Yang et al. (169) demonstrated a correlation between 
phosphorylated Ser727 levels of Stat3 with cervical intraepithelial neoplasia.  This is not 
entirely surprising since phosphorylated Ser727 has been linked to increased 
transcriptional activity (172) and increased transcription can result in enhanced cell 
proliferation, thus promoting transformation.  Constitutive pSer727 Stat3 may result in 
cancer progression; therefore Yang et al. (169) hypothesized that pSer727 Stat3 may be a 
useful biomarker to monitor the progression of cervical lesions. 
 Stat3 gene expression is positively regulated by tyrosyl phosphorylated Stat3 
dimers.  In addition to phosphorylated Stat3 dimers, nonphosphorylated Stat3 can 
participate in regulating gene expression of a different subset of genes, including anti-
apoptotic genes and oncogenes (150, 173).  Yang et al. (150) demonstrated that 
unphosphorylated Stat3 Y705F interacts with the unphosphorylated p65 subunit of NF-
kB, which can then serve as a transcriptional activator of RANTES (Regulated on 
Activation, Normal T-Expressed and Secreted).  It is possible that in cancer, 
constitutively activated Stat3 proteins increase the amount of Stat3.  The increase in Stat3 
then allows for the expression of more Stat3-mediated genes, modulated by both 
phosphorylated and unphosphorylated Stat3 dimers, lending to the oncogenic phenotype. 
Stat3 regulates gene transcription for several proteins important for cell survival, 
including Bcl-2, Bcl-xL, and Fas as well as for proteins important in the cell cycle 
including cyclin D1 and p21.  Therefore, constitutively active Stat3 may promote cell 
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survival in cancer cells.  In addition to regulating gene expression, Niu et al. (174) 
demonstrated that Stat3 can act as a transcriptional repressor of p53 expression.  In 
cancer cells expressing constitutively active Stat3, repression of p53 promotes oncogenic 
tumor growth, and blocking Stat3 in these cells induces p53-mediated apoptosis of tumor 
cells (174). 
 
Physiological function of Stat5 
 Stat5, specifically Stat5a, was initially identified as a prolactin-responsive 
transcription factor in mammary tissue (175, 176).  Stat5a and Stat5b are encoded by two 
linked genes.  The protein products share 96% amino acid identity with the divergence 
localized to the C-terminus.  Many studies have revealed that Stat5 has an ubiquitous 
tissue expression.  Subsequent work has revealed that Stat5 proteins are activated by both 
a variety of cytokines including many of the ILs, EPO, and GH, and by receptor tyrosine 
kinases, including epidermal growth factor receptor (EGFR) (177-179). 
 Several studies have shown that GH-induced Stat5 activation is important in 
physiological functions of GH including metabolism, body growth, and sexual dimorphic 
liver gene expression.  Since Stat5a and Stat5b are highly similar, it is not surprising that 
Stat5a and Stat5b display functional redundancies (180, 181).  Stat5a and Stat5b also 
display some functions that are unique to the individual transcription factor (181). 
Genetic models of Stat5a and Stat5b have given much insight into the function of 
these Stats and have revealed distinct phenotypes for the single Stat5a and Stat5b 
knockout mice.  Stat5a activated by PRL is important for mammary gland development 
and lactation (181, 182).  Genetic loss of Stat5a in females resulted in the inability to 
lactate although milk proteins were expressed (at lower levels) and secreted in Stat5a-
deficient animals (181, 182).   
The phenotype of Stat5b-deficient mice is similar to that of GH receptor-deficient 
mice (181, Udy, 1997 #2046, 183, 184).  Stat5b-deficient male mice were smaller in size 
and displayed a loss of expression of male liver-specific gene expression (184, 185).  GH 
pulses are important in maintaining male liver-specific gene expression, such that loss of 
GH signaling in Stat5b deficient mice revealed female levels of P450 and major urinary 
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protein (MUP) (185).  Stat5a knockout mice also demonstrated loss of some female-
specific, GH-regulated liver gene expression suggesting that Stat5a/b heterodimers are 
important in sex-dependent gene expression (186).  Serum IGF-1 levels were reduced in 
male Stat5b knockout animals relative to controls but were unaffected in female 
knockouts (181).  Recently, Stat5b binding sites in the IGF-1 promoter and in the second 
intron of IGF-1 were established (187, 188), further supporting Stat5b regulating IGF-1 
transcription in a GH-dependent manner, thereby contributing to overall body growth 
(188). 
Stat5a/b double knockout mice reveal the importance these transcription factors as 
deletion of Stat5a/b results in few viable mice that die within 6 weeks after birth (189-
191).  Most Stat5a/b double deficient mice are perinatally lethal (189, 191).  Surviving 
mutant mice have smaller thymi, spleen, and lymph nodes (190) indicative of the role 
Stat5 plays in lymphoid development.  Analysis of embryonic day 18.5 fetuses of 
Stat5a/b double knockout mice confirms that Stat5a/b play a critical role in the 
development of the lymphoid cells resulting in severe combined immunodeficiency (191) 
similar to the phenotype of JAK3 deficient mice.  Stat5a/b double deficient mice also 
displayed impaired hematopoietic stem cells, which fail to generate T and B cells (191).  
Conditional Stat5a/b knockout mice have also been generated to determine the function 
these transcription factors play in various tissues.  Of particular importance is the 
hepatocyte-specific deletion of Stat5a/b, which reveals reduced circulating IGF-1 levels 
and stunted growth in both males and females weeks after birth (192) consistent with 
Stat5 playing a critical role in pos-natal body growth.  However, Cui et al. (193) also 
deleted Stat5a/b specifically in the liver.  Their liver-deficient Stat5a/b mice did not have 
a reduction in body size, but rather mice developed fatty livers and had increased GH 
levels. 
 
Stat5 and Disease 
 Like Stat3, Stat5 may play a role in cancer.  An activated form of Stat5 has been 
described in chronic myelogenous leukemia.  Stat5 activation by a TEL-JAK2 fusion 
variant has also been implicated in myeloproliferative and lymphoproliferative diseases 
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(194).  Interestingly, Stat5 tetramers were found in leukemia cells from patients.  It is not 
clear whether these tetramers promote gene transcription. 
Recently, Rosenfeld and colleagues (195) identified a patient with a mutation in Stat5b.  
This was the first patient studied with a mutation in Stat5b.  The female patient presented 
with severe growth retardation and immunodeficiency (195).  By RT-PCR, Rosenfeld et 
al. (195) identified a missense mutation, which resulted in a proline substitution in the 
SH2 domain of Stat5b just upstream of the critical tyrosine.  GH and IFN-γ failed to 
stimulated the tyrosyl phosphorylation of Stat5b A630P, which suggests that this 
missense mutation disrupts dimerization and gene transcription.  Importantly, this 
patient’s serum IGF-1 levels were significantly low (195). Rosenfeld et al. point out that 
this human patient had a different phenotype than female mice deficient in Stat5b; she 
had both severe growth retardation and low serum IGF-1 levels (195).  While Stat5b 
deficient female mice have lower IGF-1 serum concentrations compared to wild-type 
mice, they were not smaller (i.e. female Stat5b knockouts were the same size as male 
Stat5b knockouts which were both smaller than male wild-type mice) (184).  To date, 
five different mutations in Stat5b have been identified in six patients with growth 
retardation (reviewed in (196)).  Five of these six patients were female, suggesting that 
Stat5b has an important role in body growth in both human males and females, unlike 
mice where Stat5b has an important role in body growth of male mice but not female 
mice. 
 
Post-translational modifications regulate Stat activity 
 Post-translational modifications play a critical role in signaling cascades.  Indeed, 
various post-translational modifications have been shown to regulate the activity of Stat 
proteins.  As already mentioned above, tyrosine phosphorylation is important for the 
overall activity of Stat proteins.  It has also been reported that Stats are phosphorylated on 
serine residues, acetylated, and methylated. 
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Tyrosine phosphorylation of Stats 
 All Stat proteins are phosphorylated on a critical tyrosine residue in their C-
terminus(197, 198).  This phosphorylated tyrosine residue interacts with the SH2 domain 
of another Stat protein to form Stat dimers.  Following dimer formation, Stats translocate 
to the nucleus and regulate gene transcription.  Mutations of the key tyrosine have shown 
that phosphorylation of this residue is critical for Stat function, specifically binding DNA. 
 
Serine phosphorylation of Stats 
 Stats 1, 3, 4, 5a, and 5b contain a conserved serine residue in their C-termini.  For 
Stats 1 (Ser727), 3 (Ser727), and 4 (Ser721), this serine is in a PMSP motif (172); for 
Stats 5a (Ser725) and 5b (Ser730), the serine is in a PSP motif (199).  This motif suggests 
that a proline-directed kinase is responsible for the phosphorylation of this conserved 
serine in these Stats.  In fact, several groups have shown that MAPKs (200), including 
ERK1/2 (201-204), p38 (205-207), and JNK (205, 208) are, in part, responsible for 
phosphorylation of this serine both in vitro and in vivo (reviewed in (209)).  Further 
support that a MAPK may be responsible for Stat serine phosphorylation comes from a 
study by David et al. (202) which demonstrated that Stat1 was able to co-
immunoprecipitate with MAPK (probably ERK1/2, 42kDa) after IFN-β stimulation.  Lim 
et al. (208) demonstrated that JNK phosphorylates Stat3 on Ser727, which negatively 
regulates the tyrosine phosphorylation of Stat3.  This, in turn, inhibits Stat3 DNA binding 
and transcriptional activation (208). 
In addition to the MAPK being activated by cytokine stimulation, the PKC 
pathway is also activated by a number of cytokines, including PRL and ILs.  PRL-
induced PKC was shown to increase Stat5a mediated β-casein gene expression (210).  
Jain et al. (211) demonstrated that a number of ligands (e.g. IL-6, OSM, LIF, EGF) 
activate PKCδ which stimulates the association with Stat3 in a number of cell types.  
Ligand-stimulated PKCδ can also phosphorylate Ser727 in Stat3 in vivo (211).  It is 
likely that several signaling pathways result in phosphorylation of this serine residue.  It 
is also likely that this serine phosphorylation is ligand- or cell-specific which adds 
another level of regulation to Stat-mediated responses. 
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 The role of Stat serine phosphorylation is unclear.  There are several reports in the 
literature where serine phosphorylation on this conserved residue in the C-terminus of 
Stat proteins enhance gene transcription (172, 212-214), whereas others (211) 
demonstrate that serine phosphorylation of this site in Stat proteins negatively regulates 
the ability of Stat to bind to DNA.  Mutation of the key serine, Ser727, of Stat1 to alanine 
(S727A) resulted in approximately 80% decreased gene transcription of an INF-γ 
responsive luciferase promoter as well as decreased levels of mRNA of an endogenous 
IFN-γ responsive gene, IRF-1, suggesting that maximal transcription requires 
phosphorylation of both Tyr701 and Ser727 of Stat1 (172).  Further support that 
phosphorylation of Ser727 is required for maximal transcription came from studies where 
IFN-γ stimulation resulted in serine phosphorylation of Stat1 and increased gene 
expression (207, 215-218).  The S727A mutation in Stat3 did not affect DNA binding to 
the m67 SIE probe in an electrophoretic mobility shift assay (172); however, maximal 
luciferase gene transcription was not achieved with the Stat3 S727A mutant (172).  In 
contrast, Jain et al. (211) showed that Ser727 phosphorylation by PKCδ negatively 
affected the ability of Stat3 to bind DNA and induce gene expression of a CAT reporter.  
It is possible that serine phosphorylation of the Stat proteins is necessary for Stat to bind 
to low-affinity DNA binding sites (219, 220).  While it is controversial whether serine 
phosphorylation of Stats affects DNA binding, it is possible that the effect is promoter or 
cell-context specific with serine phosphorylation playing an inhibitory role in some cases 
and stimulatory in others.  Several groups have performed large scale mass spectroscopy 
revealing the likely presence of numerous additional sites of phosphorylation within 
Stat3: Thr268 (221), Ser269 (221), Ser273 (221), Tyr539 (70, 222), Tyr686 (70, 223), 
and Ser691 (224).  However, it is not yet known whether phosphorylation of these sites in 
Stat3 is stimulatory or inhibitory in function. 
 Stat5 has been shown to be phosphorylated on serine residues in response to GH 
(212, 225-228) as well as PRL (199, 229, 230) and IL-2 (231).  Stat5a is serine 
phosphorylated on at least two sites: Ser725 and Ser779 (232, 233).  GH-induced gene 
transcription was only decreased when both Ser779 and Ser725 were mutated, but not 
when Ser275 alone was mutated, suggesting that phosphorylation of Ser725 does not 
regulate transcription (212).  It has also been reported that seryl phosphorylation of Stat5 
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results in increased gene transcription of a CAT reporter (231).  However, Yamashita et 
al. (199) reported that serine phosphorylation of Stats 5a and 5b was not essential for 
DNA binding or for activation of a β-casein reporter gene suggesting that the requirement 
for serine phosphorylation of Stat5 differs from that of Stats 1 and 3.  Stat4 is also 
reported to be phosphorylated on Ser721 resulting in an enhancement of transcriptional 
activity (234). 
 
Acetylation of Stats 
 In addition to being phosphorylated, Stats are also acetylated.  This is not 
completely surprising since Stats can associate with the acetyltransferases CREB binding 
protein (CBP) and p300 (235-238).  This association with CBP/p300 can increase Stat-
mediated gene transcription (235, 236).  OSM stimulated acetylation of Stat3 in MCF-7 
breast cancers cells while IFN-α stimulated acetylation of K685 in Stat3 in HeLa cells 
(237).  Acetylation of K685 in Stat3 by p300 has been shown to be critical for 
dimerization, DNA binding, and gene transcription (237).  In addition, Wang et al. (239) 
showed that acetylation of K685 by p300/CBP increases nuclear accumulation of Stat3 
which is consistent with increased Stat3 DNA binding and increased transactivation by 
Stat3.  Acetylated Stat1 has been shown to interact with NF-κB p65 resulting in 
decreased expression of anti-apoptotic genes (155).  Stat6 is acetylated in response to IL-
4 (240). 
 
Methylation of Stats 
 Stat proteins have been reported to undergo methylation (241), although Komyod 
et al. (242) and Meissner et al. (243) argue that Stats are not methylated.  Basal levels of 
methylation were detected for Stat1, and methylation increased upon further IFN-α 
treatment (241).  Mowen et al. (241) also showed that Stat1 associates with the protein 
arginine methyl-transferase PRMT1 and that PRMT1 methylated Stat1 on the highly 
conserved Arg31.  Methylation of this residue was found to be important in regulating 
transcriptional activation (241).  Stat6 is reported to be methylated on Arg27 (244).  
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When Arg27 was mutated to Ala, Stat6 was not maximally phosphorylated in response to 
IL-4, which in turn, reduced nuclear translocation and gene expression (244).  Stat3 is 
recognized by an anti-methyl antibody (245); however, it is unknown if Stat3 is 
methylated.  Methylation has not been reported for Stat5a or Stat5b. 
 
Growth hormone activates the JAK-Stat pathway 
 One of the earliest characterized cytokine receptors is the receptor for GH 
(reviewed in (196, 246)).  GH is an important regulator of body growth and metabolism.  
GH is a 191 amino acid, 22kDa polypeptide hormone that is secreted in a pulsatile 
manner from the anterior pituitary and enters the blood.  GH binds to its receptors in 
target tissues, eliciting a transient response.  In addition to being an important hormone 
for longitudinal bone growth, GH also has important metabolic actions in muscle and fat.  
GH promotes a decrease in body fat, which is counterbalanced by an increase in lean 
muscle.  GH exerts these effects, at least in part, by inhibiting lipogenesis, promoting 
lipolysis, and stimulating protein synthesis (247).  GH is also important in cardiac and 
immune function and aging. 
 GH binding to its receptor in target tissues rapidly activates JAK2.  Current 
evidence suggests that one GH molecule binds to a pre-formed GH receptor dimer (34, 
35, 38, 248) causing a conformational change (35, 248) that allows the associated JAK2 
molecules to autophosphorylate (59-67, 249).  Once activated, the JAK2 molecules 
phosphorylate tyrosines on the GH receptor as well as themselves (59, 60, 250).  These 
phosphorylated residues serve as docking sites for a variety of signaling proteins. 
One class of proteins activated by JAK2 upon GH stimulation are the Stat 
proteins (Fig. 1.4).  GH activates Stats 1, 3, 5a, and 5b ((251-255) and reviewed in (256-
258)).  Activation of these Stat proteins requires that the GH receptor-JAK2 complex be 
tyrosyl phosphorylated.  Stats 5a and 5b are recruited to phosphorylated tyrosine residues 
located in the cytoplasmic tail of the GH receptor (250, 259-262), whereas Stats 1 and 3 
interact with phosphorylated tyrosines within activated JAK2 (48, 261-264).  Stats 1 and 











Figure 1.4  Schematic representation of GH Signal Transduction. 
Growth hormone (GH) binding to its receptor activates a number of downstream signaling pathways, 
including the JAK2-Stat pathway, Ras-MAPK pathway, and the PI-3K-Akt pathway.  Activation of these 
pathways result in the initiation of gene transcription.  Arrows indicate pathways regulated by GH; Xs 




one found in the c-fos gene promoter.  Homo- and heterodimerized Stats 5a and 5b bind 
to IFNγ-activated sequences (GAS)-like elements (GLEs).  Binding of the Stat dimers to 
these elements in DNA, along with other transcription factors and transcriptional co-
activators, regulate gene transcription.  GH-induced Stat5 dimers promote gene 
transcription of liver-specific serine protease inhibitor 2.1 (Spi2.1) (265, 266), insulin-
like growth factor-1 (IGF-1) (188, 266), acid labile subunit (ALS) (267), and insulin 
(268, 269).  Stat5b also regulates GH-stimulated transcription of the negative regulators, 
SOCS-2 and SOCS-3 (270). 
 
Growth hormone activates other signaling pathways 
In addition to the JAK-Stat pathway, GH also activates the Ras/MAPK pathway 
(Fig. 1.4) (reviewed in (258)).  The activated GH receptor-JAK2 complex recruits the 
adaptor molecule Shc which is then tyrosyl phosphorylated.  Phosphorylated Shc then 
binds Grb2 and SOS, a guanine nucleotide exchange factor (GEF) for Ras.  GTP-bound 
Ras triggers the activation of Raf, which in turn activates mitogen-activated protein 
kinase (MEK) leading to the activation of extracellular-regulated protein kinases (ERKs) 
1 and 2.  The MAPK pathway may also be activated by cross-talk between the GH 
receptor and EGFR.  GH-activation has been shown to promote phosphorylation of the 
Grb2 binding site the EGFR thus activating the MAPK pathway (271).  GH also activates 
the PKC pathway (32).  Activation of ERKs promotes the activation of several 
downstream proteins (reviewed in (272)).  In GH signaling, GH-activated ERKs have 
been shown to phosphorylate C/EBPβ (273, 274), a transcription factor important in 
initiating gene transcription in the adipocyte differentiation program (275).  GH-induced 
ERK activity may also regulate the expression of CYP2C11 (276), a sexually dimorphic, 
liver-specific gene that is regulated by Stat5b (251). 
GH also phosphorylates the insulin receptor substrate (IRS) proteins, IRS-1, IRS-
2, and IRS-3 (Fig. 1.4) (reviewed in (258)).  Once phosphorylated, IRS proteins can bind 
to the p85 regulatory subunit of PI-3 kinase (PI-3K), which activates the PI-3K pathway, 
which is upstream of the Akt pathway.  GH-activated Akt, which inhibits GSK-3 
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(glycogen synthase kinase-3), has been implicated in promoting cell survival, possibly by 
inhibiting caspase-3 (277).  
GH has also been shown to be important in regulating cell motility implicating 
that GH promotes actin rearrangement.  Indeed, GH stimulation rapidly promotes 
depolymerization of actin stress fibers which was followed by repolymerization of 
localized actin complexes (278).  Further, GH promotes the phosphorylation of several 
proteins resulting in the formation of a large multiprotein complex including, but not 
limited to, p130 (Cas), CrkII, c-Src, c-Fyn, the p85 subunit of PI-3K, paxillin, tensin, and 
IRS-1 (279).  Formation of this complex may regulate GH-induced actin dynamics.  
Evidence from our lab demonstrates that GH-induced JAK2 activation of SH2B1 is 
involved in regulating the actin cytoskeleton (280, 281). 
 
GH-responsive genes 
 GH promotes the expression of a variety proteins important in cell growth and 
differentiation.  Microarray analysis on 3T3-F442A adipocytes revealed that 561 genes 
are regulated temporally by GH-stimulation (282).  GH stimulates the expression of early 
response genes, including c-fos (283, 284), c-jun (284, 285), and c-myc (286) as well as 
the expression of many other genes including the genes for SOCs proteins, IGF-1, and 
ALS.  The early response genes c-fos, c-jun, and c-myc encode transcription factors that 
in turn regulate the expression of other target genes. 
 In addition to the growth promoting effects by GH, GH induces the expression of 
IGF-1 from the liver, bone, and muscle (287).  IGF-1 expression is mediated by GH-
induced Stat5b (181, 266, 288, 289).  IGF-1 produced in the liver is released into the 
blood, and this GH-dependent circulating IGF-1 plays an essential role in somatic growth 
(288).  IGF-1 and IGF-1 receptor knockout mice exhibit impaired growth supporting that 
IGF-1 is important in the effects mediated by GH (290).  Human patients with short 
stature from a mutation in Stat5b display low serum concentrations of IGF-1 (reviewed in 
(196)) lending further support that IGF-1 is critical in body growth.  Stat5b has been 
implicated in regulating GH-induced IGF-1 expression (266), and recent work has 
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established GH-stimulated Stat5b binding sites in the promoter of IGF-1 as well as in the 
second intron (188). 
Of the GH-regulated genes, c-fos is one of the most widely studied because it is 
induced by GH 15-30 minutes post-stimulation in a variety of cell lines, making it a good 
candidate to study the earliest responses elicited by GH (283, 284).  The promoter region 
of c-fos contains several binding sites for proteins regulated by GH including an SIE 
which binds the GH-induced phosphorylated Stat1 and Stat3 homo- or heterodimers (252, 
291), an SRE (serum response element) which binds SRF dimers (serum response 
factors), and a C/EBPβ binding site (292).  C/EBPβ contains a known MAPK consensus 
phosphorylation site and has been shown to be phosphorylated in response to GH on 
Thr188 (liver activating protein, LAP) or Thr37 (liver inhibitory protein, LIP) by a kinase 
in the MAPK pathway (273).  When this site was mutated, transcription of c-fos was 
inhibited, suggesting that phosphorylation of C/EBPβ on this site is required for maximal 
transcription factor activity (273).  GH also induces the dephosphorylation of C/EBPβ, 
which allows C/EBPβ to bind to the C/EBPβ site in the c-fos promoter (293).  Piwien-
Pilipuk et al. (293) suggest that the GH-activated PI3K/Akt pathway inhibits GSK-3 
which regulates the phopshorylation of C/EBPβ.  Taken together, the GH-activated Stat, 




Identification of SSG1 
 SSG1 was originally identified as a 17 β-estradiol (E2) responsive gene by 
Marcantonio et al. (294) using differential display of RNA samples from uteri from 
ovariectomized or ovariectomized plus E2-treated rats.  SSG1 mRNA levels were found 
to be high in the uteri of ovariectomized rats, but was significantly reduced in the uteri of 
ovariectomized E2-treated rats (294).  In this initial paper, it was reported that SSG1 
mRNA had a broad tissue distribution with varying levels of mRNA expression detected 
in the ovary, uterus, mammary gland, lung, spleen, kidney, bladder, and skeletal muscle 
(294).  Since then, it has been reported that SSG1 has a wide tissue distribution.  
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Importantly, SSG1 was expressed in GH-responsive tissues including the liver, heart, and 
brain (294).  In contrast to the downregulation seen in E2-treated uterine tissues, SSG1 
mRNA was unchanged in control, E2-treated, or tamoxifen-treated mammary samples 
(294).  In a follow-up study, Marcantonio et al. (295) reported that SSG1 mRNA was 
significantly increased in the prostates of rats following castration compared to the 
prostates of sham-operated rats.  It remains unclear if androgens and/or estrogen are able 
to regulate SSG1 protein expression. 
 The size and sequence of SSG1 were incorrectly published in the first report of 
SSG1.  Full-length SSG1 has subsequently been identified by several groups using a 
variety of different screening techniques, which suggests that SSG1 may have a variety of 
functions, some of which are tissue-specific (Table 1.1). 
SSG1 has been subsequently, independently cloned as Urb, CL2, DRO1, and 
Equarin.  Murine SSG1 (Urb, upregulated in BRS-3-deficient mice) was initially 
identified in bombesin-receptor-subtype-3 (BRS-3)-deficient mice as a gene whose 
expression was increased four-fold in brown adiopose tissue compared to control mice at 
eight months of age (296).  In mice seven weeks old, there was no difference in SSG1 
gene expression in either brown or white adipose tissue comparing BRS-3-deficient mice 
and wild-type mice (296).  BRS-3-deficient mice demonstrate mild late-onset obesity 
(297).  Because SSG1 was upregulated at eight months of age, SSG1 may play an 
important role in regulating body weight and energy metabolism in adult mice.  In situ 
hybridization of brain tissue showed SSG1 mRNA in the anterior olfactory nucleus, the 
dorsal endopiriorm nucleus and the choroid plexus (296).  The gene expression pattern of 
murine SSG1 in the choroid plexus is similar to that of the leptin receptor consistent with 
SSG1 playing a role in energy metabolism. 
Recently, Okada et al. (298) demonstrated that mouse SSG1 was highly expressed 
in white adipose tissue of 7 week old mice and that SSG1 mRNA levels were lower in 
adipose tissue in genetic mouse models of obesity as well as in mice on a high fat diet.  
Further, SSG1 mRNA increased two-fold when preadipocytes were differentiated into 
adipocytes (298).  However, when adipocytes were treated with hormones or stressors, 







Table 1.1  Identification and proposed functions for SSG1 




Differential display as 
estrogen responsive in 
uterine tissues 
n/a Marcantonio (294) 
murine Urb 
Differential display of 
adipose tissue in 
 BRS-3-deficient mice 
energy metabolism Aoki (296) 
rat CL2 
Differential display of  
E1A responsiveness in 
thyroid 
tumor suppressor Visconti (299) 
rat DRO1 
Subtractive suppression 
hybridization of an 
immortalized rat kidney 
epithelial cell line 
tumor suppressor Bommer (300) 
murine Urb Differential display of bone marrow vs. osteoblasts bone formation Liu (301) 
human Urb 
Microarray comparison of 
dermal fibroblasts vs. 
papilla 






Signal sequence trap of  
chick lens cDNA library eye formation Mu (303) 
murine Urb 
Novel adipocytokines that 
are upregulated in adipose 
tissue 




extents (298).  Taken together, these results suggest that SSG1 may have a function in 
obesity. 
Human SSG1 (Urb) was identified in a differential display of undifferentiated 
bone marrow stromal cells (BMSC) and BMSC-derived osteoblasts as a gene that is 
downregulated during osteoblast differentiation of BMSC (301).  Liu et al. (301) showed 
the spatial and temporal expression profile for SSG1 in the developing cartilage during 
embryogenesis by in situ hybridization and immunohistochemistry.  SSG1 expression in 
the developing chondrocytes, but absence in osteoblasts, is consistent with SSG1 
functioning in skeletal development in the embryo.  Microarray analysis revealed that 
human SSG1 was higher in dermal papilla cells compared to dermal fibroblasts (302).  
Human SSG1 mRNA expression was induced in response to dihydrotestosterone 
suggesting that SSG1 expression may be androgen sensitive (302) in contrast to the 
negative regulation by androgens of SSG1 proposed by Marcantonio et al. (295). 
 Rat SSG1 was independently cloned as CL2 (299) and as DRO1 (down-regulated 
by oncogenes-1) (300).  SSG1/CL2 was identified using differential display as a gene 
induced by the expression of E1A 13S in infected rat thyroid PC Cl3 cells (299).  The 
mRNA expression of SSG1 was downregulated in PC E1A cells infected with v-raf, but 
not changed by the oncogenes polyoma middle-T or v-src (299).  SSG1 gene expression 
was low or absent in human thyroid carcinoma cell lines.  SSG1/DRO1 was identified 
using a subtractive suppression hybridization technique as a gene downregulated in 
RK3E rat epithelial cells neoplastically transformed by β-catenin (300).  In these studies, 
SSG1 mRNA expression was reduced in colon and pancreatic cancer cell lines and 
human colorectal cancer samples (300).  Ectopic expression of SSG1 in cells lacking 
endogenous SSG1 was able to reduce colony formation in two pancreatic cancer cell 
lines (300).  Taken together, these results are consistent with SSG1 acting as a tumor 
suppressor. 
A chicken ortholog of SSG1, equarin, was cloned from a chick E6 lens library 
using a signal sequence trap screen (303).  Alternative splicing of the equarin gene results 
in two transcripts, equarin-S and equarin-L (303).  The resultant protein products of these 
transcripts is identical in the first 592 amino acids with the longer transcript encoding an 
additional 366 amino acids at the C-terminus.  Equarin-L shares high homology with 
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mouse, rat, and human SSG1.  Equarin is expressed in the lens during embryonic 
development suggesting that equarin plays a role in eye formation (303). 
 
SSG1 protein domain structure 
Rat SSG1 is a 949 amino acid protein with a molecular weight of ~110,000.  The 
gene for SSG1 has been mapped to rat chromosome 11q21 (300) and human 
chromosome 3q13.2-3q13.3 (299, 300).  In both human (299-301) and chicken (303), 
there are two reported transcripts for SSG1, whereas there is only one reported transcript 
in mouse (296, 299) and rat (299, 300).  By motif scans and sequence analysis, SSG1 
contains a putative signal peptide, five putative bipartite nuclear localization sequences 
(NLS), and three conserved domains which we denote SRPX5 because of their similarity 
to the fifth domain in sushi repeat containing protein, X-linked (SRPX) (Fig. 1.5).  SSG1 
contains several predicted N-glycosylation sites (296, 300, 301, 303): (murine) Asn467, 
Asn666, and Asn834.  Mu et al. (303) predicts three shared N-glycosylation sites for 
Equarin-L at Asn474, Asn675, and Asn843 with two additional sites unique for Equarin-
L, Asn58 and Asn488.  Consistent with a protein containing a signal peptide, Liu et al. 
(301) demonstrated that SSG1 is secreted, though three groups were unable to detect 
secreted SSG1 in the culture medium (300, 302, 303).  One group claimed that secreted 
SSG1 was seen in the extracellular matrix of bone tissue at high magnification (301).  
The reports in the literature on the secretion of SSG1 are controversial; therefore, it 
remains unclear whether SSG1 is a secreted protein. 
Thus far, two other proteins also contain an SRPX5 domain: SRPX and SRPX2 
(SRPUL).  SRPX and SRPX2 are members of the selectin family, which includes SRPX, 
SRPX2, selectin P precursor (SELP), selectin E precursor (SELE), and selectin-like 
protein (SVEP1) (304).  The selectin family of proteins also contain a signal peptide, 
sushi domains, and a hyalin repeat (305).  The sushi domains and hyalin repeat have been 
implicated in cell adhesion (306, 307).  SRPX and SRPX2 also contain one 
uncharacterized fifth domain which is found in SSG1.  For this reason, we designated this 
domain in SSG1 SRPX5 for similar to the fifth domain in SRPX.  The three SRPX5 
domains in SSG1 have 40-50% amino acid similarity to each other and to the single 














Figure 1.5  Schematic representation of the domain structure of SSG1. 
SSG1 contains a putative signal peptide at the N-terminus (black box), three consensus repeat regions (D1, 
D2, and D3) which we denote SRPX5 domains, and five putative bipartite nuclear localization sequences 






The Carter-Su lab identified SSG1 as a protein which interacts with kinase-active 
JAK2 in a yeast two-hybrid screen of a rat adipocyte library.  The yeast two-hybrid 
screen identified the C-terminal half of SSG1 as a binding partner for JAK2.  This yeast 
two-hybrid fragment, SSG1 (477-949), preferentially interacted with kinase-active JAK2 
versus kinase-inactive JAK2 (K882E) in both the yeast two-hybrid assay and in a 
mammalian system.  Further, it was demonstrated that SSG1 (472-788) was a substrate 
for JAK2 overexpression.  Much of this early work done was using the yeast two-hybrid 
clone and not full-length SSG1.  Based on the current literature, it is unclear how SSG1 
functions at the cellular level.  To follow up on these earlier studies, I investigated the 
interaction of SSG1 with JAK2, the role SSG1 plays in GH signal transduction, and 
whether SSG1 is secreted. 
 
Aims of this thesis 
The hypothesis of this thesis project was that SSG1 is a multi-functional protein 
having a synergistic relationship with JAK2.  SSG1 regulates GH signaling by interacting 
with JAK2 thus affecting downstream GH-stimulated signaling molecules and gene 
expression.  Conversely, JAK2 regulates the function of and cellular trafficking of SSG1. 
The first aim of my thesis was to characterize the regions of interaction between 
SSG1 and JAK2 by confirming preliminary findings.  Previous work using the yeast two-
hybrid fragment of SSG1 revealed that SSG1 (477-949) interacts preferentially with 
kinase-active JAK2 versus kinase-dead JAK2.  The region of interaction in JAK2 for the 
yeast two-hybrid clone of SSG1 was shown to be the JH1 kinase domain.  In Chapter II 
of this thesis, I show that full-length SSG1 also interacts preferentially with kinase-active 
JAK2.  I also demonstrate that full-length SSG1 binds to full-length JAK2 better than to  
the JH1 kinase domain of JAK2 alone suggesting that there are two regions of interaction 
in JAK2, one within the JH1 domain and one outside of the JH1 domain.  SSG1 does not 
contain the traditional phosphotyrosine binding motifs, SH2 or PTB domains.  SSG1 does 
contain three consensus SRPX5 domains. An interaction between the second SRPX5 
domain of SSG1 and JAK2 had been previously shown by the Carter-Su lab; I tested the 
interaction of all three of these domains of SSG1 with JAK2.  As predicted, all three 
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SRPX5 domains in SSG1 interact preferentially with full-length tyrosyl phosphorylated, 
kinase-active versus inactive JAK2 (K882E) and with kinase-active JH1 versus kinase-
inactive JH1 (K882E).  Based on trunctation experiments, these SRPX5 domains are both 
necessary and sufficient for binding JAK2.  I propose that the SRPX5 domains are novel 
phosphotyrosine binding domains.  Further support for the SRPX5 domain being a 
phosphotyrosine binding domain is obtained from experiments in which JAK2 was 
shown to co-immunoprecipitate with another SRPX5 domain-containing protein, SRPX2.  
Like the SSG1-JAK2 interaction, SRPX2 binds preferentially to the kinase-active JAK2 
versus kinase-dead JAK2 (K882E). 
The second aim of my thesis was to examine the role SSG1 plays in GH 
signaling.  In Chapter III of this thesis, I demonstrate that SSG1 does not alter the kinase 
activity of JAK2.  Further, SSG1 only modestly increased the GH-dependent tyrosyl 
phosphorylation of the downstream GH signaling molecule, Stat5b.  Surprisingly, SSG1 
enhanced the phosphorylation of Stat3 on Tyr705 and appeared to promote the 
phosphorylation of an unknown residue in Stat3.  SSG1 did not alter phosphorylation of 
Ser727 of Stat3.  Because SSG1 appears to enhance Stat3 phosphorylation on Tyr705, we 
hypothesized that Stat3-mediated gene transcription would be enhanced.  However, in 
Chapter III, I confirmed previous data from the Carter-Su lab that SSG1 negatively 
regulates transcription of a c-fos reporter construct which contains a SIE which binds 
Stat1 and Stat3 homo- and heterodimers. 
The third aim of my thesis was to determine the subcellular localization of SSG1.  
SSG1 contains several putative nuclear localization motifs as well as a putative signal 
peptide.  In Chapter III, I show that SSG1 is localized to the ER and Golgi, consistent 
with it being in secretory vesicles and indicative of a secreted protein.  When SSG1 is co-
expressed with GFP-JAK2, a portion of JAK2 is colocalized with SSG1 in the region 
surrounding the nucleus.  Importantly, no cells expressed nuclear SSG1 suggesting that 
the nuclear localization signals in SSG1 are non-functional or that SSG1 does not 
accumulate in the nucleus under normal culture conditions. 
The final aim of my thesis was to determine whether SSG1 is a secreted protein 
and whether secretion is regulated by JAK2.  Reports in the literature are controversial as 
to whether SSG1 is a secreted protein.  Initial findings in our lab revealed that SSG1 was 
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not secreted, but rather got inserted into the ER membrane.  In Chapter III of this thesis, I 
demonstrate that SSG1 is a secreted protein found in the culture medium of transfected 
cells.  This secretion was blocked with Brefelin A, which suggests that SSG1 is in the 
constitutive secretory pathway.  When SSG1 was co-expressed with wild-type JAK2, 
SSG1 secretion was enhanced.  It was not enhanced with co-expressed with kinase-dead 
JAK2 (K882E).  Further, SSG1 cleavage products are prominently detected in the culture 
medium with co-expression of wild-type JAK2 but not JAK2 (K882E).  This suggests 
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 CHAPTER II  
IDENTIFICATION OF STEROID-SENSITIVE GENE-1 AS A NOVEL 
JAK2 BINDING PROTEIN AND THE SRPX5 DOMAIN AS A 
NOVEL PHOSPHOTYROSINE BINDING DOMAIN 
 
Abstract 
 Janus kinase 2 (JAK2) is the receptor-associated tyrosine kinase activated upon 
growth hormone (GH) stimulation.  JAK2 is an important signaling molecule activated 
by many of the cytokine receptors, however very few proteins have been identified as 
binding partners for JAK2.  We identified steroid-sensitive gene-1 (SSG1) as a JAK2 
binding protein that binds to the active, phosphorylated, form of JAK2 in a yeast two-
hybrid screen of an adipocyte cDNA library.  Full-length SSG1 is a 110 kDa protein that 
contains several protein motifs including three SRPX5 (sushi-repeat-containing protein, 
X-linked, domain 5) domains, which we characterize in this study.  We confirmed that 
SSG1 interacts with and is tyrsoyl phosphorylated by JAK2 in a mammalian system.  We 
show that full-length SSG1 binds to the active, tyrosyl phosphorylated form of JAK2 and 
the kinase-active JH1 domain, but not JAK2 (K882E) or JH1 (K882E).  Full-length SSG1 
binds full-length JAK2 better than the JH1 kinase domain.  All three myc-tagged SRPX5 
domains of SSG1 were found to co-immunoprecipitate with full-length, wild-type JAK2 
as well as with the kinase domain, JH1, but not with kinase-inactive JAK2 (K882E) or 
with JH1 (K882E) suggesting that all three SRPX5 domains interact preferentially with 
the tyrosyl phosphorylated, kinase-active form of JAK2.  The second SRPX5 domain had 
the strongest interaction with wild-type JH1 and the first SRPX5 domain had the weakest.  
Another SRPX5 domain-containing protein, SRPX2, also binds JAK2 in a 
phosphotyrosine-dependent manner.  These results suggest that the SRPX5 domain is a 
novel protein-protein interaction domain, most likely a phosphotyrosine binding domain. 
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Introduction 
The Janus family of tyrosine kinases, which includes JAK11, JAK2, JAK3 and 
Tyk2, plays a critical role in signaling by members of the cytokine/hematopoietin 
superfamily of receptors.  JAK2 is activated by two-thirds of these receptors including 
the receptors for growth hormone (GH), prolactin, erythropoietin, leptin, leukemia 
inhibitory factor and multiple interleukins and interferons (1).  JAK2 promotes the 
growth, proliferation and/or differentiation of many cell types (2, 3) and dysregulation of 
JAK has been linked various forms of cancer (4-10). 
Despite the fact that JAK2 is necessary for signaling by multiple cytokines, 
hormones, and growth factors, and is the most studied of the JAKs, only a handful of 
proteins have been identified thus far that bind directly to JAK2.  The negative regulators 
SOCS-1 (11), SOCS-3 (12), and protein tyrosine phosphatase (PTP)-1B (13) have all 
been shown to bind to phosphorylated Tyr 1007, the critical tyrosine for activation of 
JAK2.  Several known signaling proteins bound to a phosphorylated peptide containing 
Tyr 966 of JAK2 including Stats 5a and b, phospholipase C (PLC)-γ1, PLC-γ2, the 
adapter molecule SHC, and the p85α, p85β, and p110δ subunits of phosphatidylinositol 
(PI) 3-kinase, and a novel protein, p70, which was later renamed and characterized as 
suppressor of T cell receptor signaling-1 (Sts-1), a tyrosine phosphatase which regulates 
Zap-70 activation (14-16).  However, it is unclear whether any of these signaling 
molecules are recruited to phosphorylated Tyr 966 in activated JAK2.  Finally, 
phosphorylated Tyr813 binds SH2B1 (SH2-Bβ, PMS) (17), an adapter protein and 
enhancer of JAK2 kinase activity (18, 19), and its family member SH2B2 (formerly APS) 
(20, 21). The identification of additional signaling proteins that specifically bind to JAK2 
is essential for expanding our understanding of signaling by GH and other cytokines that 
activate JAK2. 
In this study, we identify a novel signaling protein, steroid-sensitive gene-1 
(SSG1), as a JAK2 binding protein that binds preferentially to the active, phosphorylated, 
form of JAK2 in a yeast two-hybrid screen of an adipocyte cDNA library.  SSG1 was 
originally characterized as an estrogen-regulated gene based on its cloning using 
differential display of uterine tissues from ovariectomized and ovariectomized/estrogen-
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treated rats (22).  Rat SSG1 was independently recloned both as CL2, a protein 
upregulated in E1A 13S infected rat thyroid PC Cl3 cells (23), and as DRO1 
(downregulated by oncogenes -1), a protein downregulated in RK3E rat epithelial cells 
neoplastically transformed by β-catenin (24).  Murine SSG1 was cloned as Urb, a protein 
upregulated in brown adipose tissue of bombesin receptor subtype-3-deficient mice (25).  
A chicken ortholog, Equarin-L, was cloned from a chick E6 lens cDNA library using a 
signal sequence trap screen and named for its expression in the equatorial region of the 
chick lens (26).  Rat, murine, and human SSG1 have been shown to have a wide tissue 
distribution (e.g. fat, lung, ovary, uterus, mammary gland, testis, liver, spleen, pancreas, 
kidney, heart, stomach, bladder, skeletal muscle, skin and brain) (22-25, 27, 28).  Roles 
for SSG1 in tumor suppression (23, 24), energy metabolism (25, 28), embryonic 
development and skeletal formation (27) have been suggested.  However, little to nothing 
is known about the cellular regulation and function of SSG1. 
We show here that SSG1 interacts with and is phosphorylated by JAK2.  SSG1 
binds to the active, tyrosyl phosphorylated form of JAK2 but not the inactive form of 
JAK2.  The SRPX5 domains in SSG1 are both necessary and sufficient for binding to 
JAK2.  The SRPX5 domain in SSG1 has 30% amino acid identity to the uncharacterized 
fifth region in SRPX (sushi-repeat containing protein, X-linked) (29).  This domain is 
common to a newly emerging group of proteins that includes rat, murine and human 
SSG1 (22-25, 27); chicken Equarin, an ortholog of SSG1 (26); SRPX/downregulated by 
Src (drs) (rat)/ETX1 (human) (30-32), and SRPX2 (also known as SRPUL for sushi 
repeat protein upregulated in leukemia) (33).  Finally, we show that SRPX2 also binds 
JAK2 in a phosphotyrosine-dependent manner.  These results suggest that the SRPX5 
domain is a JAK2 binding domain, most likely a phosphotyrosine binding domain. 
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Materials and Methods 
Cells and reagents. 
Sacharomyces cerevisiae EGY48 (MATα trp 1 ura3-52 his3 leu) and all yeast 
expression plasmids came from Dr. R. Brent (The Molecular Sciences Institute, Berkeley, 
CA) (34-36).  293T and COS-7 cells were from American Type Culture Collection.  
Recombinant protein A-agarose was from Repligen.  Bovine serum albumin (CRG-7) 
was from Intergen.  Dulbecco's Modified Eagle Medium (DMEM) was from Invitrogen.  
Aprotinin, leupeptin, and Triton X-100 were from Roche.  The enhanced 
chemiluminescence detection system and nitrocellulose paper were from Amersham 
Pharmacia Biotech.  X-ray film was from Kodak.  The QuickChange Site-Directed 
Mutagenesis Kit was from Stratagene.  Polyvinylpyrrolidon (PVP-360) was from Sigma. 
 
Antibodies. 
Polyclonal antibody to JAK2 (αJAK2) and monoclonal anti-phosphotyrosine 
antibody (αPY; 4G10) were used at a dilution of 1:7,500 for immunoblotting and were 
from Millipore.  Monoclonal antibody to influenza virus hemagglutinin (HA) tag (αHA; 
HA.11) was from Covance and used at a dilution of 1:100 for immunoprecipitation and 
1:10,000 for immunoblotting.  Monoclonal antibody against Myc-tag (αmyc; 9E10) was 
used at a dilution of 1:100 for immunoprecipitation and 1:10, 000 for immunoblotting 
and polyclonal antibody against myc-tag (αmyc; A14) used at a dilution of 1:1000 were 
from Santa Cruz Biotechnology, Inc.  Monoclonal anti-FLAG M2 antibody (αFLAG) 
used at a dilution of 1:1000, anti-FLAG M2 antibody (αFLAG) conjugated to agarose 
beads were from Sigma.  Monoclonal anti-GFP antibody (αGFP; JL-8) from BD 
Biosciences was used at a dilution of 1:100 for immunoprecipitation and 1:5,000 for 
immunoblotting.  Polyclonal anti-GFP antibody (αGFP) from Clontech was used at a 
dilution of 1:100 for immunoprecipitation.  Horseradish peroxidase-conjugated anti-
mouse IgG and anti-rabbit IgG were from Santa Cruz and used at a dilution of 1:7,500.  
IRDyes 680 or 800 conjugated to either affinity purified anti-mouse IgG or anti-rabbit 
IgG antibodies from Rockland and Licor were used at a dilution of 1:20,000. 
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Two hybrid library screening and cloning of full-length SSG1. 
Screening of the yeast two-hybrid rat adipose cDNA library (gift of Dr. T. A. 
Gustafson, University of Maryland) (18) was conducted as described previously (35, 36).  
Briefly, yeast (EGY48) cells were grown at 30oC in YPD medium (1% yeast extract, 2% 
polypeptone, 2% dextrose).  Yeast cells were then sequentially transformed with the 
lexAop-lacZ reporter plasmid, pEG202-JAK2, and rat adipose cDNA library prey 
plasmids (18) by the lithium acetate method (37).  Triple transformants were grown for 4 
h in liquid yeast dropout medium lacking Trp, Ura, and His and plated on the same 
dropout medium with the addition of 15% agar.  The yeast cells were grown for 4 days at 
30oC.  Colonies were then collected and replated on yeast dropout medium lacking Trp, 
Ura, His and Leu to select for Leu prototrophy.  Dextrose was substituted with galactose 
to induce expression of the activation domain hybrids.  After 5 days, colonies were 
subjected to the filter lift color assay to test for β-galactosidase activity (38, 39).  Positive 
clones were selected, and prey plasmids containing library cDNA inserts were isolated 
and transformed into DH5α bacterial strain for amplification.  The insertion cDNAs were 
subjected to DNA sequence analysis.   
 
Plasmids. 
The cDNA encoding the carboxyl-terminal portion of rat SSG1 (amino acids 477-
949) was cut from the yeast two-hybrid prey plasmid using EcoRI and XhoI and 
subcloned in-frame into the pcDNA3 mammalian expression vector (Invitrogen) with an 
amino terminal HA tag (40) and into the prk5 expression vector (BD Bioscience) 
containing a Myc tag at the amino terminus.  PCR based mutagenesis was performed 
using QuikChange Site-Directed Mutagenesis Kit from Stratagene.  All PCR products 
and junctions were verified by sequencing.  SSG1 truncation mutants were created by 
introducing stop codons into HA-SSG1 (477-949) using the following primers (mutated 
bases are in lower case and the introduced stop codons and restriction sites are 
underlined):  (stop @ 609: 5’-CCGAGTCCCAGGtAGTCAGTGGCC-3’; stop @ 663: 
5’-GGTTACTATCTTTtGaCCTGTCAACAACAGC-3’; stop @ 689: 5’-CGTGTGGT 
GGATGACtAGGACTTGGTAGAC-3’; stop @ 724: 5’-GGTCTCAGAGTCAAGtAAT 
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ACTACGAAGTGC-3’; stop @ 763: 5’-ACCTGCAAGGAGGACtAGAGGCAGTCC-
3’).  Myc-SSG1 (472-788), encoding amino acids 472-788, was generated from full-
length SSG1 cDNA using customized primers (5’-tctatcccgagactcgaattcACCATG 
GAACATGGCCATCAGGACCCAAATGTGGTG-3’; 5’-gatccgctcgagcggtctagagca 
TCATTGGGAGCAGAGATCACCAGCAACCGCC-3’) to introduce EcoRI and XhoI 
sites at the 5' and 3' ends, respectively, and subcloning the fragment in-frame into prk5 
expression vector containing an amino terminal myc tag. 
The cDNA for SSG1 (accession number AF223577) (22) was resequenced.  
Clustal analysis indicated that the sequence of rat SSG1 was identical to rat DRO1 
(accession number AY548105) (24) having only one mismatch between nucleotides 1 
and 3596 of DRO1, with no mismatches in the predicted coding sequence between 
nucleotides 389-3238 of DRO1.  Therefore, SSG1 and DRO1 are likely to be the same 
gene.  The coding sequence codes for a 949 amino acid protein.  Therefore, amino acids 
in SSG1 will be numbered according to the accession number for rat DRO1 (AAS66670).  
Full-length SSG1 with a myc tag at the C-terminus was created using the following 
primers:  5’-tctatcccgatcgatagatctaggaattccaccATGACGTGGAAAATGGGACCCCACT 
TCACC-3’ and 5’-gatccggaattccccaagcttgggttacaggtcctcctcgctgatcagcttctgctccattccGT 
AAGGGTATCCATGGTGGTAACTTTCATGATG-3’, myc tag and restriction sites are 
underlined, and the stop codon is in italics.  SSG1 was cloned in-frame into the prk5 
expression vector. 
To introduce an internal HA tag after the signal peptide in SSG1-myc, a SalI 
restriction site was introduced after amino acid 30 of SSG1-myc using the following 
primer: 5’-CAGTCTTCTGCCTTGGATgtCGAcGGCCGCCCAGG-3’ (mutations lower 
case, SalI site underlined).  Primers containing the sequence for the HA tag (bold) as well 
as the SalI overhang (underlined):  5’ TCGAGGATGTCGACGCCTACCCATACGA 
TGTTCCTGACTATGCGGTCGACGGC-3’ and 5’-TCGAAGCCCGTCGACCGCAT 
AGTCAGGAACATCGTATGGGTAGGCGTCGACCTA-3’ were annealed, labeled 
with T4 nucleotide kinase, and inserted into the newly generated SalI site in SSG1-myc 
to create SSG1-HA30-myc. 
The SRPX5 domains of SSG1 were inserted into XhoI and EcoRI restriction sites 
in the pEGFP-C1 expression vector (Clontech) or prk5-myc vector to create tagged 
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fusion proteins using the following primers (restriction sites underlined):  for GFP-SSG1 
(615-756): (5’-atcgatcgatctcgagccgatTTGGGGTCTTTCGAAGGCAAACGAAGACTC-
3’, 5’-atcgatcgatcgatcggatcccggaattcgctaGCCCTCCTTCTTCTGCTTTTCCATATC 
TTTGATTC-3’);  for myc-SSG1 (137-281):  (5’-atcgatcgatctcgaggccgatAGTTCTC 
CCAATATCCTGGCCAGCTTTGC -3’; 5’-atctgtcgacgaattcgctaACACTTTTGGA 
CAAAACCCTTCTGCCTGATTTTCTC-3’); for myc-SSG1 (615-756):  (5’-atcgatcga 
tctcgaggccgatTTGGGGTCTTTCGAAGGCAAACGAAGACTC-3’, 5’- atcgatcgatc 
gatcggatcccggaattcgctaGCCCTCCTTCTTCTGCTTTTCCATATCTTTGATT -3’); 
for myc-SSG1 (766-912):  (5’- atcgatcgatctcgaggccgatTCCCTGGAGAATTTCCTAT 
CCAGGTTCC -3’; 5’- actgtcgacgaattcgctaACAGCGCATCCCAGTGACTGCTG-3’). 
 cDNA encoding murine SRPX2 (SRPUL; accession number NM_026838) was 
obtained from OriGene.  A myc-tag was inserted between the BamHI and HindIII sites in 
the prk5 vector using the following primer which included the BamHI site (underlined), a 
NotI site (underlined), the myc tag (bold), the stop codon (italics), and a HindIII site 
(underlined): 5’-GCTACGGGATCCGCGGCCGCAGAGCAGAAGCTGATCAGCGA 
GGAGGACCTGTAGAAGCTTACGCGT-3’.  SRPX2 with a C-terminal myc tag was 
then created using PCR primers which introduced a BamHI restriction site (underlined), 
as well as a Kozak sequence (italics, ATG in bold) or a NotI site and no stop codon (5’- 
GCTACGGGATCCGCCACCATGATGACCAGTCCACTGACTCAGAGAGGTGC-3’  
and 5’-GCTACGCGGCCGCCTCGCATAGGTCCCTCTGCTCCACTCTCC-3’) were 
used to insert SRPX2 into the prk5-C myc vector between the BamHI and the Not I 
restriction sites. 
The prk5 expression vector encoding wild-type murine JAK2 (41) or murine 
JAK2 (K882E) (42) in which the critical lysine in the ATP-binding domain is mutated to 
a glutamate were provided by Dr. J. Ihle (St. Jude Children's Research Hospital).  PCMV 
tag 28 vectors encoding FLAG-tagged JAK2 (797-1132) or FLAG-tagged JAK2 (830-
1132) were described previously (17).  Carboxyl-terminally HA tagged wild-type JAK2 
(JAK-HA), mutant JAK2 lacking amino acids 548-804 (ΔJH2-HA) and the JH1-JH2 
fragment of JAK2 (535-1132) (JH1-2-ΗΑ) constructs were provided by Dr. O. 
Silvennoinen (University of Tampere, Finland) (43).  
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 Cell culture and transfection. 
293T and COS-7 cells were grown in DMEM supplemented with 1 mM L-
glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 0.25 µg/ml amphotericin B, and 
either 8% calf serum (293T) or 8% fetal bovine serum (COS-7).  Both 293T and COS-7 
cells were transiently transfected by calcium phosphate precipitation (44) and assayed 24 
or 48 h after transfection, respectively.  
 
Immunoprecipitation and immunoblotting. 
Cells were washed three times with chilled PBSV (10 mM sodium phosphate, 137 
mM NaCl, 1 mM Na3VO4 , pH 7.4) and solubilized in lysis buffer (50mM Tris, 0.1% 
Triton X-100, 150 mM NaCl, 2 mM EGTA, 1 mM Na3VO4, pH 7.5) containing 1 mM 
phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, and 10 µg/ml leupeptin.  Lysates 
were centrifuged at 16,750 xg for 10 min at 4oC.  The supernatant (cell lysate) was 
incubated with the indicated antibodies on ice for 2 h.  The immune complexes were 
collected on protein A-agarose for 1 h at 4oC.  The beads were washed three times with 
lysis buffer and boiled for 5 min in a mixture (80:20) of lysis buffer and SDS-PAGE 
sample buffer (250 mM Tris-HCl, 10% SDS, 10% β-mercaptroethanol, 40% glycerol, 
0.01% bromophenol blue, pH 6.8).  To reduce non-specific binding in some experiments, 
cells were lysed in lysis buffer supplemented with 0.1% Triton X-100 plus 1% SDS.  
Protein A agarose beads were incubated with 0.5% polyvinylpyrrolidon (PVP) in 100 
mM acetic acid (pH 6.2) for 1 hour at 4ºC prior to incubation with the cell lysate.  After 
incubation with cell lysates, protein A agrose beads were washed in 500 mM NaCl two 
times, then with lysis buffer two times.  Proteins were then boiled for 5 min in a mixture 
(80:20) of lysis buffer.  The solubilized proteins were separated on a 5-12% SDS-PAGE 
gradient gel.  Proteins in the gel were transferred to a nitrocellulose membrane and 
detected by immunoblotting with the indicated antibody using enhanced 
chemiluminescence (Fig. 2A, 3, 4) or Odyssey Infrared Imaging System (LI-COR 
Biosciences) (Fig. 2B, 5-9). 
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Results 
Identification of SSG1 as a binding partner for JAK2 in the yeast two-hybrid 
system. 
In an effort to identify novel cytokine receptor effector proteins that are recruited 
to the activated form of JAK2, full-length JAK2 was fused to the DNA binding portion of 
LexA and used to screen for JAK2 interacting proteins in a yeast two-hybrid system.  
Previous work showed that LexA-JAK2 expresses in yeast, is active as a kinase, is 
tyrosyl phosphorylated, and does not autoactivate the system (18).   
An adipose tissue library was used because GH and a number of other cytokines 
[e.g. IL-6, IL-11, LIF, leptin, IFNα, INFγ, oncostatin M] elicit multiple effects in 
adipocytes (45-50).  Activation of two reporter genes, Leu and lacZ, was used to indicate 
protein-protein interactions.  Over 110 positive clones were isolated from 11 x 106 yeast 
transformants.  Three clones, out of the 9 first sequenced, encoded a protein that closely 
corresponded to the carboxyl-terminal portion of rat SSG1.  SSG1 was initially cloned 
from rat uterus (GenBank accession number AF223677) and predicted to be a 385 amino 
acid, 41.8 kDa protein (22).  The presence of multiple mismatches between the sequence 
of our yeast two-hybrid clone and the published sequence for SSG1 (22) led us to 
resequence the full-length SSG1 cDNA of Marcantonio et al. (22).  Resequencing 
revealed that in contrast to what was reported initially (22), the cloned rat SSG1 cDNA 
predicts a 110 kDa protein of 949 amino acids.  The sequence of our yeast two-hybrid 
clone corresponds to the C-terminal portion, amino acids 477-949, of the full-length 
clone (Fig. 1A).  The sequence of rat SSG1 is identical to the subsequently cloned rat 
CL2 (23) and rat DRO1 (GenBank accession no. AY548105) (24).  The amino acid 
sequence of rat SSG1 shares high identity with murine Urb (94%) (GenBank accession 
no. AB075019), also cloned from adipose tissue (25), and human Urb (84%) (GenBank 
accession no. AF506819).  SSG1 also shares considerable amino acid sequence identity 
(69%) with chicken Equarin-L (GenBank accession no. AB086824).   
Sequence analysis indicates that SSG1 contains a signal peptide (amino acids 1-
24), a glycine rich region (amino acids 285-307), a proline rich region (amino acids 322-
353), a threonine rich region (amino acids 332-386), a lysine rich region (amino acids  
 71 
 
Figure 2.1  Identification of SSG1 as a binding partner for JAK2 in the yeast two-
hybrid system. 
(A) Domain structures for full-length SSG1 and for the yeast two-hybrid fragment of SSG1, SSG1 (477-
949), are shown.  The shaded boxes represent the different domains within SSG1.  The SRPX5 domains, 
D1, D2, D3, are noted.  (B) Clustal W plot of the three SRPX5 domains (D1, D2, and D3) in SSG1 along 
with the fifth domains of the SRPX/drs/ETX1 and SRPX2/SRPUL proteins.  Identical amino acids are 
shaded in grey; similar amino acids are boxed.  (C) Yeast cells transformed with cDNA encoding SSG1 
(477-949) in the prey vector with cDNA encoding either JAK2 (WT) or JAK2 (K882E) (KE) fused to a 
LexA DNA binding domain were streaked onto 15% agar-containing dropout medium in presence of 
leucine (+ leucine) or the absence (- leucine) or with galactose to induce β-galactosidase activity. 
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487-589) which contains 2 out of a total of 5 putative bipartite nuclear localization 
signals, and three consensus repeat domains (amino acids 137-281 [designated domain 1 
or D1], 615-756 [D2], and 766-912 [D3]) (Fig. 1A).  The consensus repeat domains 
display approximately 30% amino acid identity and 40-50% amino acid similarity to each 
other (Fig. 1B) and to the fifth domain of murine SRPX (GenBank accession no. 
CAM18748) (29).  We have designated these domains SRPX5 domains.  An SRPX5 
domain is also present in murine SRPX2 (GenBank accession no. NP_081114.1). The 
SRPX5 domains of SSG1 are highly conserved between species, with rat and mouse 
SSG1 showing 95%, 94%, 97% amino acid identity for D1, D2 and D3 respectively; rat 
and human SSG1 showing 98%, 94%, 97% amino acid identity, and rat SSG1 and 
chicken Equarin-L showing 88%, 85%, 89% amino acid identity for D1, D2 and D3 
respectively. 
 
Interaction of SSG1 with JAK2 requires JAK2 kinase activity in a yeast system. 
To determine whether JAK2 kinase activity and/or tyrosyl phosphorylation of 
JAK2 is required for the interaction of JAK2 with SSG1 (477-949), the SSG1 (477-949) 
prey plasmid was retransformed into yeast along with either LexA-JAK2 or the 
catalytically inactive LexA-JAK2 (K882E) in which a critical lysine in the ATP binding 
loop is mutated to glutamate.  As judged by the ability to activate the Leu and lacZ 
reporter genes embedded in the prey plasmid, SSG1 (477-949) bound LexA-JAK2 but 
not LexA-JAK2 (K882E) (Fig. 1C).  This result suggested that SSG1 interacts 
preferentially with tyrosyl phosphorylated, kinase-active JAK2.  
 
SSG1 (477-949) associates preferentially with and is phosphorylated by kinase-
active JAK2 in mammalian cells. 
To verify that SSG1 and JAK2 interact in mammalian cells, 293T cells were co-
transfected with cDNA encoding vector alone or HA-SSG1 (477-949), and cDNA 
encoding wild-type JAK2, JAK2 (K882E), JAK2 (Y1007F), or empty vector.  JAK2 
(K882E) is completely inactive (42).  In JAK2 (Y1007F), the activating tyrosine in the 
kinase domain of JAK2 is mutated to a phenylalanine.  This mutation markedly reduces 
but does not completely inhibit the kinase activity of JAK2 (51).  HA-SSG1 (477-949) 
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was immunoprecipitated using anti-HA antibody (αHA) and the immunoprecipitated 
proteins were immunoblotted with αJAK2 (Fig. 2A, top panel).  HA-SSG1 (477-949) co-
immunoprecipitated JAK2 to a much greater extent than either JAK2 (K882E) or JAK2 
(Y1007F).  Reprobing the blot with αPY (Fig. 2A, second panel) demonstrated that HA-
SSG1 (477-949) and the co-precipitated JAK2 were both tyrosyl phosphorylated when 
SSG1 was co-expressed with JAK2 but not when SSG1 was co-expressed with either of 
the two kinase-inactive forms, JAK2 (K882E) or JAK2 (Y1007F).  HA-SSG1 (477-949) 
migrated as a 60 kDa protein as predicted.  Immunoblotting the lysates with αJAK2 and 
αHA (Fig. 2A, lower panels) shows that expression of HA-SSG1 (477-949) and the JAK 
proteins did not vary substantially for the different conditions.   
 Because the HA tag contains tyrosines, the assay was repeated with a myc-tagged 
version of SSG1, myc-SSG1 (472-788).  The myc tag contains no tyrosines.  293T cells 
were co-transfected with cDNA encoding either wild-type JAK2 or JAK2 (Y1007F) and 
cDNA encoding myc-SSG1 (472-788).  Proteins in the cell lystates were 
immunoprecipitated with αmyc and the immunoprecipitated proteins were 
immunoblotted with αpY (Fig. 2B).  Consistent with SSG1 forming a complex with 
JAK2, myc-SSG1 (472-788) co-immunoprecipitated with a tyrosyl phosphorylated 
protein with a molecular weight appropriate for JAK2 whereas there was no detectable 
phosphorylated protein corresponding to JAK2 (Y1007F).  A tyrosyl phosphorylated 
protein with a molecular weight appropriate for myc-SSG1 (472-788) was observed when 
cells co-expressed wild-type JAK2, but not JAK2 (Y1007F) (Fig. 2B, second panel).  
Immunoblotting the lysates with αJAK2 and αmyc (Fig. 2B, bottom two panels) shows 
that differences in expression of myc-SSG1 (472-788) and the JAK proteins could not 
explain the difference in degree of SSG1 phosphorylation detected.  Together these 
findings indicate that SSG1 (477-949) interacts preferentially with tyrosyl 
phosphorylated, kinase-active JAK2, and that SSG1 is tyrosyl phosphorylated and most 







Figure 2.2  SSG1 (477-949) associates preferentially with and is phosphorylated by 
kinase-active JAK2 in mammalian cells. 
(A)  293T cells were transfected with 3 µg empty vector (lane 1 and 3) or cDNA encoding HA-SSG1 (477-
949) (lanes 2, 4-6), in combination with 2 µg of empty vector (lanes 1 and 2) or cDNA encoding JAK2 
(lanes 3 and 4), JAK2 (K882E) (lane 5) or JAK2 (Y1007F) (lane 6).  HA-SSG1 (477-949) was 
immunoprecipitated (IP) with αHA and immunoprecipitated proteins immunoblotted (IB) with αJAK2 (top 
panel) or αPY (second panel).  Lysates from the transfected cells were immunoblotted with αJAK2 (third 
panel) and αHA (bottom panel).  The migration of JAK2, HA-SSG1 (477-949), and a 90 kDa molecular 
weight marker is indicated.  (B)  293T cells were transfected with cDNA encoding myc-SSG1 (472-788) 
and either JAK2 (lane 1) or JAK2 (Y1007F) (lane 2).  myc-SSG1 (472-788) was immunoprecipitated (IP) 
with αmyc and immunoblotted (IB) with αPY (top two panels).  Lysates from the transfected cells were 
immunoblotted with αJAK2 (third panel) and αmyc (bottom panel).  The migration of JAK2 and myc-
SSG1 (472-788) is indicated.  n=2-5 
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SSG1 (477-949) interacts with the kinase domain of JAK2. 
Because SSG1 binds to tyrosyl phosphorylated JAK2, we sought to define the 
region within JAK2 responsible for binding to SSG1 (477-949) by using JAK2 truncation 
and deletion mutants (Fig. 3A).  Myc-SSG1 (477-949) was co-expressed with various 
HA-tagged truncation and deletion mutants of JAK2.  Myc-SSG1 (477-949) was 
immunoprecipitated with αmyc and precipitated proteins immunoblotted with αHA.   
Full length HA-JAK2, HA-JAK2 with the JH2 domain deleted [HA-JAK2 (Δ 549-803), 
designated HA-ΔJH2] and just the JH1 and JH2 domains of JAK2 [HA-JAK2 (535-
1132), designated HA-JH1-2], all co-immunoprecipitated with SSG1 (477-949) (Fig. 
3B), implicating the kinase domain of JAK2, JH1, in SSG1 binding.  
 To confirm the involvement of the JAK2 kinase domain in SSG1 binding, myc-
SSG1 (477-949) was co-expressed with either FLAG-tagged JAK2 (797-1132) 
containing JH1 and a portion of the linker region between the JH1 and JH2 domains, or 
the just the JH1 domain [FLAG-JAK2 (830-1132)] (Fig. 3A).  Myc-SSG1 (477-949) co-
immunoprecipitated with both JAK2 (797-1132) and JAK2 (830-1132) (Fig. 3C), 
confirming that SSG1 (477-949) interacts with the kinase domain (JH1) of JAK2.   
  
Identification of the SRPX5 domain within SSG1 as a region of interaction with 
JAK2. 
We next determined what region of SSG1 binds JAK2.  The yeast two-hybrid and 
co-immunoprecipitation experiments in 293T cells revealed that amino acids 477-949 in 
SSG1 are sufficient to bind to JAK2.  cDNAs encoding a series of carboxyl-terminal 
truncation mutants of HA-SSG1 (477-949) were created (Fig. 4A) and the various 
mutants were co-expressed with JAK2 in 293T cells.  JAK2 co-immunoprecipitated with 
all but the shortest SSG1 truncation mutant, HA-SSG1 (477-608) (Fig. 4B, top panel, 
lane 8), suggesting that the region in SSG1 between amino acids 609 and 662 comprising 
the N-terminal half of D2, the second SRPX5 domain, is sufficient for SSG1 binding to 
JAK2.  As expected, none of the SSG1 truncation mutants bound to either of the kinase 
deficient JAK2 mutants, JAK2 (K882E) or JAK2 (Y1007F) (data not shown).  
 Having implicated that the N-terminal half of the D2 domain of SSG1 in JAK2 
binding, we examined whether the isolated D2 is sufficient to mediate binding to JAK2.  
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Figure 2.3  SSG1 (477-949) interacts with the kinase domain of JAK2. 
(A)  Domain structure and truncation mutants of JAK2 are shown.  JH, JAK homology domain.  (B) 293T 
cells were transfected with 4 µg of vector alone (lanes 1 and 2) or cDNA encoding HA-JAK2 (lanes 3 and 
4), HA-ΔJH2 (lanes 5 and 6) or HA-JH1-2 (lanes 7 and 8), with (lanes 2, 4, 6 and 8) or without (lanes 1, 3, 
5 and 7) 2 µg of cDNA encoding myc-SSG1 (477-949).  Myc-SSG1 (477-949) was immunoprecipitated 
(IP) with αmyc and immunoprecipitated proteins were immunoblotted (IB) with αHA (top panel).  Lysates 
were immunoblotted with αHA (middle panel) and αmyc (bottom panel).  Due to a substantially higher 
expression of HA-JH1-2, lanes 7 and 8 were exposed for a shorter period of time.  Migration of HA-JAK2, 
HA-ΔJH2, JH1-2 and myc-SSG1 (477-949) is indicated.  (C)  293T cells were transfected with 3 µg of 
vector (lanes 1 and 2) or cDNA encoding FLAG-JH1 (797-1132) (lanes 3 and 4) or FLAG-JH1 (830-1132) 
(lanes 5 and 6) and 2 µg vector (lanes 1, 3, 5) or cDNA encoding myc-SSG1 (477-949) (lanes 2, 4, 6).  
myc-SSG1 (477-949) was immunoprecipitated (IP) with αmyc and immunoprecipitated proteins 
immunoblotted (IB) with αFLAG (top panel).  Lysates were immunoblotted with αmyc (middle panel) and 
αFLAG (bottom panel).  Migration of FLAG-JH1 (797-1132), FLAG-JH1 (830-1132), and SSG1-myc is 




Figure 2.4  Identification of the SRPX5 domain within SSG1 as a region of 
interaction with JAK2. 
(A)  Domain structure for a series of carboxyl-terminal truncation mutants of HA-SSG1 (477-949).  (B)  
293T cells were transfected with 2 µg of cDNA encoding JAK2 (lanes 2-8) and 2 µg of cDNA encoding 
either HA-SSG1 or HA-SSG1 truncation mutant as noted.  HA-SSG1 was immunoprecipitated (IP) with 
αHA and immunoprecipitated proteins immunoblotted (IB) with αJAK2 (top panel).  Lysates were 
immunoblotted with αHA (middle panel) and αJAK2 (bottom panel) to assess levels of expression of the 
HA-SSG1 mutants and JAK2, respectively.  (C)  GFP-SSG1 (615-756) encoding the D2  domain of SSG1 
(designated GFP-SRPX5-D2) (3 µg cDNA) (lanes 2, 3) or vector alone (lanes 1, 4) was co-expressed 
without (lanes 1, 2) or with (lane 3, 4) JAK2 (2 µg cDNA) in 293T cells.  GFP-SSG1 (615-756) was 
immunoprecipitated (IP) with αGFP and immunoprecipitated proteins immunoblotted (IB) with αJAK2 
(top panel).  Lysates were immunoblotted with αJAK2 (middle panel) and αGFP (bottom panel) to assess 
levels of expression of JAK2 and GFP-SSG1 (615-756), respectively.  The migration of JAK2 and GFP-
SSG1 (615-756) is indicated.  n=2 
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GFP-SSG1 (615-756) fusion protein, corresponding to D2 of SSG1 (Fig. 4A), was co-
expressed with JAK2 in 293T cells.  JAK2 clearly co-precipitated with GFP-SSG1 (615-
756) when both were co-expressed (Fig. 4C). This finding suggests that an SRPX5 
domain is not only necessary for JAK2 binding to SSG1 but also sufficient. 
 
All three SRPX5 domains of SSG1 interact with kinase-active JAK2. 
Since the second SRPX5 domain (D2) of SSG1 interacts with JAK2, we 
hypothesized that the other SRPX5 domains (D1 and D3) within SSG1 might also 
interact with JAK2.  cDNAs encoding D1, D2, and D3 fused to the myc tag were 
transfected into 293T cells with cDNA encoding JAK2 or JAK2 (K882E).  JAK2 co-
immunoprecipitated with all three SRPX5 domains of SSG1 (Fig. 5, top panel) to a 
significantly greater extent than JAK2 (K882E).  Similar results were obtained with GFP-
tagged D1, D2, and D3 domains (data not shown).   
  
The SRPX5 domains of SSG1 interact with the kinase-active kinase domain of 
JAK2. 
The experiments in Figs. 3-5 indicate that the SRPX5 domains in SSG1 interact 
with the kinase domain (JH1) of JAK2.  To test this more directly, myc-tagged D1, D2, 
and D3 of SSG1 were co-expressed in 293T cells with either kinase-active FLAG-JAK2 
(797-1132) [designated FLAG-JH1 wt], or kinase-inactive FLAG-JAK2 (797-1132, 
K882E) [designated FLAG-JH1 (K882E)].  As predicted, the kinase-active JH1 domain 
of JAK2 co-precipitated with all three of the SRPX5 domains of SSG1 (Fig. 6, top panel, 
lanes 5, 8, and 11) while the kinase-inactive FLAG-JH1 (K882E) did not (Fig. 6, top 
panel, lanes 6, 9, and 12).  The interaction of JH1 with D2 appeared to be the strongest 












Figure 2.5  All three SRPX5 domains of SSG1 interact with kinase-active JAK2. 
293T cells were transfected with 1.5 µg of vector or cDNA encoding the designated myc-SRPX5 domains 
of SSG1 (D1, D2, or D3) and 1 µg vector or of cDNA encoding either wild-type JAK2 (wt) or JAK2 
(K882E) (KE).  The myc-SRPX5 domains of SSG1 were immunoprecipitated (IP) with αmyc and 
immunoprecipitated proteins immunoblotted (IB) with αJAK2 (top panel).  The blot was reprobed with 
αmyc (middle panel).  Lysates were immunoblotted with αJAK2 (bottom panel).  The migration of JAK2 













Figure 2.6  The SRPX5 domains of SSG1 interact with the kinase-active kinase 
domain of JAK2. 
293T cells were transfected with 1.5 µg of vector or cDNA encoding one of the myc-SRPX5 domains of 
SSG1 (D1, D2, and D3) and either 1 µg of vector or cDNA encoding wild-type FLAG-tagged JAK2 (797-
1132) [FLAG-JH1 wt; designated wt] or 3 µg FLAG-tagged JAK2 (797-1132, K882E) [FLAG-JH1 
(K882E), designated KE].  The myc-SRPX5 domains of SSG1 were immunoprecipitated (IP) with αmyc 
and precipitated proteins immunoblotted (IB) with αFLAG (top panel).  The blot was reprobed with αmyc 
(middle panel).  Lysates were immunoblotted with αFLAG (bottom panel).  The migration of FLAG-JH1 
and of the myc-SRPX5 domains is indicated.  n=4 
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Full-length SSG1 interacts with full-length, kinase-active JAK2. 
We have shown that truncated versions of the yeast two-hybrid clone of SSG1 
(Fig. 4) as well as all three individual SRPX5 domains within SSG1 bind preferentially to 
kinase-active JAK2 (Fig. 5).  To confirm that full-length SSG1 and JAK2 interact in 
mammalian cells, an HA tag was inserted after the signal peptide at the thirtieth amino 
acid in full-length SSG1 and a myc tag fused at the C-terminus (denoted SSG1-HA-myc).  
This cDNA expresses a full-length protein of the appropriate size (~110kDa) for full-
length SSG1.  SSG1-HA-myc was co-expressed in 293T cells with either wild-type 
FLAG-tagged JAK2 or JAK2 (K822E).  JAK2 co-immunoprecipitated SSG1-HA-myc to 
a much greater extent than JAK2 (K882E) (Fig. 7, top panel).  These findings show that 
like SSG1 (477-949) and the SRPX5 domains of SSG1, full-length SSG1 interacts 
preferentially with tyrosyl phosphorylated, kinase-active JAK2.   Similar results were 
obtained using full-length SSG1-myc (data not shown). 
 
SSG1 interacts with full-length JAK2 better than JH1. 
All three of the SRPX5 domains bind kinase-active JAK2 (Fig. 5), however D1 
appears to bind full-length JAK2 to a greater extent than to the JH1 domain alone (Figs. 5 
and 6).  Therefore, we hypothesized that full-length SSG1 might bind full-length JAK2 at 
more than one site.  To compare the binding of full-length SSG1 to both full-length JAK2 
and to the JH1 domain of JAK2, SSG1-HA-myc was co-expressed in 293T cells with 
FLAG-JAK2 or FLAG-JH1.  FLAG-JAK2 and FLAG-JH1 were immunoprecipitated 
using αFLAG and the immunoprecipitated proteins were blotted with αHA (Fig. 8).  
Full-length JAK2 co-immunoprecipitated SSG1-HA-myc (Fig. 8, lane 3) to a much 
greater extent than JH1 (Fig. 8, lane 4).  This finding suggests that the three SRPX5 
domains in SSG1 interact with multiple sites in JAK2 and that at least some of these 













Figure 2.7  Full-length SSG1 interacts with full-length, kinase-active JAK2. 
293T cells were transfected with 3 µg empty vector (lane 1) or cDNA encoding SSG1-HA-myc (lanes 2-4), 
in combination with 2 µg of empty vector (lanes 1 and 2) or cDNA encoding wild-type FLAG-tagged 
JAK2 (lane 3) or FLAG-tagged JAK2 (K882E) (lane 4).  FLAG-JAK2 was immunoprecipitated (IP) using 
αFLAG agarose beads and precipitated proteins immunoblotted (IB) with αHA (top panel).  The blot was 
reprobed with αFLAG to show relative levels of FLAG-JAK2 and FLAG-JAK2 (K882E) (second panel).  
Cell lysates were immunoblotted with αHA (lower panel).  The migration of the FLAG-tagged JAK2 











Figure 2.8  SSG1 interacts with full-length JAK2 better than JH1. 
293T cells were transfected with 3 µg of cDNA encoding full-length SSG1-HA-myc or empty vector and 
co-transfected with 2 µg cDNA encoding either wild-type FLAG-JAK2 or FLAG-JH1 or vector.  JAK2 and 
the kinase domain were immunoprecipitated (IP) using αFLAG and the precipitated proteins were 
immunoblotted (IB) with αHA (top panel).  The blot was reprobed with αFLAG and the regions of the blot 
containing FLAG-JAK2 (second panel) and FLAG-JH1 (third panel) are shown.  Lysates were 




SRPX2, another SRPX5 domain-containing protein, binds kinase-active JAK2. 
We hypothesized that the SRPX5 domains in SSG1 may represent a novel JAK2 
binding domain.  To test whether other SRPX5 domain-containing proteins would bind 
preferentially to kinase-active JAK2, SRPX2-myc was co-expressed in 293T cells with 
FLAG-tagged JAK2 or JAK2 (K882E).  As observed for SSG1, SRPX2 co-












Figure 2.9  SRPX2, another SRPX5 domain-containing protein, binds kinase-active 
JAK2. 
293T cells were transfected with 3 µg of cDNA encoding SRPX2-myc or vector and 2 µg of cDNA 
encoding either FLAG-tagged wild-type JAK2 (wt), JAK2 (K882E) (KE), or vector.  SRPX2-myc was 
immunoprecipitated (IP) with αmyc and immunoprecipitated proteins immunoblotted (IB) with αJAK2 
(top panel).  Lysates were immunoblotted with αmyc (middle panel) and reprobed with αJAK2 (bottom 




In this study, we identified a new JAK2 binding protein, SSG1, by screening a rat 
adipose cDNA library with JAK2 using the yeast two-hybrid system.  Although SSG1 
had been previously cloned (22), its size and sequence were reported incorrectly and 
nothing was known about its function at the cellular level.  Here, we provide evidence 
that rat SSG1 is a protein of 949 amino acids (~110 kDa) that is identical to rat DRO1 
(24) and rat CL2 (23), binds to activated JAK2 and is phosphorylated by JAK2.  We also 
provide evidence that the SRPX5 domain within SSG1 is a novel protein-protein 
interaction domain that is necessary and sufficient for binding to the kinase domain of 
kinase-active, tyrosyl phosphorylated JAK2. 
SSG1 is a protein of unknown function that is expressed in a number of tissues in 
both the embryo and adult.  It has been shown to be downregulated in thyroid, ovarian, 
pancreatic, and colon cancer cell lines and tumors (23, 24).  Overexpression of SSG1 in 
colorectal and pancreatic cancer cell lines inhibits malignant growth and suppressed 
anchorage independent growth (24), suggesting that SSG1 may be a tumor suppressor.  It 
is intriguing to speculate whether the interaction between SSG1 and JAK2 affects the 
apparent tumor suppressing functions of SSG1.  Murine SSG1 (Urb) has also been 
recently shown to be highly expressed in adipose tissue (28), the tissue used to prepare 
the library used in our yeast two-hybrid screen.  SSG1 mRNA expression was found to be 
downregulated in obese mouse models, including ob/ob, KKAy and diet-induced obese 
mice.  In 3T3-L1 adipocytes, insulin, TNF-α, H2O2 and hypoxia decrease SSG1 mRNA 
levels, suggesting that these factors may contribute to the down-regulation of SSG1 seen 
with obesity (28).  The presence of an N-terminal signal peptide suggests that SSG1 is a 
secreted protein.  However, secretion of SSG1 has only been detected in a few studies 
(26-28), and whether it is secreted remains somewhat controversial (24).  If it is a 
secreted protein, it is intriguing to speculate that association with JAK2 prior to secretion 
may affect the rate of secretion of SSG1.  Alternatively, if a portion of SSG1 remains in 
an intracellular compartment, it seems possible that association with SSG1 could affect 
the trafficking of JAK2, or initiate SSG1-dependent cellular signaling pathways.  The 
demonstration that SSG1 (472-788) appears to be phosphorylated on tyrosines when co-
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expressed with kinase-active JAK2 but not kinase-inactive forms of JAK2 suggests that 
SSG1 could recruit and bind downstream signaling molecules that contain SH2 or PTB or 
other phosphotyrosine binding domains. 
Having identified SSG1 as a JAK2 interacting protein, we focused in this manuscript 
on the molecular basis for that interaction.  Defining the regions of interaction was of 
great interest because SSG1 clearly bound preferentially to the kinase-active, tyrosyl 
phosphorylated form of JAK2.  Thus, in the yeast two-hybrid assay which is generally 
considered to assess direct interactions, SSG1 (477-949) preferentially interacted with 
kinase-active JAK2 and not kinase-inactive JAK2 (K882E).  Both full-length SSG1 and 
the yeast two-hybrid fragment of SSG1, SSG1 (477-949), co-immunoprecipitate from 
mammalian cells with wild-type, tyrosyl phosphorylated JAK2 but not with kinase-
inactive JAK2 (K882E) or JAK2 (Y1007F).  This suggested that SSG1 might be binding 
to phosphorylated tyrosines within JAK2.  However, SSG1 lacks SH2, PTB, or C2 
domains, domains known to bind to phosphorylated tyrosines (52-58).  Thus, it seems 
possible that SSG1 might be binding to JAK2 via a novel phosphotyrosine binding 
domain. 
Experiments using both N- and C-terminally truncated forms of SSG1 identified a 
region of SSG1, which binds to tyrosyl phosphorylated JAK2.  We have called this 
domain the SRPX5 domain because it was first described as an uncharacterized, C-
terminal fifth domain in the protein SRPX (29).  This domain was subsequently identified 
in SRPX2/SRPUL (33) and then in SSG1 which has three SRPX5 domains (25) which 
share roughly 30% amino acid identity with the single SRPX5 domain in SRPX and 
SRPX2.  SRPX and SRPX2 belong to the selectin gene family which is currently 
comprised of five genes: SRPX, SRPX2, selectin P precursor (SELP), selectin E 
precursor (SELE), and selectin-like protein (SVEP1) (59).  Selectins are receptors at the 
cell surface that are important in cell adhesion and the binding of carbohydrates to 
facilitate cell rolling (60, 61).  The SRPX and SRPX2 genes encode for proteins with 
similar domain structures which include a signal peptide, three sushi domains, and a 
hyalin repeat (59).  SELP, SELE, and SVEP1 also contain sushi domains (62).  It has 
been suggested that the sushi domains and the hyalin repeat play a role in cell adhesion 
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(62, 63).  Of the selectin family of proteins, only SRPX and SRPX2 have the SRPX5 
domain. 
 Results using truncated forms of JAK2 implicated the kinase domain of JAK2 
(JH1 domain) in SSG1 binding.  This finding adds SSG1 to the growing list of proteins 
(e.g. SOCS-1 (11), SOCS-3 (12), PTP-1B (13), and Sts-1 (14)) that appear to bind to the 
JH1 domain of JAK2.  Although, all three of the SRPX5 domains in SSG1 bound to the 
JH1 domain of JAK2, the second (D2) and third (D3) domains were much more effective 
than the first (D1) domain.  In contrast, full-length JAK2 did not show differential 
binding to the different SRPX5 domains of SSG1 (i.e. binding of D1, D2 and D3 were 
roughly equivalent).  In addition, full-length SSG1 bound to full-length JAK2 much 
better than it did to the JH1 domain of JAK2.  Furthermore, when we attempted to 
determine which tyrosines in JAK2 bound to SSG1, we were unable to disrupt binding of 
either full-length SSG1 or isolated SRPX5 domains to JAK2 by mutating single tyrosines 
in JAK2, except for those tyrosines whose mutation inhibited JAK2 activity and thus 
phosphorylation of all the tyrosines within JAK2 (data not shown).  This raised the 
possibility that the individual SRPX5 domains in SSG1 bind multiple phosphorylated 
tyrosines in JAK2 and that maximal binding of SSG1 to JAK2 may involve at least two 
sites of interaction, with at least one in the JH1 domain and one lying outside the JH1 
domain. 
If the SRPX5 domain is a novel JAK2 binding domain and possibly a 
phosphotyrosine binding domain, we reasoned that other proteins which contain the 
SRPX5 domain should also bind JAK2.  In agreement with this hypothesis, SRPX2 
(SRPUL) was also found to bind kinase-active JAK2 but not kinase-dead JAK2 (K882E).  
Thus, we have identified SRPX2 as another JAK2 interacting protein.  In addition, SRPX 
is a likely candidate to bind JAK2.  Little is known about SRPX2 and what is known 
sheds little light on its cellular function.  SRPX2 mRNA is expressed in the heart, ovary, 
and placenta (33) and protein was visualized in the brain (64).  Inhibition of expression of 
E2A-HLF oncoprotein using a dominant negative form of E2A-HLF suppressed the gene 
expression of SRPX2 (33).  Mutations in SRPX2 may play a role in Rolandic/Sylvian 
epileptic seizures and perisylvian polymicrogyria (59, 64).  A human mutation, N372S, 
results in partial gain of N-glycosylation resulting in increased SRPX2 protein secretion 
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as well as protein misfolding (64).  Human variation, R75K, in the hypervariable loop in 
the first sushi domain of SRPX2 (59) has been hypothesized to have functional 
importance in protein-protein interactions and play a role in two disorders of the 
Rolandic/Sylvian speech area in the brain (59).  The determination that JAK2 binds 
SRPX2 (SRPUL) suggest that investigations of ligands that activate JAK2 in the affected 
tissues could be fruitful for better understanding and potentially managing these medical 
conditions. 
In summary, we identified SSG1/DRO1/CL2/Urb as a novel JAK2 binding 
protein of Mr~110,000.  The interaction with JAK2 occurred via the SRPX5 domains of 
SSG1.  Because the three SRPX5 domains of SSG1 only interact with kinase-active, 
tyrosyl phosphorylated JAK2, the SRPX5 domain is quite possibly a novel 
phosphotyrosine binding domain with at least some specificity for JAK2.  Consistent 
with the SRPX5 domain serving as a JAK2 binding site, we demonstrated that a second 
SRPX5 domain-containing protein, SRPX2 (SRPUL), could also bind activated, tyrosyl 
phosphorylated JAK2.   The fact that SSG1 is expressed in a large number of tissues both 
in the embryo and adult, that its level of expression appears to be highly regulated, and 
that it has been implicated in such a wide variety of functions, including tumor 
suppression, suggests that SSG1 may play an important and fundamental role in cell 
function.  The fact that it appears to be secreted from adipocytes and downregulated in 
obesity raises the possibility SSG1 plays a role in fat and carbohydrate metabolism.  We 
also observed that SSG1 is tyrosyl phosphorylated in the presence of activated JAK2. 
Therefore, JAK2 has the potential to influence SSG1 at multiple levels ranging from 
localization of SSG1 to specific cellular regions to regulation of SSG1 function. 
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1The abbreviations used are: C2, conserved domain 2 for PKCδ; DRO1, down-regulated 
by oncogene1; drs, downregulated by Src; ER, endoplasmic reticulum; GH, growth 
hormone; JAK2, Janus kinase 2; PAGE, polyacrylamide gel electrophoresis; PTB, 
phosphotyrosine binding domain; PY, phosphotyrosine; SH2, Src-homology 2; SOCS, 
suppressor of cytokine signaling; SRPUL, sushi repeat protein upregulated in leukemia; 
SRPX, sushi repeat containing protein, X-linked; SSG1, steroid-sensitive gene-1; Stat, 
signal transducer and activator of transcription; Urb, upregulated in brown adipose tissue 
of bombesin-receptor-subtype-3-deficient mice. 
 
Note:  This chapter will be submitted for publication, in modified form, to Biochemistry 
under the title: “Identification of steroid-sensitive gene-1 as a novel JAK2 binding protein 
and the SRPX5 domain as a novel phosphotyrosine binding domain” by Erin E. O’Leary, 
Anna M. Mazurkiewicz-Muñoz, Lawrence S. Argetsinger, Hung T. Huynh, and Christin 
Carter-Su.  Dr. Anna Mazurkiewicz-Muñoz provided part of Fig. 2.1 and Figs. 2.2-2.4 
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PHYSIOLOGICAL CONSEQUENCES OF THE  
INTERACTION BETWEEN JAK2 AND SSG1 
 
Abstract 
Growth hormone (GH) is an important regulator of body growth and metabolism.  
GH binding to its receptor activates the receptor associated tyrosine kinase, JAK2, which 
in turn, initiates multiple signaling cascades, including activation of Stats 1, 3, 5a, and 5b.  
Previously, we identified a novel JAK2 binding protein, steroid-sensitive gene-1 (SSG1), 
as a binding partner for activated JAK2.  This study aims to identify the physiological 
consequences of the interaction between SSG1 and JAK2.  In this study, we show that 
SSG1 does not alter JAK2 kinase activity and only modestly increases the 
phosphorylation of Stat5b on Tyr694.  In contrast, SSG1 enhances phosphorylation of 
Stat3 on Tyr705 in the presence and absence of GH.  Antibody to phospho-Ser727 of 
Stat3 revealed that SSG1 does not affect phosphorylation of Ser 727.  However, 
phosphatase experiments suggest that SSG1 may enhance GH-independent 
phosphorylation of a different residue in Stat3.  We also show that SSG1 negatively 
regulates the GH-responsive gene, c-fos.  By fluorescent microcopy, we show that SSG1 
co-localizes with markers for both the ER and the Golgi.  By confocal microscopy, we 
saw that portion of JAK2 co-localizes with SSG1 in this subcellular compartment.  We 
also demonstrate that SSG1 contains a functional signal peptide and is a secreted protein, 
which is blocked by BFA.  We also show that JAK2 enhances both the secretion and 
cleavage of SSG1.  Interestingly, we also detect extracellular staining of SSG1, which is 
enhanced by the presence of wild-type JAK2. 
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Introduction 
 The cytokine/hematopoietin family of receptors includes receptors for growth 
hormone (GH), prolactin, erythropoietin, leptin, and multiple interleukins and interferons.  
The Janus family of tyrosine kinases includes JAK1, JAK2, JAK3, and Tyk2 (1-5).  
Cytokine receptors signal through the associated JAK family kinases with nearly two-
thirds of the cytokine receptor family activating JAK2 (6, 7).  Activation of JAK family 
kinases promotes growth, proliferation, and differentiation in the cell types in which they 
are expressed and activated.  It is not surprising, then, that activating mutations in JAK 
kinases and dysregulation of JAK signal transduction have deleterious effects, causing 
various cancers and immune disorders (reviewed in (8)). 
GH is an important regulator of body growth and metabolism, yet the mechanism 
by which GH elicits these responses is not completely understood.  In GH signal 
transduction, GH binding to the GH receptor activates the associated tyrosine kinase, 
JAK2, resulting in tyrosyl phosphorylation of both JAK2 and the GH receptor (9-19).  
These phosphorylated tyrosine residues in JAK2 and the GH receptor serve as docking 
sites for downstream signaling molecules and recruit a number of signaling molecules to 
the GH receptor-JAK2 complex, some of which also become phosphorylated by JAK2.  
Proteins recruited to the GH receptor-JAK2 complex include SH2B1 (SH2B) and SH2B2 
(APS), adaptor proteins which bind to phosphotyrosine 813 in JAK2 and enhance kinase 
activity of JAK2 and cell motility (12, 20, 21); Shc which activates the Ras-MAP kinase 
pathway (7, 22, 23); insulin receptor substrates 1/2 which leads to the activation of the 
phosphoinositide 3-kinase pathway (reviewed in (23)); proteins involved in the regulation 
of the cytoskeleton (reviewed in(23)); and signal transducers and activators of 
transcription (Stat) proteins (reviewed in (23-25)).   
Stat proteins are latent cytoplasmic transcription factors that are activated by 
phosphorylation by JAK kinases with Stats 1, 3, 5a, and 5b playing roles in mediating 
responses to GH (23-26).  Phosphorylation by JAK2 allows for the Stat proteins to homo- 
(27) or heterodimerize (28-30) via reciprocal phosphorylated tyrosine-SH2 domain 
interactions.  Dimerization allows for translocation to the nucleus where the Stat proteins 
bind to DNA and act as transcription factors for target genes (31, 32) including the GH-
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regulated target genes c-fos, c-jun, IGF-1, and serine protease inhibitor (Spi) 2.1 (33-37).  
Stat proteins differ in their DNA binding specificities as well as in their tissue 
distribution, resulting in a large number of genes being regulated by Stat transcription 
factors. 
 Previously, we identified steroid-sensitive gene-1 (SSG1) in a yeast two-hybrid 
screen as a novel protein, which binds to kinase-active JAK2, but not inactive JAK2 
(O’Leary et al., manuscript in preparation).  We also showed that SSG1 is 
phosphorylated by JAK2 and identified a novel JAK2 binding domain in SSG1 (O’Leary 
et al., manuscript in preparation).  SSG1 was initially identified as a gene that was 
downregulated in response to estrogen using differential display of uterine tissues from 
ovariectomized versus ovariectomized/estrogen-treated rats (38).  SSG1 was 
subsequently independently identified as DRO1, CL2, Urb, and Equarin in different 
contexts.  Rat SSG1/DRO1 (downregulated by oncogenes-1) was identified using 
subtractive suppression hybridization as a protein whose gene expression was decreased 
in cells neoplastically transformed by β-catenin (39).  Rat SSG1/CL2 was also identified 
as a protein induced by the adenovirus E1A gene but downregulated in adenomas and 
carcinomas (40).  These results led both Bommer et al. (39) and Visconti et al. (40) to 
propose that SSG1/DRO1/CL2 may function as a tumor suppressor.  The gene encoding 
murine SSG1, also known as Urb, was identified by differential display as a gene 
upregulated in brown adipose tissue with a proposed function in energy metabolism (41).  
Liu et al. (42) identified SSG1 through a differential display as a gene that is 
downregulated during osteoblast differentiation, suggesting a role for SSG1/Urb in bone 
development.  A chicken ortholog of SSG1, Equarin, was identified using a signal 
sequence trap screen and implicated in eye development (43).  However, the role SSG1 
has at the cellular level, as well as how the cell regulates SSG1 remains unclear. 
This study aimed to identify the physiological consequences of the previously 
described interaction between SSG1 and JAK2.  We show that SSG1 does not enhance 
JAK2 kinase activity and only modestly increases phosphorylation of Stat5b on Tyr694, 
which is required for activation of Stat5b.  In contrast, SSG1 enhances phosphorylation 
of Stat3 on Tyr705 and may promote the phosphorylation of another residue in Stat3.  
SSG1 negatively regulates basal and GH-dependent c-fos gene transcription.  We show 
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that SSG1 co-localizes with both ER and Golgi markers and that JAK2 partially co-
localizes with SSG1 in COS-7 cells.  Finally, we show that SSG1 has a functional signal 
peptide resulting in SSG1 secretion.  SSG1 secretion and cleavage are enhanced in the 
presence of kinase-active JAK2 but not kinase-inactive JAK2 (K882E).  Because JAK2 
has also been shown not only to bind SSG1 but also to phosphorylate SSG1 on tyrosines, 
these results raise the possibility that the interaction of SSG1 with JAK2 enhances SSG1 
secretion. 
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Materials and Methods 
Cells and reagents. 
293T and COS-7 cells were from American Type Culture Collection.  Chinese 
hamster ovary cells expressing amino acids 1-454 of rat GH receptor (CHO454) were 
provided by Dr. G. Norstedt (Karolinska Institute, Stockholm, Sweden) (44).  The stock 
of 3T3-F442A preadipocyte cells were kindly provided by H. Green (Harvard 
University).  Dulbecco's Modified Eagle Medium (DMEM), antibiotic-antimycotic, 
trypsin-EDTA, and Magic Mark molecular weight standards were from Invitrogen.  Calf 
serum and fetal bovine serum were from Atlanta Biologicals.   Bovine serum albumin 
was from Intergen (CRG-7) and Proliant.  Recombinant 22,000-Da Growth Hormone was 
a kind gift from Eli Lilly & Co. (Indianapolis, IN) and was used at a concentration of 500 
ng/ml unless otherwise noted.  Aprotinin, leupeptin, Triton X-100, and alkaline 
phosphatase were from Roche.  Lambda protein phosphatase (λ ppase) was from New 
England Biolabs.  Recombinant protein A-agarose was from Repligen.  Hybond-C Extra 
nitrocelluolose paper was from Amersham Biosciences.  The QuickChange Site-Directed 
Mutagenesis Kit was from Stratagene.  Trichloroacetic acid was from J. T. Baker.  
Paraformaldehyde was from Electron Microscopy Sciences.  Brefeldin A dissolved in 
ethanol was from Sigma. 
 
Antibodies. 
Polyclonal antibody to JAK2 (αJAK2, 1:7500), antibody recognizing a peptide 
containing phosphorylated tyrosines 1007 and 1008 of JAK2 (αpY1007/1008 JAK2, 
1:2000), monoclonal anti-phosphotyrosine antibody (αPY; 4G10, 1:7500), and 
monoclonal pY705Stat3 (αpY705Stat3, 1:1000) were from Millipore, Inc. and were used 
for immunoblotting.  Monoclonal JAK2 (691) antibody (Invitrogen) was used for 
immunoblotting at 1:2000.  Monoclonal antibody to influenza virus hemagglutinin (HA) 
tag (αHA; HA.11) was from Covance and used at a dilution of 1:100 for 
immunoprecipitation and 1:1000 for immunoblotting.  Rat monoclonal HA antibody 
(αHA; 3F10) used at a dilution of 1:2000 was from Roche.  Monoclonal antibody against 
myc-tag (αmyc; 9E10) was from Santa Cruz Biotechnology, Inc. and used at a dilution of 
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1:100 for immunoprecipitation and 1:10,000 for immunoblotting.  Polyclonal antibody 
against the myc-tag (αmyc; A14) was from Santa Cruz Biotechnology, Inc. and used at a 
dilution of 1:1000 for immunoblotting and 1:200 for immunocytochemistry.  Polyclonal 
Stat3 antibody (αStat3, K-15, 1:1000), and monoclonal Stat5b antibody (αStat5b, G-2, 
1:5000) were from Santa Cruz Biotechnology, Inc.  Monoclonal pS727Stat3 antibody 
(αpS727Stat3, 1:000) was from Cell Signaling.  Polyclonal antibody against pY694Stat5 
(αpY694Stat5, 1:7500) was from Zymed.  Monoclonal anti-FLAG M2 antibody 
(αFLAG, 1:1000) was from Sigma.  Anti-FLAG M2 antibody conjugated to agarose 
beads was from Sigma.  Affinity purified anti-mouse IgG, anti-rabbit IgG, anti-rat IgG, 
and anti-GFP antibodies conjugated to IRDyes 680 and 800 were from Rockland, 
Molecular Probes, and Licor were used at a dilution of 1:20,000 for western blotting.  
Polyclonal antibody against giantin (αGiantin, 1:500) was from Covance.  Polyclonal 
antibody against calnexin (αCalnexin, 1:500) was from Stressgen.  AlexaFluor 488 
conjugated anti-mouse IgG (1:500, Molecular Probes), AlexaFluor 594-conjugated anti-
rabbit IgG (1:500, Molecular Probes), and Oregon Green anti-rabbit IgG (1:1000, 
Molecular Probes) were used to visualize the proteins by immunocytochemistry. 
 
Plasmids. 
 The prk5 expression vector encoding wild-type murine JAK2 (45) or murine 
JAK2 K882E in which the critical lysine in the ATP-binding domain is mutated to a 
glutamate (46) were provided by Dr. J. Ihle (St. Jude Children's Research Hospital, 
Memphis, TN).  The mammalian expression vector encoding murine wild-type JAK2 
with an N-terminal FLAG tag, FLAG-JAK2, was described previously (47). FLAG-
JAK2 K882E was prepared using primers 5’ GGTGGTCGCTGTGgAgAAACTCCA 
GCACAGCAC 3’ and 5’ GTGCTGTGCTGGAGTTTcTcCACAGCGACCACC 3’ using 
the QuikChange mutagenesis kit.  The mammalian expression vector encoding FLAG-
Stat3 was kindly provided by R. Jove (City of Hope National Medical Center, CA).  The 
GFP-Stat5b expression vector was previously described (48).  The mammalian 
expression vector pLM108 encoding rat GHR was provided by G. Norstedt (Karolinska 
Institute, Sweden).  Mammalian expression vectors encoding SSG1 with a C-terminus 
myc tag (SSG1-myc) and SSG1 with an HA tag after amino acid 30 and a C-terminal 
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myc tag (SSG1-HA-myc) were described previously (O’Leary et al., manuscript in 
preparation).  c-fos/Luc reporter plasmid, containing the 379 base pairs of mouse c-fos 
promoter immediately 5' of the transcription start site, cloned upstream of a luciferase 
gene (49) was provided by Dr. J. Schwartz (University of Michigan).  The RSV β-
galactosidase plasmid was provided by Dr. M. Uhler (University of Michigan).  GFP-
JAK2 was created by first inserting a NotI site (underlined) in pEGFP-C1 vector with 
primers 5’ TCGAGGTCGAGGGATCCGATGCGGCCGCACGT 3’ and 
5’CTAGACGTGCGGCCGCATCGGATCCGTCGACC 3’.  Wild-type JAK2 was 
subcloned from prk5-JAK2 into the pEGFP-C1 NotI vector using the SalI and NotI 
restriction sites to create an N-terminal fusion protein, GFP-JAK2.  The same primers 
listed above were used to produce the K882E mutation in GFP-JAK2, GFP-JAK2 
K882E.  All constructs and mutations were verified by sequencing. 
 
Cell culture and transfection. 
293T and 3T3-F442A preadipocyte cells were grown in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 1 mM L-glutamine, 100 U/ml penicillin, 
100 µg/ml streptomycin 0.25 µg/ml amphotericin B, and 8% calf serum.  COS-7 cells 
were grown in the same medium except containing 8% fetal bovine serum instead of calf 
serum.  293T and COS-7 cells were transiently transfected by calcium phosphate 
precipitation (50) and assayed between 24 and 48 h after transfection.  3T3-F442A cells 
were electroporated using the Nucleofactor system (Amaxa).  For GH treated cells, cells 
were washed twice in DMEM, and medium was replaced with DMEM supplemented 
with 1% BSA for 18 h prior to GH addition for the indicated time.  For Brefeldin A 
(BFA) treated cells, cells were washed once in DMEM and medium was replaced with 
DMEM supplemented with 1% calf serum with the indicated concentration of BFA for 
16 h. 
CHO454 cells were cultured in F12 medium supplemented with 1 mM L-
glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 0.25 µg/ml amphotericin B, and 
8% fetal bovine serum.  CHO454 cells grown in 35 mm wells were transiently 
transfected  by calcium phosphate precipitation with 0.5 µg c-fos/Luc, 0.1 µg RSV β-
galactosidase plasmid DNA and increasing amounts of cDNA encoding SSG1.  24 h after 
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transfection, cells were incubated overnight in serum-free medium containing 1% BSA.  
Cells were then treated for 4 h with 500 ng/ml of GH at 37oC and rinsed three times with 
PBS (10 mM sodium phosphate, 137 mM NaCl [pH 7.4]).  In a separate series of 
experiments, CHO454 were transiently transfected with 0.5 µg c-fos/Luc, 0.1 µg RSV β-
galactosidase, and varying amounts of cDNA encoding SSG1 and either JAK2 or JAK2 
(K882E) and assayed after 24 h incubation in medium containing 1% BSA.  All 
experiments were carried out at 37ºC.  The amount (µg) of cDNA/well in all experiments 
was kept constant using empty vector. 
 
Immunoprecipitation and immunoblotting. 
Cells were washed three times with chilled PBSV (10 mM sodium phosphate, 137 
mM NaCl, 1 mM Na3VO4 , pH 7.4) and solubilized in lysis buffer (50mM Tris [pH 7.5], 
0.1% Triton X-100, 150 mM NaCl, 2 mM EGTA, 1 mM Na3VO4) containing 1 mM 
phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, and 10 µg/ml leupeptin.  Lysates 
were centrifuged at 16,750 xg for 10 min at 4oC.  The cell lysate was incubated with the 
indicated antibody on ice for 2 h.  The immune complexes were collected on protein A-
agarose during an 1 h incubation at 4oC.  In the experiments in which proteins were 
immunoprecipitated with αFLAG conjugated agarose beads, lysate was incubated with 
the beads for 2 h at 4oC.  Both sets of beads were washed three times with lysis buffer 
and boiled for 5 min in a mixture (80:20) of lysis buffer and SDS-PAGE sample buffer 
(250 mM Tris-HCl [pH 6.8], 10% SDS, 10% β-mercaptroethanol, 40% glycerol, 0.01% 
bromophenol blue).  The solubilized proteins were separated on a 5-12% SDS-PAGE 
gradient gel.  Proteins in the gel were transferred to a nitrocellulose membrane and 
detected by immunoblotting with the indicated antibody using the Odyssey Infrared 
Imaging System (LI-COR Biosciences).  The intensity of the bands in immunoblots was 
quantified using LI-COR Odyssey 2.1 software.  Values for phosphorylated proteins were 
normalized to total level of unphosphorylated protein with background subtracted values.  
Experiments were performed at least 2 times, usually 3 or more, with similar results.  




Whole cell lysate. 
Cells were washed three times with chilled PBSV (10 mM sodium phosphate, 137 
mM NaCl, 1 mM Na3VO4 , pH 7.4) followed by the addition of boiling SDS-PAGE 
sample buffer to the cells.  Samples were then boiled and vortexed several times.  
Samples were diluted 1:4 with lysis buffer before proteins were separated on a 5-12% 
SDS-PAGE gradient gel, transferred to nitrocellulose membrane, and detected by 
immunoblotting with the indicated antibody using the Odyssey Infrared Imaging System 
(LI-COR Biosciences).  In some cases, cells were scraped in PBSV, briefly centrifuged 
and then resuspended in PBSV.  Equal volumes were separated into two tubes: one for 
solubilizing protein cell lysates and one to create whole cell lysates. 
 
Phosphatase assay. 
Proteins were dephosphorylated as previously described (20).  Briefly, cells were 
stimulated with 500 ng/ml of GH for the indicated times.  FLAG-Stat3 was 
immunoprecipitated with αFLAG conjugated agarose beads.  The immunoprecipitates 
were washed in 50 mM Tris-HCl, 0.1 mM EDTA, pH 8.5 and then incubated in 100 µl of 
the same buffer containing 40U of alkaline phosphatase with or without 10 mM Na3VO4 
for one hour at 37°C.  For λ phosphatase, immunoprecipitates were washed in 50 mM 
Tris-HCl, 100 mM NaCl, 2mM MnCl2, 0.1 mM EGTA, 2 mM dithiothreitol, 0.01% Brij 
35, pH 7.5, then incubated with 50 µl of the same buffer containing 200U λ phosphatase 
with or without 10 mM Na3VO4 at 30°C for 30 min. The dephosphorylation reactions 
were terminated by adding SDS-PAGE sample buffer and boiling.  As controls, 
immunoprecipitates were treated identically, but no phosphatase was added.  The 




 10 h post-transfection, medium was changed to 1% calf serum.  Medium was 
collected 26 h post-transfection and briefly centrifuged at 2500 rpm for 2 min to remove 
dead cells.  Proteins in the medium were precipitated by adding TCA (15% final 
concentration) to 1mL of medium and incubating on ice for 5 min.  Precipitated proteins 
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were pelleted by centrifugation at 16,750 xg for 5 min.  The pellet was resuspended in 




COS-7 cells on coverslips were transfected using calcium phosphate precipitation.  
24 h later, cells were fixed by adding 16% paraformaldehyde (PFA) directly to the 
growth medium for a final concentration of 4% PFA and incubated for 15 min at 37ºC.  
The 4% PFA-containing medium was removed and the cells were permeabilized with 
0.1% TritonX-100 in PBS containing 4% PFA for 7 min at room temperature.  The cells 
were then washed twice with PBS and incubated in 5% fat free milk in PBS for 30 min at 
room temperature.  The cells were incubated with primary antibody in 5% milk in PBS at 
the indicated dilutions for 30 min.  The cells were then rinsed twice with PBS before the 
addition of the secondary antibody in 5% milk in PBS and incubation for 30 min.  The 
chromosomal/nuclear stain DAPI (Molecular Probes) was added to double distilled H20 
(ddH20) at a concentration of 2 ng/ml and incubated for 10 min at room temperature.  The 
cells were then rinsed in ddH20 to wash away residual salts and excess DAPI.  Prolong 




The cells were visualized by fluorescence microscopy (Nikon Eclipse TE200) 
with a 60X oil objective.  Images were captured using a CoolSnap HQ digital camera 
(Roper Scientific) and viewed using MetaVue imaging software (Molecular Devices, 
Sunnyvale, Ca).  Pictures were captured using equal exposure times to assess differences 
in signal intensity.  SSG1 images showing extracellular staining were taken in a different 
focal plane than the JAK2 images; SSG1 images were focused on the coverslip; JAK2 
images were focused on the cell.  The intensity of the extracellular staining due to 
secreted SSG1-myc was assessed by a blinded observer.  Briefly, the observer randomly 
selected 8-10 isolated SSG1-myc positive cells per experiment per condition.  Using 
MetaVue’s “trace region” function, the observer manually selected a region of 
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extracellular staining that surrounded the cell and used the “region statistics” function to 
quantify the average signal intensity of the region selected.  The trace was then dragged 
outside of the are of SSG1-myc secretion and a second average intensity measurement 
was taken and used to calculate the background signal.  Background subtracted values 
were plotted.  The experiment as performed 3 times.  Means ± SEM are shown. 
 
Confocal microscopy. 
Analysis of SSG1-myc and GFP-JAK2 subcellular distribution was performed 
with an Olympus FluoView 500 laser scanning confocal microscope utilizing a 60X oil-
immersion objective and FluoView version 5.0 software.  AlexaFluor 594 fluorescence 
was excited with a Green Helium Neon (HeNe) laser at 543 nm and emission was 
measured through a 560 nm long pass filter (560 and above).  GFP and/or Oregon Green 
conjugated secondary fluorescence was excited with an Argon (Ar) laser at 488 nm and 
emission was measured through a 505-525 nm filter. Images depicting co-localization of 




Cells were solubilized in 100 mM potassium phosphate, 0.2% Triton X-100, 1 
mM dithiothreitol, pH 7.8.  Luciferase or β-galactosidase activity was measured using an 
Opticomp Luminomenter (MGM Instruments, Inc., Sherman, CT).  The luciferase values 
were normalized to β-galactosidase activity. 
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Results 
The effect of SSG1 on JAK2 kinase activity. 
We have previously shown that SSG1 binds JAK2 in a kinase-dependent manner 
(O’Leary et al., manuscript in preparation).  To determine the physiological importance 
of the SSG1-JAK2 interaction, we first examined whether SSG1 affects JAK2 kinase 
activity.  293T cells were co-transfected with cDNA encoding vector alone or SSG1-HA-
myc, which has an internal HA tag after amino acid 30 and a C-terminal myc tag, in the 
presence or absence of cDNA encoding FLAG-tagged JAK2.  FLAG-JAK2 was 
immunoprecipitated with αFLAG-M2 agarose beads and the immunoprecipitated 
proteins were immunoblotted with αpY1007/pY1008.  Tyrosine 1007 is the activating 
tyrosine in JAK2, thus, the amount of pY1007 generally reflects the amount of kinase-
active JAK2 (14).  SSG1 was found not to affect the kinase activity of JAK2 when 
normalized to the amount of JAK2 (Fig. 1, compare lanes 3 and 4).  Similar results were 
obtained using SSG1-myc which has only the C-terminal myc tag (data not shown).  In 
four experiments, the mean ± SEM for pY1007/pY1008 JAK2 normalized to the amount 
of JAK2 in the presence of SSG1 versus the absence of SSG1 was 0.99 ± 0.10. 
 
The effect of SSG1 on phosphorylation of Stat5b and Stat3. 
 We next examined whether overexpression of SSG1 affects the ability of GH to 
stimulate the phosphorylation of Stat5b and Stat3 on Tyr694 and Tyr705, respectively.  
Phosphorylation on these tyrosines by JAK2 is a necessary first step in the activation by 
GH of Stats 5b and 3, respectively (23-26).  293T cells were co-transfected with cDNA 
encoding GFP-Stat5b or FLAG-Stat3, rat GH receptor, and SSG1-myc.  Cells were 
incubated in serum-free medium for 18 h, and then stimulated with or without 500ng/ml 
GH for 15 min.  Figure 2 reveals a very modest increase (28 ± 11%, p<0.05, n=5) in the 
levels of GH-dependent phosphorylation of Tyr694 in Stat5b SSG1-expressing cells 












Figure 3.1  The effect of SSG1 on JAK2 kinase activity. 
293T cells were transfected with 3 µg empty vector or cDNA encoding SSG1-HA-myc in combination 
with 2 µg of empty vector or cDNA encoding FLAG-JAK2.  FLAG-JAK2 was immunoprecipitated (IP) 
with αFLAG agarose beads and immunoprecipitated proteins were immunoblotted (IB) with 
αpY1007/pY1008 (top panel).  This blot was reprobed with αJAK2 to show relative levels of 
immunoprecipitated JAK2 (second panel).  Lysates from the transfected cells were immunoblotted with 
αHA to reveal levels of expression of SSG1-HA-myc.  The migration of FLAG-JAK2 and SSG1-HA-myc 













Figure 3.2  The effect of SSG1 on tyrosyl phosphorylation of Stat5b. 
293T cells were co-transfected with cDNA encoding GFP-Stat5b (500ng), rat GHR (250 ng), and SSG1-
myc (1 µg) as indicated.  35 h post-transfection, cells were washed and medium was replaced with 1% 
BSA/DMEM for 17 h.  Cells were stimulated with 500 ng/ml GH for 15 min, and lysates were prepared.  
Lysates were immunoblotted (IB) with αpY694-Stat5 (top panel) and reprobed with αStat5b (middle 
panel).  Whole cell lysates were immunoblotted with αSSG1 (bottom panel).  The migration of GFP-Stat5b 
and SSG1-myc is indicated.  n=5 
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In contrast, SSG1 had several effects on phosphorylation in Stat3.  SSG1 
dramatically promoted both basal (Fig. 3A, compare lanes 3 and 5) and GH-dependent 
phosphorylation of Tyr705 (Fig. 3A, compare lanes 4 and 6).  SSG1 increased basal 
levels of pTyr705 to levels similar to (Fig. 3B) or even above (Fig. 3A) GH-stimulated 
levels in control cells.  Levels of Tyr705 phosphorylation in GH-treated cells were on 
average 4.33 ± 0.622 times higher in cells expressing SSG1 than in control cells.  The 
two pTyr705-Stat3 bands observed in the SSG1-expressing cells in both the absence and 
presence of GH migrated slightly higher than the corresponding bands observed for the 
control, GH-treated cells.  Overexpression of SSG1 also significantly changed the 
distribution between the two pTyr705-Stat3 bands so that in SSG1 overexpressing cells, 
the upper band dominated. 
An upward shift in migration of a protein is consistent with the presence of one or 
more posttranslational modifications.  Because both Stat3 bands are detected with 
αpY705, the upward shift must be due to some other post-translational modification.  
Stat3 has also been shown to be phosphorylated on Ser727.  We therefore examined 
whether SSG1 affected phosphorylation of Stat3 on Ser727.  Cells were prepared as for 
Fig. 3A.  Confirming the results shown in Fig. 3A, lysates immunoblotted with αpY705-
Stat3 showed that SSG1 promotes the phosphorylation of Tyr705 in Stat3 both in the 
absence and presence of GH (Fig. 3B, second panel).  In contrast, Stat3 was 
phosphorylated on Ser727 in the absence of GH, and when normalized to levels of Stat3, 
phosphorylation of Ser727 was not reproducibly affected by either GH stimulation or 
expression of SSG1 (Fig. 3B, top panel).  Furthermore, both the upper and lower Stat3 
bands were phosphorylated on Ser727, indicating that the difference between the upper 
and lower Stat3 bands is not phosphorylation of Stat3 on Ser727.  Taken together, these 
results suggest that SSG1 enhances the phosphorylation of Tyr705 on Stat3 both in the 
presence and absence of GH.  It also most likely promotes one or more additional post-






Figure 3.3  SSG1 stimulates the tyrosyl phosphorylation of Stat3. 
293T cells were transfected with cDNA encoding FLAG-Stat3 (500 ng), rat GHR (250 ng), and SSG1-myc 
(1 µg).  35 h post-transfection, cells were washed and medium was replaced with 1% BSA/DMEM for 18 
h.  Cells were stimulated with 500 ng/ml GH for 15 min, and lysates were prepared.  (A) Lysates were 
immunoblotted (IB) with αpY705-Stat3 (top panel) and reprobed with αStat3 (middle panel).  A second set 
of lysates was probed αmyc (bottom panel).  (B) Lysates were blotted with αpS727-Stat3 (top panel), 
αpY705-Stat3 (second panel), or αFLAG (third panel).  Whole cell lysates were probed with αmyc 
(bottom panel).  The migration of FLAG-Stat3 and SSG1-myc is indicated.  n=4-6 
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To gain insight into whether the SSG1-induced upward shift in migration of Stat3 
is due to phosphorylation, we performed a phosphatase assay using alkaline phosphatase, 
a non-specific protein phosphatase that dephosphorylates phosphotyrosines, 
phosphoserines, and phosphothreonines.  FLAG-Stat3 and rat GH receptor were co-
expressed with or without SSG1-myc in 293T cells.   The following day, cells were 
incubated in serum-free medium for 18 h, and then stimulated with or without 500ng/ml 
GH for 15 min.  FLAG-Stat3 was immunoprecipitated with αFLAG-M2 agarose beads, 
washed and then incubated in the presence or absence of alkaline phosphatase in the 
presence or absence of sodium orthovanadate, an inhibitor of alkaline phosphatase.  
Immunoblotting the immunoprecipitates with αpY705-Stat3 revealed that alkaline 
phosphatase dephosphorylated Tyr705 of Stat3 in both control (- SSG1) (Fig 4A, lane 3) 
and SSG1-expressing cells (Fig 4A, lane 7) and that sodium orthovanadate blocked 
dephosphorylation (Fig 4A, compare lanes 3 and 4; lanes 7 and 8).  Immunoblotting the 
cell lysates with αpY705-Stat3 show that Stat3 was phosphorylated on Tyr705 before 
phosphatase treatment.  In contrast, alkaline phosphatase did not dephosphorylate Ser727 
in Stat3 in control (-SSG1) or SSG1-expressing cells (Fig. 4B, top panel), suggesting that 
pSer727 was protected from dephosphorylation.  Further, alkaline phosphatase did not 
change the ratio of the different Stat bands seen using αStat3, αpSer727-Stat3, or 
αpY705-Stat3, indicating that either the upper band contains a phosphorylated amino 
acid, that like pSer727, is not susceptible to desphosphorylation by alkaline phosphatase 
or contains a different post-translational modification (e.g. acetylation, methylation, 
sumoylation) than the bottom band. 
Because alkaline phosphatase did not dephosphorylate pSer727, we repeated the 
experiment using λ phosphatase, another phosphatase with activity towards 
phosphorylated serine, threonine, and tyrosine residues.  Immunoblots using αpY705-
Stat3 revealed that in contrast to alkaline phosphatase, λ phosphatase did not 
dephosphorylate pTyr705-Stat3 in control (- SSG1) or SSG1-expressing cells (Fig. 5A, 
top panel).  However, the Stat3 bands containing pY705-Stat3 migrated as lower 
molecular weight proteins after λ phosphatase treatment in SSG1-expressing cells but not 





Figure 3.4  The effect of alkaline phosphatase on Stat3. 
293T cells were co-transfected with 500 ng of cDNA encoding FLAG-Stat3, 250 ng rat GHR, and 1 µg 
SSG1-myc.  10 h post-transfection, cells were washed and media was replaced 1% BSA/DMEM for 16 h. 
Cells were stimulated with 500ng/ml GH for 15 min. FLAG-Stat3 was immunoprecipitated (IP) with 
αFLAG agarose beads.  Immunoprecipitated proteins were incubated in the presence or absence of 40U of 
alkaline phosphatase (AP) in the presence or absence of 10 mM sodium orthovanadate (Na3VO4) for 1 h 
and immunoblotted (IB) with αpY705-Stat3 (A, top panel) or αpS727-Stat3 (B, top panel).  
Immunoprecipitated proteins were reprobed with αStat3.  Lysates were immunoblotted (IB) with αpY705-
Stat3 (A, third panel) and αmyc (A, bottom panel.  The migration of pY705-Stat3, pS727-Stat3, FLAG-





Figure 3.5  The effect of λ phosphatase on Stat3. 
500 ng of  cDNA encoding FLAG-Stat3, 250 ng rat GHR, and 1 µg SSG1-myc were co-expressed in 293T 
cells.  30 h post-transfection, cells were washed and media was replaced with 1% BSA/DMEM for 18 h.  
Cells were stimulated with 500ng/ml GH for 15 min.  FLAG-Stat3 was immunoprecipitated (IP) with 
αFLAG agarose beads.  Immunoprecipitated proteins were incubated in the presence or absence of 200U of 
λ phosphatase (λ ppase) in the presence or absence of 10 mM sodium orthovanadate (Na3VO4) for 30 min 
and immunoblotted (IB) with αpY705-Stat3 (A, top panel) or αpS727-Stat3 (B, top panel).  
Immunoprecipitated proteins were reprobed with αStat3.  Lysates were immunoblotted (IB) with αpY705-
Stat3 (A, bottom panel) or αpS727-Stat3 (B, bottom panel).  The migration of pY705-Stat3, pS727-Stat3, 
and FLAG-Stat3 is indicated.  n=2 
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Stat3 other than Tyr705 is being dephosphorylated by λ phosphatase.  In fact, in the  
presence of λ phosphatase, the migration of the two Stat3 bands in SSG1-expressing cells 
became similar to the migration of the two Stat3 bands from control cells (- SSG1).  
Treating with sodium orthovanadate partially prevented the dephosphorylation, revealing 
three distinct Stat3 bands, all of which are phosphorylated on Tyr705.  λ phosphatase was 
able to dephosphorylate Ser727 of Stat3 in control and SSG1-expressing cells (Fig. 5B).  
The addition of orthovanadate partially restored pSer727.  It also revealed the presence of 
three bands all of which are phosphorylated on Ser727.  These findings suggest that: 
Stat3 migrates as two distinct bands in control cells; SSG1 increases the apparent 
molecular weight of Stat3; phosphatase treatment returns the apparent molecular weight 
of Stat3 in SSG1-expressing cells back to the apparent molecular weight in control cells 
without altering phosphorylation of Tyr705; and partial inhibition of the phosphatases 
reveal that Stat3 undergoes at least two post-translational modifications in addition to 
phosphorylation on Tyr705 and Ser727.  One is present even in the absence of SSG1 
accounting for the detection of two bands by αStat3.  The second modification appears to 
be a phosphorylation that is enhanced by SSG1. 
 
SSG1 negatively regulates the GH-responsive gene c-fos. 
Because SSG1 enhances Stat3 phosphorylation, we hypothesized that SSG1 might 
affect Stat3-mediated gene expression.  The finding that SSG1 promotes the 
phosphorylation of Tyr705 suggested that SSG1 might increase basal and GH-stimulated 
expression of Stat3 regulated genes.  However, the ability of SSG1 to enhance 
phosphorylation of an additional, as yet, unidentified site leaves open the possibility that 
SSG1 might actually inhibit expression of Stat3 regulated genes.  GH rapidly (15-30 min) 
induces the expression of c-fos (34) which encodes a transcription factor implicated in 
cell growth and differentiation (51).  The regulatory region of c-fos contains multiple 
regulatory sequences, including the sis-inducible element (SIE) which binds Stat3 and 
Stat1 homo- and heterodimers.  To determine whether SSG1 regulates c-fos promoter 
expression, SSG1-myc was expressed in GH-responsive CHO454 cells in combination 
with a luciferase reporter driven by wild type c-fos promoter (from -379 to +1).  CHO454 
cells stably express a truncated form of the GH receptor (GHR 1-454) that is capable of 
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stimulating expression of c-fos (52, 53).  These cells were chosen because they express 
higher levels of GH receptor than CHO cells expressing full-length GH receptor.  GH 
treatment doubled c-fos promoter expression (Fig. 6A) as reported previously (54).  
Overexpression of SSG1 inhibited both basal and GH-stimulated expression of the c-fos 
reporter. 
Because SSG1 binds to JAK2, we tested whether SSG1 blunts the stimulatory 
effect of JAK2 on c-fos promoter activation.  SSG1 was co-expressed with either JAK2 
or JAK2 (K882E), along with the c-fos driven luciferase reporter, in CHO454 cells (Fig. 
6B).  JAK2 (K882E) lacks a critical lysine in the ATP binding loop and as a 
consequence, is completely inactive as a kinase (46).  Overexpressed JAK2 stimulated c-
fos promoter activity to ~300% of control values.  At the lowest level (25 ng cDNA) of 
SSG1 expression tested, stimulation of c-fos reporter activity by JAK2 was not 
significantly different from that seen in the absence of SSG1; however, 100 ng of SSG1 
cDNA decreased basal c-fos reporter activity by ~50% and JAK2-stimulated c-fos 
reporter activity by ~70%.  As expected, JAK2 (K882E) did not stimulate c-fos promoter 
activity in the presence (Fig. 6B) or absence (data not shown) of SSG1.  These findings 





Figure 3.6  SSG1 negatively regulates the GH-responsive gene c-fos. 
(A) CHO454 cells were transfected with cDNA encoding SSG1-myc (0, 25, 50, or 100 ng cDNA as 
indicated) in combination with a luciferase reporter driven by wild type c-fos promoter (from -379 to +1).  
After 48 h, cells were treated with vehicle (open bars) or GH (black bars) for 4 h and analyzed for 
luciferase activity.  The data are expressed as the mean ± SEM of three independent experiments each 
assayed in triplicate.  The one-tailed, paired Student’s t test was used to assess statistical differences.  
Significant differences (p<0.05) are denoted with a circle (o) when controls with SSG1 are significantly 
different than controls without SSG1; a plus (+) when GH-treated with SSG1 are significantly different 
than GH-treated without SSG1; and an asterisk (*) when GH-treated are significantly different than control 
samples for a given concentration of SSG1.  (B) CHO454 cells were transfected with cDNA encoding 
SSG1-myc (0, 25, 100 µg cDNA as indicated) in combination with cDNA encoding either JAK2 or JAK2 
(K882E) as indicated and luciferase reporter driven by wild type c-fos promoter (from -379 to +1).  After 
48 h, cells were analyzed for luciferase activity.  The data are expressed as the mean ± SEM of nine (0 ng 
SSG1 cDNA) or three (25 and 100 ng SSG1 cDNA) replicates in a representative experiment.  The one-
tailed, paired Student’s t test was used to assess statistical differences.  Significant differences (p<0.05) are 
denoted with a circle (o) when controls (0 ng JAK2) with SSG1 are different than controls without SSG1; a 
plus (+) when JAK2 expressing cells with SSG1 are different than JAK2 expressing cells without SSG1; 
and an asterisk (*) when control cells with SSG1 are different than JAK2 expressing cells with SSG1. 
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Localization of SSG1. 
SSG1 contains several putative nuclear localization sequences, suggesting that 
SSG1 might have a nuclear function that might contribute to its inhibitory effect on c-fos 
gene transcription.  To examine the subcellular localization of SSG1, full-length SSG1-
HA-myc, which has a tag at both the C-terminus and 30 amino acids after the N-
terminus, was overexpressed in COS-7 cells (Figs. 7A-C).  The cells were fixed and 
immunostained using αHA (Figs. 7A and C) and αmyc (Fig 7B) to visualize SSG1.  
αmyc and αHA staining was seen in the perinuclear region in COS-7 cells (Fig. 7) in a 
pattern suggesting the endoplasmic reticulum and/or Golgi apparatus.  The fact that the 
staining with αmyc and αHA was indistinguishable argues against SSG1 being cleaved 
into N- and C-terminal cleavage products capable of localizing to different parts of the 
cell. 
To test whether SSG1 co-localizes in the endoplasmic reticulum or Golgi 
apparatus, SSG1-myc was overexpressed in COS-7 cells.  SSG1-myc localized in a 
manner indistinguishable from the subcellular localization observed with SSG1-HA-myc 
(Fig. 7D and G).  These cells were also immunostained with a marker for the Golgi 
(Giantin), an endoplasmic reticulum marker (calnexin), or a nuclear marker (DAPI).  
SSG1-myc co-localized with both the Golgi marker, Giantin, (Fig. 7E-F) and the ER 
marker, calnexin, (Fig. 7H-I) in COS-7 cells.  Only rarely was SSG1 seen in the nucleus 
(data not shown).  This localization pattern is not consistent with a nuclear function for 
SSG1.  Rather, it is more consistent with the localization pattern of proteins in the 
secretory pathway.  These data suggest that SSG1 is unlikely to act directly in the nucleus 
to regulate gene expression. 
 
Localization of SSG1 in the presence of wild-type JAK2. 
Because of our finding that SSG1 immunoprecipitates with wild-type JAK2, but 
not kinase-inactive JAK2 (Fig. 7P), we next examined the subcellular localization of 
SSG1 and JAK2.  Full-length SSG1-myc was co-expressed with GFP or GFP-JAK2 in 
COS-7 cells.  The cells were fixed and immunostained with αmyc and visualized by 
confocal microscopy.  As in Figs. 7A and D, SSG1-myc was present in the perinuclear 









Figure 3.7A-I  Localization of SSG1. 
COS-7 cells were transfected with 500 ng of cDNA encoding SSG1-HA-myc (panels A-C) or with 500ng 
of cDNA encoding SSG1-myc (panels D-I) alone.  Cells were fixed with 4% paraformaldehyde and 
immunostained using αmyc or αHA (as indicated) followed by staining with AlexaFluor594 (panels A, C, 
D, F, G, and I) or AlexaFluor488 (panel B).  Cells were stained with the Golgi marker, Giantin, (panels E 
and F) or the ER marker, calnexin, (panels H and I) followed by staining with Oregon Green.  Nuclei were 
visualized with DAPI (panels F, and I).  Panels A-I are fluorescent images.  Exposure times were selected 
to avoid saturation where possible.  Panel C is a shorter exposure of the cell in panel A.  The dotted line 






Figure 3.7J-P Localization of SSG1. 
COS-7 cells were transfected with 500 ng of cDNA encoding SSG1-myc in combination with 500ng GFP 
(panels J-L)  or in combination with 500 ng of GFP-JAK2 (panels M-O).  Cells were fixed with 4% 
paraformaldehyde and immunostained using αmyc followed by staining with AlexaFluor594 (panels J and 
M).  Nuclei were visualized with DAPI (panels L, and O).  Panels J-O are confocal images.  Exposure 
times were selected to avoid saturation where possible.  (P) 3 µg of cDNA encoding SSG1-myc was 
expressed alone or with 2 µg of cDNA encoding either wild-type FLAG-JAK2 or FLAG-JAK2 (K882E) in 
293T cells.  FLAG-JAK2 was immunoprecipitated (IP) with αFLAG agarose beads and 
immunoprecipitated proteins were immunoblotted (IB) with αmyc (top panel).  This blot was reprobed 
with αFLAG to show relative levels of immunoprecipitated JAK2 (second panel).  Lysates from the 
transfected cells were immunoblotted with αmyc to reveal levels of expression of SSG1-myc.  The 
migration of FLAG-JAK2 and SSG1-myc is indicated. 
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GFP-JAK2 overlapped with SSG1-myc staining, although JAK2 localization was more 
widespread (Fig 7, panels M-O).  This raises the possibility that JAK2 is likely to be 
interacting with SSG1 in the ER and Golgi. 
 
SSG1 is a secreted protein. 
The finding that SSG1 co-localizes with both an ER marker, calnexin, and a Golgi 
marker, Giantin, (Fig. 7 D-I) and also contains a putative signal peptide suggested that 
SSG1 was likely to be a secreted protein.  Previous reports in the literature had 
conflicting evidence about whether SSG1 was secreted.  Several groups suggest that 
SSG1 is not a secreted protein (39, 55).  Others have suggested that SSG1 is secreted (42, 
56).  Mu et al. (43) were unable to detect C-terminally tagged Equarin-L in the culture 
medium; however, they reported detecting Equarin-S (which contains the N-terminal 601 
of 958 amino acids) by western blot analysis.  To examine whether the signal peptide at 
the N-terminus of SSG1 serves as a functional secretion signal, 293T cells were 
transfected with cDNA C-terminally tagged SSG1-myc, or SSG1-HA-myc which has an 
HA tag just following the putative signal peptide.  Ten hours after transfection, the 
medium was changed to 1% calf serum.  After 16 h, medium was collected, proteins were 
precipitated using trichloroacetic acid (TCA), and TCA precipitated proteins were 
immunoblotted with αmyc.  Cell lysates were also prepared and SSG1 in the cell lysate 
were blotted with αmyc.  Fig. 8A (lanes 1-3) shows that SSG1 migrates as a tight band of 
~120kDa and a diffuse band of ~125-175kDa suggesting that SSG1 undergoes post-
translational modification.  Blotting TCA precipitated proteins (lanes 4-6) with αmyc 
revealed a diffuse band migrating ~125-175kDa only in SSG1-expressing cells, 
consistent with the presence of only the glycosylated forms of SSG1 in the medium. 
To confirm that SSG1 is secreted from cells, we added 1 µg/ml Brefeldin A 
(BFA) to cells expressing SSG1-myc during the 16 h incubation with 1% serum.  BFA 
blocks secretion.  Only minimal cell death was detected.  TCA precipitated proteins were 
immunoblotted with αmyc.  As shown in lane 8 of Fig. 8A, SSG1-myc was detected in 






Figure 3.8  SSG1 is a secreted protein. 
(A) 293T cells were transfected with 3 µg empty vector or cDNA encoding SSG1-myc or SSG1-HA-myc 
as indicated.  Cells in lanes 7-12 were treated with or without the 1 µg/ml of BFA for 16 h as indicated.  
Cell lysates were prepared (lanes 1-3, 10-12), and proteins in the medium were precipitated using TCA 
(lanes 4-6, 7-9).  Proteins were resolved by SDS-PAGE and immunoblotted (IB) with αmyc.  The 
migration of the molecular weight standards, SSG1-HA-myc, and SSG1-myc is indicated. (B) cDNA 
encoding SSG1-myc or empty vector were introduced into 3T3-F442A preadipocyte cells by 
electroporation.  TCA precipitates and cell lysates were prepared.  For reference, SSG1-myc overexpressed 
in 293T cells was included as a positive control (lane 3, light exposure).  The migration of SSG1-myc is 
indicated. 
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of SSG1-myc (Fig. 8A, lane 9).  Taken together, these results suggest that SSG1 is a 
highly glycosylated protein secreted by the constitutive secretory pathway. 
To test whether SSG1 is secreted from a GH-responsive cell line that contains 
endogenous SSG1, SSG1-myc was expressed in 3T3-F442A preadipocytes.  Medium was 
collected and proteins were precipitated using TCA.  A band corresponding to SSG1-myc 
from 3T3-F442A was present in the TCA precipitates only in lanes where SSG1-myc had 
been overexpressed, suggesting that SSG1-myc is also secreted from 3T3-F442A cells 
(Fig. 8B, top panel).  Again, SSG1-myc from 3T3-F422A cells migrated at a higher 
molecular weight than SSG1-myc found in the cell lysate, suggesting that SSG1-myc 
undergoes post-translational modification before being secreted.  3T3-F442A cells 
appeared to secrete the majority of protein made as there was very little SSG1-myc 
present in the cell lysate.  Lysates prepared from both transfected cell lines show that 
SSG1-HA-myc or SSG1-myc is expressed in the cell before it is secreted.  Further, when 
the lysate is blotted for SSG1, there is a smear above SSG1 consistent with SSG1 
undergoing post-translational modification/N-glycosylation prior to being secreted from 
the cell. 
 
SSG1 secretion is enhanced by kinase-active JAK2. 
Previously, we have shown that kinase-active JAK2, not kinase-inactive JAK2, 
interacts with SSG1 (O’Leary et al., manuscript in preparation, Fig. 7P of this 
manuscript).  Having just demonstrated that at least a portion of SSG1 is secreted (Fig. 
8), we hypothesized that JAK2 kinase activity may affect the secretion of SSG1.  To test 
this hypothesis, SSG1-HA-myc was co-expressed with FLAG-tagged JAK2 or JAK2 
(K882E) in 293T cells.  Medium was collected after 16 h, and proteins were precipitated 
using TCA.  The precipitated proteins were resolved by SDS-PAGE and immunoblotted 
with αmyc or αHA.  As shown in Fig. 8, a band corresponding to SSG1 was present in 
the medium (Fig. 9, lane 1).  An additional band assumed to be a C-terminal cleavage 
product due to the presence of the C-terminal myc tag migrated as a ~60 kDa protein.  
The amount of this 60kDa protein, as well as total SSG1, was significantly greater when 
JAK2 was overexpressed than in control cells when JAK2 was not expressed or when 









Figure 3.9  SSG1 secretion is enhanced by kinase-active JAK2. 
293T cells were co-transfected with cDNA encoding SSG1-HA-myc (3 µg) and either wild-type FLAG-
JAK2 (wt) or FLAG-JAK2 (K882E) (KE) (2 µg).  Proteins in the medium were precipitated using TCA, 
and resolved by SDS-PAGE.  Proteins from TCA samples (top panels) and lysates (bottom panels) of the 
transfected cells were immunoblotted (IB) with αmyc (left panels) or αHA (right panels).  The migration of 
the molecular weight standards, SSG1-HA-myc, and N- and C-terminal cleavage products (unlabeled 
brackets) are indicated. 
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of ~125-175,000 was also present in the medium when proteins were blotted with αHA. 
As expected from the presence of C-terminal cleavage products detected with αmyc, N-
terminal cleavage products detected with αHA migrating with molecular weights 
~80,000 and ~40,000 when wild-type JAK2 was co-expressed (Fig. 9, lane 5) than in 
control or JAK2 (K882E) expressing cells.  These results suggest that both secretion and 
post-translation processing (i.e. proteolytic cleavage) of SSG1 is enhanced in the 
presence of wild-type JAK2.  This increased expression due to the presence of JAK2 
appears to be at least partially specific, since JAK2 did not appear to increase the 
secretion of SRPX2, a JAK2 interacting protein belonging to the selectin family (data not 
shown). 
 
Localization of SSG1 in the presence of wild-type JAK2. 
Because it seems that JAK2 enhances SSG1 secretion, we wanted to determine if 
extracellular SSG1 could be visualized by microscopy.  To confirm our results in Fig. 9, 
we overexpressed SSG1-myc in COS-7 cells, fixed the cells in the presence of medium, 
and immunostained using αmyc.  Visualizing SSG1-myc overexpressing cells by 
fluorescence microscopy revealed low, but detectable αmyc staining in a halo-like 
pattern surrounding the cell which we believe is SSG1 secreted into the extracellular 
matrix (Fig. 10).  This halo was only present in SSG1 transfected cells.  When GFP-
JAK2 was co-expressed with SSG1-myc, the halo-like effect was enhanced (Fig. 10C, 
compare to 10A).  This result was specific to kinase-active JAK2.  When kinase-dead 
GFP-JAK2 (K882E) was co-expressed with SSG1-myc, the halo pattern (Fig. 10E) was 
similar to that seen when SSG1-myc was expressed alone (Fig. 10A).  Quantification of 
the intensity of the “halo” reveals that wild-type JAK2 enhances the presence of 
extracellular SSG1 by more than three-fold (Fig. 10M).  Taken together, these data 
suggest that a portion of SSG1-myc co-localizes with GFP-JAK2 (Fig. 7O) and that co-
expression with wild-type JAK2 enhances the secretion of SSG1-myc. 
 
BFA inhibits SSG1 extracellular staining. 
To confirm that the staining seen in the extracellular matrix surrounding SSG1-
expressing cells was secreted SSG1, we overexpressed SSG1-myc in COS-7 cells.  Cells 
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were treated with or without 10µg Brefeldin A (BFA) overnight. Cells were fixed and 
stained as above.  Cells which were not treated with BFA had a similar staining pattern as 
before, with SSG1 localizing to the ER, Golgi, and in the extracellular matrix (Fig. 10, 
panels G, I, and J).  When the cells were treated with BFA, SSG1 localization was 
completely intracellular (dark extracellular background) with SSG1 staining in the ER 
(Fig. 10, panels H, K, and L).  There was no extracellular staining in of SSG1 
overexpressing cells treated with BFA.  From this, we conclude that SSG1 is a secreted 
protein which can be seen in the extracellular matrix and perhaps binds to a component of 








Figure 3.10A-F  Localization of SSG1 in the presence of wild-type JAK2. 
COS-7 cells were transfected with 500 ng of cDNA encoding SSG1-myc alone (panels A-B) or in 
combination with cDNA encoding 500 ng of GFP-JAK2 (panels C-D) or GFP-JAK2 (K882E) (panels E-F).  
24 h after transfection, cells were fixed with 4% PFA and immunostained with αmyc followed by 
AlexaFluor594.  Cells were visualized using a Nikon Eclipse TE200 fluorescent microscope.  The dotted 
line represents the cell boundaries. 
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Figure 3.10G-M  Localization of SSG1 in the presence of wild-type JAK2. 
COS-7 cells were transfected with 500 ng of cDNA encoding SSG1-myc alone (panels G-H) or in 
combination with cDNA encoding 500 ng of GFP-JAK2 (panels I-L).  Cells were treated with (panels H, 
K, and L) or without (G, I, and J) 10 µg/ml BFA for 16 h prior to fixation.  24 h after transfection, cells 
were fixed with 4% PFA and immunostained with αmyc followed by AlexaFluor594.  Cells were 
visualized using a Nikon Eclipse TE200 fluorescent microscope. (M) The intensity of extracellular SSG1 
was calculated as described in Materials & Methods.  The data are expressed as the mean ± SEM of three 
independent experiments in which 8-10 cells were assessed for each condition.  The dotted line represents 
the cell boundaries. 
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Discussion 
 Previously, we identified SSG1 as a binding partner for kinase-active JAK2 from 
a yeast two-hybrid screen of a rat adipocyte cDNA library (O’Leary et al., manuscript in 
preparation).  We confirmed in a mammalian system that SSG1 interacts with kinase-
active wild-type JAK2, but not kinase-dead JAK2 (K882E) and identified the interacting 
regions within SSG1 to be the SRPX5 domains, named for their similarity to an 
uncharacterized fifth domain within SRPX (O’Leary et al., manuscript in preparation).  
Based on this interaction, we hypothesized that SSG1 might affect signaling molecules in 
the GH signaling pathway.  We also hypothesized that JAK2 might affect the function of 
SSG1. 
In this paper, we have shown that SSG1 does not affect JAK2 kinase activity, and 
only modestly affects phosphorylation of Stat5 on Tyr694, which is required for GH-
activation of Stat5.  However, SSG1 was shown to enhance the phosphorylation of Stat3 
on Tyr705 and likely promote the phosphorylation of another amino acid in Stat3 in both 
the presence and the absence of GH stimulation.  Because phosphorylation of Tyr705 is 
required for activation of Stat3, we predicted that this increase in Stat3 Tyr705 
phosphorylation would enhance Stat3-mediated gene transcription.  However, the 
expression of a c-fos promoter construct containing a Stat3 responsive sis-inducible 
element was found to be negatively regulated by the presence of SSG1.  One can envision 
several ways in which SSG1-induced phosphorylation of this as yet unidentified amino 
acid could negatively regulate c-fos gene expression.  It could interfere with the ability of 
Stat3 to form dimers, bind to importin-α3 and be transported into the nucleus, bind to 
DNA, or interact with co-factors.  Phosphorylation could directly affect these events or 
indirectly affect them by affecting the ability of Stat3 to undergo other post-translational 
modifications, such as acetylation.  Acetylation of Stat3 has been reported to be 
important for Stat3 to form stable dimers and induce gene transcription (57).  Until we 
map the site of phosphorylation, we also cannot rule out the possibility that the SSG1-
induced changes in Stat3 phosphorylation and inhibition of GH- and JAK2-induced c-fos 
promoter activity are independent events.  The inhibition of c-fos promoter activity could 
be mediated by a response element in the c-fos promoter other than the SIE that binds 
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Stat3 since this promoter construct also contains a serum response element (SRE), CRE 
(CCAAT/enhancer-binding protein beta (C/EBPβ) response element), and AP1 response 
element which bind other transcription factors important in regulating c-fos gene 
expression (49). 
There are clearly multiple candidates for the proposed SSG1-promoted site of 
phosphorylation in Stat3.  A number of amino acids in Stat3 in addition to Ser727 and 
Tyr705 have been shown to be phosphorylated by mass spectroscopy.  These sites 
include:  Thr268 (58), Ser269 (58), Ser273 (58), Tyr539 (59, 60), Tyr686 (60, 61), and 
Ser691 (62).  It is not known whether phosphorylation of these sites in Stat3 alters the 
function of Stat3 nor is it known what the kinase is for these sites.  It will be interesting to 
determine if the SSG1-promoted phosphorylation in Stat3 coincides with any of these 
predicted sites or is a previously unidentified site, and what kinase is responsible for that 
phosphorylation. 
Overexpression of SSG1 in colorectal and pancreatic cancer cell lines led to the 
inhibition of malignant growth and suppression of anchorage independent growth (39), 
suggesting that SSG1 may function as a tumor suppressor.  SSG1 has also been reported 
to be downregulated in a number of cancer cell lines and tumors including, thyroid, 
ovarian carcinoma, pancreatic, and colon cancer (39, 40). Our observation that SSG1 is a 
negative regulator of GH- and JAK2-dependent c-fos gene transcription is consistent with 
SSG1 being a tumor suppressor.  Constitutive activation of JAK2 and/or Stat proteins has 
been associated with various cancers including thyroid, ovarian, pancreatic, and colon 
cancers (63-74). 
 Fluorescent and confocal microscopy revealed SSG1 to be present in the 
perinuclear region of the cell as well as in a distinct punctate pattern throughout the 
cytoplasm suggestive of it being in the ER and Golgi.  In fact, SSG1 co-localized with 
both ER and Golgi markers.  Bommer et al. (39) also reported partial overlap of human 
SSG1 with Golgi and ER markers, while others reported perinuclear staining of SSG1 
(40-42).  SSG1 has several putative nuclear localization sequences (NLS).  However, 
only rarely did we see SSG1 in the nucleus.   Bommer et al. (39) and Lui et al. (42) also 
reported an absence of SSG1 in the nucleus.  However, Visconti et al. (40) reported 
seeing some nuclear-nucleolar localization of SSG1-GFP in 5-10% of cells.  The basis for 
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this apparent discrepancy in results is unknown.  However, the Visconti report of nuclear 
localization leaves open the possibility that SSG1, or an SSG1 cleavage product, can 
accumulate in the nucleus but only under certain conditions not met in our experiments.  
Visualizing SSG1-HA-myc, which has an HA tag just downstream of the putative signal 
sequence and a C-terminal myc tag, with αmyc and αHA revealed the same subcellular 
localization as each other and as SSG1-myc suggesting that SSG1 does not get cleaved, 
with one of the cleavage products going to the nucleus.  It also reveals that the HA tag 
does not interfere with protein folding and/or trafficking. 
 Although we observed co-precipitation of SSG1 with JAK2 and decreased 
expression of a c-fos promoter construct, suggesting a cellular function for SSG1, we 
were intrigued by the presence of a putative signal peptide in SSG1.  Literature reports 
were contradictory about whether this was a functional signal peptide resulting in the 
secretion of SSG1.  Bommer et al. (39) did not find SSG1 in conditioned medium of COS 
and 293 cells overexpressing human SSG1 assessed by western blot analysis.  Cha et al. 
(55) also failed to detect endogenous human SSG1 in conditioned medium of dermal 
papilla cells.  However, Liu et al. (42) reported detecting by western blot analysis the 
presence of overexpressed C-terminally tagged murine SSG1 in conditioned medium.  
Mu et al. (43) failed to detect C-terminally tagged Equarin-L in the medium but were able 
to detect Equarin-S.  Because of this controversy, we examined whether we could detect 
any secreted SSG1.  Using both western blot analysis of proteins that had been TCA 
precipitated from the medium of SSG1-HA-myc or SSG1-myc overexpressing cells and 
immunofluorescence of those cells fixed in the presence of medium, we readily detected 
extracellular SSG1.  The fact that Brefeldin A blocked the appearance of extracellular 
SSG1 assessed by either assay provides strong support for at least a portion of SSG1 
being secreted.  While this manuscript was being written, Okada et al. (56) also reported 
that they were able to detect SSG1 in the medium from cells stably expressing SSG1 as 
well as endogenous SSG1 secreted from cultured human adipocytes derived from adipose 
derived stromal cells. 
We observed that SSG1 in cell lysates migrates primarily as a tight band of Mr 
~120,000 whereas the soluble secreted SSG1 detected by immunoblotting migrates as a 
broad band of Mr~125,000-175,000.  This increased apparent molecular weight of 
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extracellular SSG1 along with its diffuseness suggests that secreted SSG1 is highly 
glycosylated.  Lui et al. (42) also saw this dual migration pattern of a tight band and a 
more diffuse, slower migrating band for murine SSG1.  SSG1 contains several predicted 
N-glycosylation sites.  Consistent with SSG1 being subject to N-linked glycosylation, Lui 
et al. (42) report that treatment of cells with tunicamycin, an inhibitor of N-linked 
glycosylation, reduced the amount of the diffuse SSG1 band but not of the faster 
migrating, tight SSG1 band.  Bommer et al. (39) also reported that treating cells with 
tunicamycin reduces the apparent molecular weight of cellular SSG1.  
The fact that we visualized extracellular SSG1 by fluorescent microscopy 
suggests that at least a portion of secreted SSG1 may bind to the extracellular matrix.  
Two other groups have reported results consistent with secreted SSG1 being in the 
extracellular matrix (42, 43).  This raises the possibility that SSG1 might be working 
locally as an autocrine or paracrine factor, along the lines of members of the FGF family, 
which are also reported to bind to extracellular matrix components (reviewed in (75)). 
By expressing the double tagged SSG1-HA-myc with an HA tag just downstream 
of the signal sequence and an N-terminal myc tag, we were able to show that cells secrete 
full-length SSG1.  In addition, we observed both a C-terminal fragment of SSG1 in cell 
medium that is recognized by αmyc and several N-terminal fragments recognized by 
αHA.  The N-terminal fragments migrated primarily as ~80 kDa and 40 kDa proteins, 
with presumably the 40 kDa fragment being a further proteolytic product of the 80 kDa 
fragment since both contain the HA tag.  The C-terminal fragment migrated primarily as 
a ~60 kDa fragment and sometimes as a ~40 kDa fragment.  SSG1 cleavage products 
have also been reported by others (39, 43, 56), although significant differences exist in 
the sizes of the fragments reported for both cell lysates and cell medium.  In our hands, 
SSG1 fragments were more reproducibly detected in the TCA precipitate from the 
medium than in cell lysates, suggesting that the cleavage occurs after SSG1 is secreted.  
There is precedence for secreted proteins being proteolyzed.  For example, secreted 
members of the FGF family of growth factors have been shown to be proteolyzed by 
proteases in the extracellular matrix (reviewed in (75)).  Of potential relevance is the 
finding that there are two alternatively spliced gene products of Equarin, one that encodes 
a long form (Equarin-L, 958 amino acids) and one that encodes a short form (Equarin-S) 
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that corresponds to the first 601 amino acids of Equarin-L.  Two human SSG1 transcripts 
have been identified; however, they are predicted to encode the same open reading frame; 
only one transcript has been reported for rat and mouse (38-42).  Thus, while it seems 
unlikely that there is a splice variant of rodent or human SSG1 equivalent to Equarin-S, it 
is possible that a short form equivalent to Equarin-S is produced by proteolytic cleavage.  
GH receptor provides precedence of a protein that exists in both a long and a short form 
with the short form being either the proteolytic cleavage product of the long form (e.g. 
human, rabbit) or the product of a separate transcript (e.g. mouse, rat) (76, 77).  
Identification of any protease(s) responsible cleaving SSG1 and the cleavage site(s) along 
with the fate of the cleavage product(s) would provide insight into whether secreted 
SSG1 functions as a full-length protein or one or more proteolytic cleavage products. 
 An intriguing question that arises from our work is how SSG1 can be secreted 
and also bind JAK2.  One possibility is that there are two separate pools of SSG1.  One is 
secreted and one is not.  In support of this, preliminary studies not shown using in vitro 
transcription and translation of SSG1 transcript in the presence and absence of 
microsomes showed that most SSG1 was not protected against proteolysis by trypsin, as 
would be expected if all the translated SSG1 were inside the microsomes as predicted for 
a secreted protein.  In contrast, secreted alkaline phosphatase was not degraded.  
Consistent with the presence of two pools of SSG1, there are reports in the literature that 
suggest that proteins containing a signal peptide can localize to the cytosol and Golgi as 
well as be secreted ((78-80) and reviewed in (81)).  Since SSG1 at least partially 
appeared to co-localize with JAK2 in the ER, our data raise the possibility that some 
SSG1 interacts with JAK2 in the ER without being full taken up into Golgi vesicles and 
subsequently secreted.  Preliminary data not shown also suggest that there may be a small 
pool of SSG1 that is cytoplasmic or even present at the plasma membrane that could 
interact with cytoplasmic JAK2.  The interaction of one of these pools of SSG1 with 
JAK2 may be important for the enhanced GH-dependent phosphorylation of Stat3 and/or 
decreased GH- and JAK2-dependent expression of the c-fos promoter construct.  Lavoie 
et al. (82) demonstrated that JAK2 has kinase activity in an in vitro microsome system 
replicating transitional ER membranes.  There are also reports in the literature 
demonstrating that JAK2 interacts with cytokine receptors in the ER and is important for 
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the processing and cell surface localization of cytokine receptors (83, 84).  Therefore, it is 
possible that SSG1 interacts with JAK2 in this cellular compartment. 
Intriguingly, our data reveal that SSG1 secretion is enhanced when SSG1 is co-
expressed with wild-type kinase-active JAK2 but not kinase-dead JAK2 (K882E) (Figs. 9 
and 10).  Because we have found that SSG1 forms a complex with kinase-active JAK2 
but not kinase-inactive JAK2 (K882E), it is tempting to speculate that this interaction is 
critical for the stimulatory effect of JAK2 on SSG1 secretion.  One can envision 
phosphorylation of SSG1 by JAK2 somehow enhancing SSG1 secretion from the cell, 
since JAK2 appears capable of phosphorylating SSG1 on tyrosines (O’Leary et al., 
manuscript in preparation).  There is a great deal of precedence for secreted proteins 
being phosphorylated, and that phosphorylation regulates the function of the secreted 
protein (85-87).  Our observation that the presence of wild-type but not kinase-dead 
JAK2 substantially increased the amount of cleaved SSG1 found in the medium raises the 
possibility that phosphorylation of secreted SSG1 increases its susceptibility to cleavage.  
If instead there are two pools of SSG1, the ability of JAK2 to bind SSG1 and to stimulate 
its secretion may be independent events.  This would allow for the possibility that JAK2 
promotes secretion of SSG1 indirectly by phosphorylating a protein involved in the 
trafficking or secretion of SSG1.  The fact that overexpression of JAK2 does not appear 
to enhance the secretion of another JAK2 binding protein, SRPX2 (data not shown), 
argues against the stimulatory effect of JAK2 on SSG1 secretion being a non-specific 
effect of JAK2 on secretion.   
JAK2 is activated by nearly two-thirds of the cytokine receptors including the 
leptin receptor.  SSG1 has a wide tissue distribution (38-40) with high expression in 
adipose tissue (56).  It seems likely that SSG1 plays a role in signaling not just by GH, 
but also by other ligands that bind to members of the cytokine family of receptors.  To 
support this hypothesis, Aoki et al. (41) reported that patterns of gene expression are 
similar for murine SSG1 and leptin, another cytokine that activates JAK2.  They 
demonstrated that SSG1 is expressed white and brown adipose tissue as well as in the 
chroid plexus in the brain, regions were the long form of the leptin receptor are also 
expressed (41).  They proposed that SSG1 plays a role in energy metabolism based on 
their finding that expression of SSG1 is upregulated in brown adipose tissue from 
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bombesin-receptor-subtype (BRS)-3-deficient mice which display mild obesity (41, 88).  
An inhibitory role of SSG1 on leptin-dependent gene expression would be consistent with 
this finding because BRS-3-deficient mice exhibit characteristics associated with reduced 
leptin signaling (obesity, hyperphagy and reduced metabolic rate) (88).  Further support 
that SSG1 may play a role in energy metabolism came from a study reporting that mouse 
models of obesity demonstrate a downregulation of SSG1 mRNA levels (56).  Okada et 
al. (56) proposes that this is not a function of SSG1 acting intracellularly.  Rather, they 
propose that SSG1 is a novel adipocytokine.  It is intriguing to speculate that secreted 
SSG1 may play a role in carbohydrate metabolism similar to other secreted proteins 
important in leptin signaling (i.e. adiponectin). 
It is intriguing to think that SSG1 may have dual functions: tumor suppressor and 
regulator of energy metabolism.  Indeed, SSG1 has been identified in multiple different 
screens assessing different functions in different cells and tissues.  In this study, we show 
that SSG1 does not affect JAK2 kinase activity or alter the phosphorylation of Stat5b.  
Rather, SSG1 enhances the tyrosyl phosphorylation of Stat3 and most likely a novel, 
unidentified site within Stat3.  SSG1 also negatively regulates c-fos gene expression, 
consistent with SSG1 functioning as a tumor suppressor.  SSG1 localizes to the ER and 
Golgi, with a portion co-localizing with wild-type JAK2.  We also report that SSG1 
contains a functional signal peptide resulting in SSG1 secretion, which is blocked with 
BFA.  When co-expressed with JAK2, SSG1 secretion is enhanced, as is proteolysis of 
the secreted SSG1.  Because SSG1 is highly expressed in adipose tissue and 
downregulated in obesity, secreted SSG1 may play a role in maintaining energy balance. 
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The abbreviations used are: BSA, bovine serum albumin; BFA, Brefeldin A; DMEM, 
Dulbecco’s modified Eagle’s medium; DRO1, down-regulated by oncogene1; drs, 
downregulated by Src; ER, endoplasmic reticulum; GH, growth hormone; JAK2, Janus 
kinase 2; PFA, paraformaldehyde; PAGE, polyacrylamide gel electrophoresis; PY, 
phosphotyrosine; SDS, sodium dodecyl sulfate; SOCS, suppressor of cytokine signaling; 
SSG1, steroid-sensitive gene-1; Stat, signal transducer and activator of transcription; 
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CONCLUSIONS & FUTURE DIRECTIONS 
 
Summary 
 JAK2 is an important signaling protein in GH signal transduction, yet few 
proteins have been identified as JAK2-interacting proteins.  Steroid-sensitive gene-1 
(SSG1) was identified in our lab as a novel binding protein of kinase-active JAK2 from a 
yeast two-hybrid screen of a rat adipocyte cDNA library.  SSG1 has also previously been 
identified by others using numerous different screens thus suggesting a potential role for 
SSG1 in a variety of functions including tumor suppression and regulation of energy 
metabolism.  However, these studies revealed very little about SSG1 at the cellular level.  
My hypothesis was that SSG1 is a multi-functional protein having a synergistic 
relationship with JAK2.  SSG1 regulates GH signaling by interacting with JAK2 thus 
affecting downstream GH-stimulated signaling molecules and gene expression.  
Conversely, JAK2 regulates the function of and cellular trafficking of SSG1. 
 
SSG1 as a JAK2 interacting protein 
 In Chapter II of this thesis, I describe the molecular basis for the interaction 
between JAK2 and SSG1.  This was of particular interest because SSG1 interacts 
preferentially with kinase-active JAK2; however SSG1 contains no known 
phosphotyrosine binding motifs.  Therefore, I characterized the regions of interaction 
within both SSG1 and JAK2.  In SSG1, I demonstrated that the three consensus regions, 
the SRPX5 domains, interact with kinase-active JAK2 but not kinase-inactive JAK2.  The 
SRPX5 domain was found to be necessary and sufficient for binding to kinase-active 
JAK2.  These results suggested that this domain may be a novel protein-protein 
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interaction domain.  To further support the hypothesis that the SRPX5 domain is a novel 
protein-protein interaction domain, I showed that SRPX2, another SRPX5 domain-
containing protein, interacts with kinase-active JAK2.  All three SRPX5 domains (D1, 
D2, and D3) of SSG1 interact with the JH1 kinase domain of JAK2.  The interaction of 
JH1 with D2 was the strongest, while the interaction with D1 was the weakest.  The 
finding that the SRPX5 domains interacted preferentially with the kinase-active form of 
JH1 compared to the kinase-inactive JH1 (K882E) and the kinase-active form of JAK2 
but not the kinase-inactive JAK2 (K882E) suggests that the SRPX5 domain may define a 
novel phosphotyrosine-binding domain. 
I also demonstrated that full-length SSG1 preferentially interacts with kinase-
active JAK2 compared to kinase-inactive JAK2.  When I tested the ability of SSG1 to 
bind to JH1 compared to full-length JAK2, I observed that SSG1 interacts with full-
length JAK2 better than JH1.  This result was not entirely surprising since all three of the 
SRPX5 domains of SSG1 bind JAK2.  This result suggested that there are at least two 
regions of interaction between SSG1 and JAK2, with one site of interaction within the 
JH1 domain and one site of interaction outside of the JH1 domain of JAK2.  Further, in 
Chapter III of this thesis, I was able to demonstrate that a portion of JAK2 co-localizes 
with SSG1 in the Golgi/ER compartment of the cell.  It has been reported that JAK2 has 
kinase activity in the ER (1), and therefore, it is possible that SSG1 complexes with 
JAK2 in the ER, resulting in JAK2 phosphorylating SSG1.  Previous data from our lab 
demonstrated that SSG1 is phosphorylated by JAK2 (2).  From the data presented in 
Chapter II of this thesis, I concluded that full-length SSG1 is a binding partner for full-
length, kinase-active JAK2 (Fig. 4.1). 
 
SSG1 as a regulator of Stat3 signaling 
 In Chapter II of this thesis, I showed that SSG1 binds JAK2 in a kinase-dependent 
manner.  To determine the physiological importance of the SSG1-JAK2 interaction, I 
examined whether SSG1 affects GH-stimulated signaling molecules in the JAK-Stat 
pathway, and regulates GH-induced gene expression.  I first looked to see if SSG1 affects 










Figure 4.1  Schematic representation of SSG1 as a JAK2 interacting protein. 
Full-length SSG1 is a binding partner for full-length kinase-active JAK2.  SSG1 interacts with kinase-
active JAK2 but not kinase-inactive JAK2 (K882E) via the SRPX5 domains within SSG1.  SRPX2, another 
SRPX5 domain-containing protein, also interacts with kinase-active JAK2. 
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does not alter JAK2 kinase activity.  I next looked at the downstream GH signaling 
molecules Stat3 and Stat5b.  GH-dependent phosphorylation of Tyr694, required for 
Stat5b transcriptional activation, was only modestly increased in the presence of SSG1.  
Interestingly, SSG1 substantially promoted the phosphorylation of tyrosine 705 of Stat3 
required for transcriptional activation, both in the absence and presence of GH 
stimulation.  Perhaps the most intriguing finding of this thesis project was that SSG1 also 
appears to promote the phosphorylation of a novel site in Stat3 as seen with the upward 
mobility shift of the Stat3 band in cells overexpressing SSG1 in the absence of GH 
stimulation.  Stat3 migrates as two distinct bands in control cells, and in the presence of 
SSG1 the apparent molecular weight of Stat3 increased.  λ phosphatase treatment 
reduced the migration of the two Stat3 in SSG1-expressing cells to that seen in control 
cells without altering phosphorylation of Tyr705.  Experiments using alkaline and λ 
phosphatases also reveal that Stat3 undergoes at least two post-translational modifications 
in addition to phosphorylation on Tyr705 and Ser727: one is present even in the absence 
of SSG1, accounting for the two bands detected by αStat3; the second is a 
phosphorylation that is enhanced by SSG1.  Expression of a c-fos promoter reporter 
construct, which contains a Stat1/Stat3 binding site, was negatively regulated in cells 
overexpressing SSG1.  This finding suggests that SSG1 may blunt Stat3 activity perhaps 
as a consequence of this novel phosphorylation.  The inhibition of Stat3 would be 
consistent with SSG1 functioning as a tumor suppressor.  Constitutive activation of the 
Stat3 pathway has been linked with numerous cancers ((3-7) reviewed in (8, 9)).  SSG1’s 
proposed role as a tumor suppressor is based on several findings.  Bommer et al. (10) 
demonstrated that overexpression of SSG1 in colorectal and pancreatic cancer cell lines 
leads to the inhibition of malignant growth and suppression of anchorage independent 
growth.  SSG1 has been reported to be downregulated a number of cancer cell lines and 
tumors including thyroid, ovarian carcinoma, pancreatic and colon cancer (10, 11).  
Taken together, these findings support my hypothesis that SSG1 regulates GH signaling 
by interacting with JAK2 and affecting downstream GH-stimulated signaling molecules 










Figure 4.2  Schematic representation of SSG1 as a regulator of Stat signaling. 
SSG1 binds JAK2 in a kinase-dependent manner, but does not affect JAK2 kinase activity.  SSG1 only 
modestly increases phosphorylation of Tyr694 of Stat5b.  SSG1 promotes the phosphorylation of Tyr705 in 
Stat3 in the absence and presence of GH stimulation.  SSG1 does not affect the phosphorylation of Ser727 
of Stat3, but SSG1 appears to promote the phosphorylation of a novel site in Stat3.  SSG1 negatively 
regulates c-fos gene expression. 
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SSG1 as a secreted protein 
 In Chapter III of this thesis, I also show that JAK2 may regulate the secretion of 
SSG1.  SSG1 contains a functional signal peptide.  I demonstrated that SSG1 is a 
secreted protein from cells overexpressing epitope-tagged SSG1 as SSG1 is found in the 
medium.  Secreted SSG1 migrated as a diffuse band corresponding to a molecular weight 
of ~125,000-175,000 compared to a tighter, faster migrating band of ~120,000 observed 
in the cell lysate.  This suggests that SSG1 undergoes post-translational modifications 
before being secreted and is consistent the presence of predicted N-glycosylation sites 
within SSG1.  I was able to block the appearance of SSG1 in the medium completely by 
treating the cells with Brefeldin A, an inhibitor of the constitutive secretory pathway.  
When SSG1 was co-expressed with wild-type JAK2, more SSG1 was detected in the 
medium of JAK2 overexpressing cells compared to control cells.  This SSG1 came in the 
form of full-length SSG1 as well as cleaved SSG1, with the combined amount of these 
bands being greater when the cells co-expressed JAK2 than when SSG1 was expressed 
alone or with kinase-dead JAK2 (K882E).  These results suggest that JAK2 enhances the 
secretion and possibly the cleavage of SSG1.  SSG1 cleavage products were most 
commonly seen when looking at secreted SSG1.  While SSG1 has protease cleavage 
sites, our data suggest that most of the proteolytic cleavage of SSG1 occurs once SSG1 
has been secreted from the cell.  There are reports in the literature that trafficking of 
cytokine receptors to the membrane requires interaction with JAK2 in the ER/Golgi, with 
JAK2 being important for the processing and cell surface localization of cytokine 
receptors (12, 13).  It has also been reported that JAK2 has kinase activity in the ER (1).  
Our findings that SSG1 co-immunoprecipitates with kinase-active JAK2 and that JAK2 
partially co-localizes with SSG1 in what appears to be the ER/Golgi complex suggest that 
SSG1 and JAK2 may functionally interact in the ER/Golgi.  Previous data from our lab 
demonstrated that SSG1 is phosphorylated by JAK2 (2).  It is possible that JAK2 
phosphorylation of SSG1 enhances the activity of secreted SSG1 or its susceptibility to 
proteases.  Therefore, it is possible that SSG1 is phosphorylated by JAK2 in the ER and 
that this phosphorylation aids in the enhanced processing/secretion of SSG1.  Taken 
 151 
together, these findings support my hypothesis that JAK2 regulates the secretion and 
processing of SSG1 (Fig. 4.3). 
 
Future Directions 
 This thesis project leaves many questions unanswered.  The potential that SSG1 
has both an intracellular function as well as extracellular function is interesting.  The 
following future directions probe both the interaction between SSG1 and JAK1 as well as 
the potential that secreted SSG1 may have a physiological role. 
 
SSG1 interaction with JAK2 
Does SSG1 interact with JAK2 in vivo? 
 In Chapter II of this thesis, I demonstrated that full-length SSG1 and JAK2 
interact in an overexpression system.  Because both JAK2 and SSG1 are expressed in 
adipose tissue and SSG1 was identified from a yeast two-hybrid screen of a rat adipocyte 
cDNA library, we would predict that endogenous SSG1 and JAK2 would interact in vivo 
in adipocytes.  To test this hypothesis, 3T3-F4442A preadipocytes, which express 
endogenous SSG1 (preliminary data, not shown), would be treated with GH to activate 
JAK2.  JAK2 would then be immunoprecipitated and immunoprecipitates would be 
immunoblotted with αSSG1 to detect GH-dependent JAK2-SSG1 interaction in vivo.  If 
we are unable to detect this interaction in preadipocytes, preadipocytes will be 
differentiated into adipocytes, which have a higher level of expression of SSG1 than 
preadipocytes (preliminary data, not shown).  Our data suggest that SSG1 is mostly 
secreted from these cells, and as a result, we can detect a minimal amount of SSG1 in the 
cell lysate, which might make detecting the interaction of SSG1 with JAK2 difficult.  
Thus, it may be necessary to use multiple plates of cells to detect the interaction of 
endogenous SSG1 with endogenous JAK2.  It may also be possible to increase 
intracellular levels of SSG1 using Brefeldin, A which causes SSG1 to accumulate in the 










Figure 4.3  Schematic representation of SSG1 as a secreted protein. 
SSG1 contains a functional signal peptide resulting in SSG1 secretion.  SSG1 secretion and proteolytic 
processing, resulting in cleavage fragments of SSG1, is enhanced in the presence of wild-type JAK2.  




JAK2.  We have a limited amount of the αSSG1 antibody; therefore, we may need to 
make a new, high affinity antibody to SSG1 for these experiments to be successful. 
 
Does the SRPX5 domain represent a novel phosphotyrosine-binding domain? 
 In Chapter II of this thesis, I demonstrated that all three of the SRPX5 domains in 
SSG1 interacts with the activated form of JAK2 as well as the activated JH1 kinase 
domain of JAK2.  From these results, we predict that the SRPPX5 domain represents a 
novel phosphotyrosine-binding domain.  Definitive proof for the hypothesis of the 
SRPX5 domain being a phosphotyrosine-binding domain will come from solving the 
crystal structure of the SRPX5 domain in complex with a phosphopeptide.  Additional 
support for this hypothesis would be obtained by showing that the isolated SRPX5 
domain of SRPX2 and the SRPX5 domain of SRPX also bind to the kinase-active JAK2 
and not to the kinase-inactive JAK2.  Identification of the tyrosine (or tyrosines) within 
JAK2 that bind the SRPX5 domain would also provide additional support. 
 
The role SSG1 plays in Stat3 phosphorylation 
Identify the novel site of phosphorylation on Stat3 and determine its function. 
 In Chapter III of this thesis, I demonstrate that SSG1 promotes the 
phosphorylation of Stat3 on Tyr705 as well as the phosphorylation of another residue 
within Stat3.  To determine the novel phosphorylation site in Stat3, cDNA encoding Stat3 
will be overexpressed in 293T cells in the presence or absence of SSG1-myc and rat GH 
receptor.  Cells will be incubated in serum-free medium overnight and stimulated with 
GH for 15 min.  Phospho-Stat3 will be purified from cell lysates and analyzed by mass 
spectroscopy to identify the novel site of phosphorylation seen in the presence of SSG1.  
Several candidates exist as sites of this novel phosphorylation, though SSG1 may 
promote the phosphorylation of a completely novel, uncharacterized residue.  Potential 
sites of Stat3 phosphorylation identified by mass spectroscopy include:  Thr268 (14), 
Ser269 (14), Ser273 (14), Tyr539 (15, 16), Tyr686 (16, 17), Ser691 (18).  If mass 
spectroscopy fails to identify this novel phosphorylation site, two dimensional 
 154 
phosphopeptide mapping combined with site-directed mutagenesis can be done to see if 
any of the above sites is the site of SSG1-regulated phosphorylation in Stat3.  
Identification of this site will allow us to create non-phosphorylatable mutants by site-
directed mutagenesis as well as mutants that mimic phosphorylation if this site is a Ser or 
Thr.  These mutants will be useful tools to determine the function of this novel 
phosphorylation site in Stat3.  The characterized post-translational phosphorylation sites 
within Stat3 (i.e. Ser727 and Tyr705) have been shown to play a role in protein-protein 
interaction, nuclear translocation, DNA binding, and transcriptional activation resulting 
in regulation of apoptosis, the cell cycle, and cell growth.  Therefore, these mutant 
constructs will allow us to determine if this novel site also plays a role in any of these 
functions using the appropriate assay to test the specific function. 
 
Does the novel phosphorylation site on Stat3 impair Stat3 dimer formation? 
 Once this novel phosphorylation site has been identified, it will be important to 
determine if it plays a role in any of the downstream events of activated Stats:  
dimerization, translocation, DNA binding, transcriptional activation.  To determine if this 
novel phosphorylation site on Stat3 interferes with Stat3 dimer formation, Stat3 mutant 
constructs will be made in which the phosphorylation site has been mutated to the 
appropriate non-phosphorylated amino acid analog.  Additionally, if this site is a Ser or 
Thr, mutants that mimic phosphorylation will be created.  Both mutant and wild-type 
Stat3 proteins will be tagged with FLAG or with myc.  Combinations of mutant and wild-
type differentially tagged Stat3 constructs will be overexpressed in 293T cells in the 
absence or presence of SSG1 and rat GH receptor.  GH will be added, FLAG-Stat3 will 
be immunoprecipitated with αFLAG, and immunoprecipitates will be immunoblotted 
with αmyc.  Co-immunoprecipitation of the differentially tagged wild-type constructs 
will serve as positive controls for dimer formation.  A finding that the differentially 
tagged wild-type Stat3 proteins do not co-immunoprecipitate in the presence of SSG1 
would suggest that SSG1 prevents the association between the two Stat3 molecules.  An 
additional finding that the mutated Stat3 proteins lacking the proposed site of SSG1-
induced phosphorylation can dimerize in response to GH would provide evidence that the 
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SSG1-dependent phosphorylation site is responsible for lack of dimerization of wild-type 
Stat3 in SSG1 overexpressing cells.  If dimers are unable to form in the presence of SSG1 
as a result of this novel phosphorylation, activated Stat3 might not be able to translocate 
to the nucleus to initiate gene transcription.  This would support the results in Chapter III 
of this thesis where I demonstrate that SSG1 negatively regulates c-fos gene transcription. 
 
Does the novel phosphorylation inhibit Stat3 translocation to the nucleus? 
If SSG1 does not affect Stat3 dimer formation, I would next test whether SSG1 
prevents Stat3 dimers from translocating to the nucleus.  cDNA encoding wild-type or 
mutant GFP-tagged Stat3 will be transfected into COS-7 cells along with cDNA encoding 
rat GH receptor in the presence or absence of cDNA encoding SSG1.  Cells will be 
grown on coverslips and incubated in serum-free medium overnight and then stimulated 
with GH for 15 min.  GH rapidly promotes the phosphorylation of Stat3 and its 
accumulation in the nucleus.  Nuclear accumulation of GFP-Stat3 in living cells can be 
visualized by fluorescent microscopy.  Cells can also be fixed, stained for pTyr705-Stat3 
(in red) and visualized to determine nuclear accumulation of the pTyr705 Stat3 dimers.  
A finding that wild-type Stat3 fails to accumulate in the nucleus in the presence of SSG1 
would suggest that this novel phosphorylation promoted by SSG1 interferes with the 
nuclear accumulation of Stat3.  Further support would come from experiments where the 
mutant GFP-Stat3 lacking the proposed site of phosphorylation is able to translocate to 
the nucleus in the presence of SSG1 suggesting that SSG1-dependent phosphorylation is 
important for the nuclear translocation of Stat3.  Taken together, these results would be 
consistent with the novel phosphorylation site in Stat3, promoted by the presence of 
SSG1, interfering with the nuclear accumulation of Stat3.  However, if wild-type GFP-
Stat3 still accumulates in the nucleus in the presence of SSG1, this would suggest that 
this novel phosphorylation site is not important for the nuclear translocation of Stat3. 
If the immunocytochemistry results are ambiguous, 293T cells will be co-
transfected with cDNA encoding wild-type and mutant FLAG-Stat3 and rat GH receptor 
in the presence or absence of SSG1.  Cells will be incubated in serum-free medium 
overnight and stimulated with GH for 15 min.  Nuclear and cytoplasmic fractions will be 
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harvested and samples will be immunoblotted with αpTyr705-Stat3 to determine if SSG1 
prevents nuclear accumulation of pTyr705-Sat3 and whether this can be attributed to the 
novel phosphorylation site in Stat3.  A finding of less wild-type pTyr705-Stat3 in the 
nuclear fraction of SSG1-expressing cells compared to control cells would be consistent 
with the novel phosphorylation site in Stat3 promoted by SSG1 interfering with the 
nuclear accumulation of Stat3.  Further support that SSG1-dependent phosphorylation of 
Stat3 is important for the nuclear translocation of Stat3 would be if mutant GFP-Stat3 is 
detected in the nuclear fraction in the presence of SSG1. 
In this series of experiments, a finding that wild-type Stat3 is not seen in the 
nucleus upon GH stimulation when SSG1 is co-expressed would suggest SSG1 interferes 
with nuclear translocation of Stat3.  If wild-type Stat3 is still able to translocate to the 
nucleus in the nucleus, this would suggest that function of the novel phosphorylation site 
in Stat3 is not related to nuclear translocation. 
 
Does SSG1 alter Stat3 binding to the promoter of target genes? 
 Another important function of Stat3 is the ability of Stat3 dimers to bind to DNA 
to regulate gene transcription.  If SSG1 does not alter the ability of Stat3 to dimerize or 
translocate to the nucleus, it is possible SSG1 alters the ability of the Stat3 dimer to bind 
to DNA.  To test this hypothesis, I performed electrophoretic mobility shift (EMSA) 
assays using the m67 region of the SIE as a probe for Stat3 binding.  I overexpressed 
cDNA encoding FLAG-Stat3 and rat GH receptor in the presence and absence of cDNA 
encoding SSG1 in 293T cells.  I prepared nuclear extracts and performed a radioactive 
EMSA to look at the ability of Stat3 to bind DNA in the presence and absence of SSG1.  
Unfortunately, I was unable to conclude if the presence of SSG1 had any effect on the 
ability of Stat3 to bind DNA.  The amounts of Stat3 I had to overexpress to detect Stat3 
binding to the probe no longer demonstrated the SSG1-dependent phosphorylation 
detected by immunoblotting, presumably due to saturation of a rate-limiting endogenous 
protein. 
As an alternative, chromatin immunoprecipitation (Chip) assays, which also test 
the ability of proteins to bind DNA, may be able to be performed.  Again, the levels of 
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proteins needed to detect this interaction may be an important limitation.  Therefore, it 
may be necessary to perform the Chip assay in 3T3-F442A cells where endogenous 
SSG1 has been knocked down and compare the ability of endogenous Stat3 to bind c-fos 
in the presence and absence of endogenous SSG1 using an antibody to total Stat3.  In this 
experiment, if SSG1 is affecting the ability of Stat3 to bind c-fos, I would predict that less 
Stat3 would be detected in the presence of endogenous SSG1 compared to when SSG1 is 
knocked down.  This would be consistent with SSG1 interfering with Stat3’s ability to 
bind DNA due to the phosphorylation promoted by SSG1.  Because SSG1 is expressed in 
the liver (19), GH-responsive liver cell lines lacking endogenous Stat3 can be obtained.  
Wild-type or mutant Stat3 could be introduced into these cells, and then stimulated with 
GH.  A Chip assay using total Stat3 antibody will be performed comparing the ability of 
wild-type and mutant Stat3 to bind c-fos in the presence of endogenous SSG1.  In these 
experiments, a finding that wild-type Stat3 fails to bind to DNA upon GH stimulation 
when SSG1 is co-expressed would suggest SSG1 interferes with the ability of Stat3 to 
bind DNA.  If mutant Stat3 is able to bind DNA, this would support the hypothesis that 
SSG1-dependent phosphorylation is important in regulating the ability of Stat3 to bind 
DNA.  If wild-type Stat3 in the presence of SSG1 is still able to bind DNA, it would 
suggest that SSG1 may be interfering with other transcriptional machinery to negatively 
regulate gene transcription. 
 
Does Stat3 enhance or inhibit other GH-regulated genes in the presence of SSG1? 
 To determine the effect of SSG1 on Stat3-regulated gene expression, I would 
compare gene expression profiles of Stat3-mediated genes from 3T3-F442A cells 
expressing endogenous SSG1 to cells with SSG1 knocked down.  Cells would be 
incubated in serum-free medium overnight and stimulated with GH to activate JAK2, 
which, in turn, would activate Stat3.  RNA would be harvested from these cells and 
expression of established Stat3-regulated genes would be analyzed by QT-PCR.  If SSG1 
negatively affects the Stat3 signaling pathway, I would predict that a subset of Stat3-
mediated genes would have reduced expression when SSG1 is expressed compared to 
cells in which SSG1 has been knocked down. 
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SSG1 and signaling 
Does SSG1 influence other signaling pathways activated by GH? 
 In Chapter III of this thesis, I demonstrate that SSG1 affects phosphorylation of 
Stat3.  SSG1 also modestly affects the phosphorylation of Stat5b on Tyr694, another 
important transcription factor activated in response to GH stimulation.  GH stimulation 
also leads to the activation of the Ras-MAPK and PI-3K/Akt pathways.  To determine if 
SSG1 affects other signaling pathways activated by GH, cDNA encoding SSG1-myc will 
be stably overexpressed in 3T3-F442A cells.  Cells will be incubated in serum-free 
medium overnight and stimulated with GH for different lengths of time.  Cell lysates will 
be prepared and immunoblotted with αpERK1/2 and αpAkt.  The presence of SSG1 may 
or may not affect the activation of these pathways. 
Additionally, these pathways activate transcription factors important in regulating 
c-fos gene transcription.  For instance, the transcription factor C/EBPβ is phosphorylated 
on Thr188 by MAPK in response to GH (20), and mutation of this site results in 
inhibition of c-fos gene transcription suggesting that phosphorylation of this site in 
C/EBPβ is necessary for maximal transcriptional activation (20).  Therefore, it will be 
interesting to determine if SSG1 plays a role in other signaling pathways activated by 
GH, which may shed some light on the results presented in Chapter III in which SSG1 
negatively regulates c-fos gene transcription. 
 
Does knock down of SSG1 alter phosphorylation and signaling of Stat3?  Other signaling 
pathways activated by GH? 
 I have demonstrated that overexpressed SSG1 alters the GH-induced Stat3 
signaling pathway.  It will be interesting to determine what happens to signaling 
pathways when SSG1 is knocked down.  To test this hypothesis, SSG1 RNAi constructs 
will be engineered and stably introduced into 3T3-F442A cells to knock down 
endogenous levels of SSG1.  Control cell lines will also be created for comparison.  Cells 
will be incubated in serum-free medium overnight and then stimulated with GH.  Lysates 
 159 
will be immunoblotted with antibodies for: pTyr705-Stat3, pTyr694-Stat5b, pERK1/2 
and pAkt to determine if knockdown of SSG1 has any effect on these GH signal 
transduction pathways.  If endogenous SSG1 is knocked down, then I would predict that 
phosphorylation of Tyr705 of Stat3 after GH stimulation would not be different 
compared to phosphorylation of Tyr705 in the presence of endogenous SSG1, nor would 
Stat3 be phosphorylated on this novel residue.  However, it is possible that this novel 
phosphorylation in the presence of SSG1 primes Stat3 allowing for the enhanced 
phosphorylation of Tyr705.  If this is the case, I would predict that knocking down SSG1 
may reduce the levels of phosphorylation of Tyr705 of Stat3.  Additionally, if SSG1 
affects the MAPK and/or PI-3K/Akt pathways (tested above), I would expect to see 
changes in these pathways when SSG1 is knocked down.  To determine the effect of 
SSG1 on gene expression mediated by activation of these pathways, I would compare 
gene expression profiles from 3T3-F442A cells expressing endogenous SSG1 to cells 
with SSG1 stably knocked down.  Cells would be incubated in serum-free medium 
overnight and stimulated with GH.  RNA would be harvested from these cells and gene 
expression would analyzed by QT-PCR.  If SSG1 negatively affects these signaling 
pathways, I would predict that a subset of genes would have reduced expression when 
SSG1 is expressed compared to cells in which SSG1 has been knocked down. 
SSG1 has been shown to be upregulated in adipose tissue (21, 22).  Therefore, it 
will be interesting to determine if SSG1 knock down cells can be differentiated into 
adipocytes.  Control cell lines and SSG1 knockdown cell lines will be differentiated into 
adipocytes and stained with Oil Red-O to determine if knockdown of SSG1 has any 
effect on the ability of preadipocytes to differentiate into adipocytes.  QT-PCR analysis 
on other adipocyte specific genes can also be performed to see if relative amounts of gene 
expression are altered when SSG1 is knocked down. 
 
Does SSG1 influence cell migration or cell motility? 
 SSG1/CL2/DRO1 was found to be downregulated in human carcinoma cell lines 
and tumors suggesting that SSG1 may function as a tumor suppressor (10, 11).  Bommer 
et al. (10) demonstrated that ectopic expression of SSG1/DRO1 in cancer cell lines 
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reduced colony formation, growth in soft agar, and inhibited anchorage-independent cell 
growth.  Therefore, it would be interesting to see if SSG1 affects the ability of cells to 
migrate in the presence or absence of growth hormone.  GH has been shown to promote 
cell motility (23, 24).  To test this hypothesis, I would perform a migration assay 
comparing control cells and SSG1-expressing cells or control cells and SSG1 knockdown 
cells.  Cells would be transfected with control vector or cDNA encoding full-length 
SSG1.  Alternatively, SSG1 knockdown cells can also be used as a control for cells 
expressing endogenous levels of SSG1.  Cells would be grown to confluency, wounded, 
incubated in serum-free medium overnight, and then stimulated with or without GH.  The 
ability of cells to migrate into the wound would be assessed and compared for control and 
SSG1-expressing cells and/or SSG1 knockdown cells.  A decrease in migration of SSG1 
expressing cells would be consistent with SSG1 functioning as a tumor suppressor. 
 
Is SSG1 involved in other cytokine signaling pathways? 
 JAK2 is activated by nearly two-thirds of the cytokine receptors including the 
leptin receptor, and it has been reported that SSG1 has a wide tissue distribution (10, 11, 
19) with high expression in adipose tissue (22).  Therefore, it seems likely that SSG1 
plays a role in signaling not just by GH, but also by other ligands that bind to members of 
the cytokine family of receptors.  To support this hypothesis, Aoki et al. (21) reported 
that patterns of gene expression are similar for murine SSG1 and leptin, another cytokine 
that activates JAK2.  They demonstrated that SSG1 is expressed in white and brown 
adipose tissue as well as in the chroid plexus in the brain, regions where the long form of 
the leptin receptor is also expressed (21).  They proposed that SSG1 plays a role in 
energy balance based on their finding that expression of SSG1 is upregulated in brown 
adipose tissue from bombesin receptor subtype (BRS)-3-deficient mice which display 
mild obesity (21, 25).  An inhibitory role of SSG1 on leptin-dependent gene expression 
would be consistent with this finding because BRS-3-deficient mice exhibit 
characteristics associated with reduced leptin signaling (obesity, hyperphagy and reduced 
metabolic rate) (25). 
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To examine whether SSG1 is involved in signaling by leptin, we can take 
advantage of the leptin (L. Rui) or EPO/leptin (M. Myers) systems developed by our 
collaborators at the University of Michigan.  These stable cell lines expressing either the 
leptin receptor or the EPO-leptin chimeric receptor (EPO ligand binding and 
transmembrane domains fused to the intracellular leptin receptor) are useful tools in 
studying leptin signaling.  Leptin activates Stat3 (26), and these tools will help to 
determine if SSG1 can also influence Stat3-mediated gene expression by another 
cytokine other than GH.  To test the hypothesis that SSG1 regulates leptin-stimulated 
gene expression, I would overexpress SSG1-myc or vector in either of these cell lines.  
Cells would be incubated in serum-free medium overnight and stimulated with the 
appropriate ligand to activate the associated JAK2 molecules, which in turn, would 
activate Stat3.  RNA would be harvested from these cells and expression of Stat3-
regulated genes would be analyzed by QT-PCR.  If SSG1 also negatively affects the 
Stat3 signaling pathway in the leptin system, I would predict that a subset of Stat3-
mediated genes would have reduced expression when SSG1 is overexpressed.  I would 
also test the effect SSG1 has on leptin signaling and gene expression using the siRNA 
constructs created above.  I would predict that leptin-stimulated Stat3-mediated gene 
transcription would be unchanged or possibly elevated when SSG1 has been knocked 
down. 
 
Does SSG1 interact with JAK family members or other receptor tyrosine kinases? 
 In Chapter II of this thesis, I demonstrated that full-length SSG1 interacts 
preferentially with activated JAK2 but not kinase-dead JAK2.  It would be interesting to 
determine if SSG1 is a binding partner for the other JAK family members or activated 
receptor tyrosine kinases.  The experimental design would be the same as that used for 
JAK2.  Briefly, SSG1-myc would be overexpressed in 293T cells with or without the 
JAK family member.  JAK would be immunoprecipitated with JAK specific antibody and 
immunoprecipitates would be immunoblotted with αmyc for SSG1.  If SSG1 interacted 
with any of the JAK family members, preferential binding to the kinase-active form 
would be assessed by overexpressing SSG1 alone or in the presence of activated JAK or 
 162 
kinase-dead JAK2.  Similar experimental design would be used to determine if SSG1 is a 
binding partner for receptor tyrosine kinases.  In these experiments, ligand-activated or 
constitutively activated forms of the receptors would be used.  In these sets of 
experiments, I would predict that SSG1 would interact with activated forms of the JAK 
family members and potentially interact with the activated forms of the receptor tyrosine 
kinases. 
 Because SSG1 interacts with kinase-active JAK2 and I hypothesize that the 
SRPX5 domain is a novel phosphotyrosine binding domain, it will be useful to determine 
which phosphotyrosines in JAK2 are responsible for binding SSG1.  To identify these 
phosphorylated tyrosine(s) in JAK2 is responsible for binding to SSG1, immobilized 
peptides containing non-phosphorylated or phosphorylated tyrosines from JAK2 will be 
used.  Lysates from cells overexpressing SSG1 will be incubated with these JAK2 
peptides.  We predict that SSG1 will interact with some of the phosphorylated peptides 
but not the non-phosphorylated peptides of JAK2. 
 
Secreted SSG1 
Is secreted SSG1 phosphorylated on tyrosines? 
 Previous data from our lab demonstrated that SSG1 is phosphorylated by JAK2 
(2).  In Chapter III of this thesis, I demonstrated that SSG1 is a secreted protein.  Because 
it has been reported that JAK2 has kinase activity in the ER (1), it is possible that SSG1 
is phosphorylated by JAK2 in this subcellular compartment prior to secretion.  It will be 
interesting to determine if secreted SSG1 is phosphorylated on tyrosines.  To test this 
hypothesis, SSG1-myc will be co-expressed with FLAG-tagged JAK2 or JAK2 (K882E) 
in 293T cells.  Medium will be changed to 1% serum ten hours post-transfection and 
collected after 16 h of incubation with the cells.  Phosphatase inhibitors will be added to 
the medium and proteins will be precipitated using TCA.  The precipitated proteins will 
be resolved by SDS-PAGE and immunoblotted with αpY to determine if secreted SSG1 
is phosphorylated.  If my hypothesis is correct, I would expect to see phosphorylated 
SSG1 secreted when co-expressed with wild-type JAK2 but not when co-expressed with 
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JAK2 (K882E).  If I cannot definitively say if the band detected is indeed, 
phosphorylated SSG1, I can purify secreted SSG1 and blot with αpY. 
 
Does GH stimulate the secretion of SSG1? 
 As shown in Chapter III of this thesis, SSG1 secretion from 293T cells was 
enhanced when JAK2 was co-expressed but not when JAK2 (K882E) was expressed.  
Secretion was also blocked when cells were treated with Brefeldin A.  It will be 
interesting to see if GH promotes secretion of SSG1.  Initially, I would co-transfect 293T 
cells with cDNA encoding rat GH receptor in the presence or absence of SSG1.  Cells 
would be incubated in serum-free medium overnight and then stimulated with GH.  
Medium from transfected cells would be collected, proteins in the medium would be 
precipitated with TCA, and samples would be immunoblotted with αmyc to see SSG1 
secreted into the medium.  The caveat to this experiment is that large amounts of SSG1 
seem to be secreted in the basal state; therefore, an increase may not be detected when 
cells are stimulated with GH.  Because I do not know how long cells must be stimulated 
with GH, I would do a GH timecourse and look to see if secretion of SSG1 is altered with 
varying times of GH treatment.  This experiment can also be performed in GH-treated 
3T3-F442A preadipocytes, which express endogenous SSG1, using an antibody to detect 
SSG1.  The SSG1 knock down stable cell line could also serve as a negative control since 
no SSG1 is expressed, there will be no SSG1 secretion. 
 
Is secreted SSG1 able to enter cells?  Are there SSG1 receptors?  What is the function of 
this intracellular SSG1? 
 Because SSG1 is a secreted protein, it is intriguing to speculate that SSG1 
interacts with a cell surface receptor and/or is internalized and therefore has an 
intracellular function.  Eventually, I would like to determine if there are cell surface 
receptors for SSG1 and/or if SSG1 or an SSG1 cleavage product gets internalized into 




What are the proteases that cleave SSG1? 
 In Chapter III of this thesis, I demonstrate that secreted SSG1 is seen both as a 
full-length protein as well as a series of N- or C-terminal truncated proteins.  Because 
secreted SSG1 was seen as both a full-length protein as well as these various cleavage 
products, I hypothesize that the majority of proteolytic cleavage occurs once SSG1 has 
been secreted.  SSG1 cleavage products were most often seen when visualizing secreted 
SSG1; however, SSG1 truncation products were also seen in the cell lysate, suggesting 
that some intracellular proteases are also able to recognize and cleave SSG1 inside the 
cell.  It will be interesting to determine whether cleavage is physiological or adventitious 
and if physiological, what proteases cleave full-length SSG1 into these N- and C-terminal 
fragments and whether cleavage cleavage products have distinct functions. 
 
Physiological function of SSG1 
What is the physiological role for SSG1 in vivo? 
One way to determine the physiological role for SSG1 would be to generate SSG1 
knockout mice.  Because SSG1 has a wide tissue distribution and seems to have several 
possible functions, including a role in embryogenesis (27), conditional knockout mice 
with SSG1 deleted in particular tissues will help to determine the tissue-specific function 
of SSG1 in adult mice.  For instance, a mouse with SSG1 conditionally deleted in adipose 
tissue would help determine the role SSG1 plays in energy metabolism.  Likewise, a 
conditional knockout in bone will help determine if SSG1 plays a role in bone formation.  
These mice would be valuable tools to examine the physiological effects of SSG1 in vivo. 
 
What role, if any, does secreted SSG1 play in adipogenesis and osteoblastogenesis? 
SSG1 has high expression in adipose tissue (22) and is down regulated in bone 
(27).  These tissues are derived from a common progenitor cell.  Therefore, it is not 
surprising that a subset of genes is upregulated in one tissue that is downregulated in the 
other.  Wnt10b is a secreted protein that inhibits adipogenesis and stimulates 
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osteoblastogenesis (reviewed in (28)).    To test whether SSG1 stimulates adipogenesis 
and inhibits osteoblastogenesis, adipose and bone tissue from the SSG1 conditional, 
whole-body knockout mice will be analyzed for difference in fat depots as well as bone 
density compared to wild-type controls.  To determine if SSG1 expression plays a role 
the in fate determination of these cells, SSG1 knockdown cells can be differentiated into 
adipocytes or osteoblasts and the rate of differentiation compared to control cells.  I 
would predict that cells expressing SSG1 would differentiate into adipocytes, but that 
these cells may not differentiate into osteoblasts as well as control cells.  In contrast, I 
would predict that cells in which SSG1 has been knocked down would differentiate into 
osteoblasts more robustly than control (+ SSG1) cells.  Similarly, it would be interesting 
to determine if cells treated with purified SSG1 would differentiate into adipocytes, and 
conversely, if cells treated with purified SSG1 would inhibit differentiation into 
osteoblasts. 
Because SSG1 is upregulated in adipose tissue (22), is expressed in regions of the 
brain similar as the leptin receptor (21), and is a secreted protein, it is tempting to 
speculate that secreted SSG1 may function in maintaining energy balance.  Further 
support that SSG1 may play a role in energy metabolism came from a study reporting 
that mouse models of obesity demonstrate a downregulation of SSG1 mRNA levels in 
adipose tissue (22).  Okada et al. (22) propose that SSG1 is a novel adipocytokine.  It is 
intriguing to speculate that secreted SSG1 plays a role in carbohydrate metabolism 
similar to other secreted proteins such as leptin and adiponectin. 
 
Conclusion 
In this thesis, I have examined the cellular function of SSG1 (Fig. 4.4).  I first 
demonstrated that SSG1 interacts with activated JAK2.  SSG1 promotes the GH-
dependent phosphorylation of Tyr705.  It also appears to stimulate phosphorylation of a 
novel residue on Stat3.  SSG1 appears to negatively regulate c-fos gene expression.  I 
also showed that SSG1 localizes to the ER and Golgi, and that a portion of JAK2 co-
localizes with SSG1.  SSG1 contains a functional signal peptide resulting in SSG1 










Figure 4.4  Model of SSG1 in GH Signal Transduction. 
SSG1 interacts with kinase-active JAK2, but does not alter the kinase activity of JAK2.  SSG1 promotes 
phosphoryation of Tyr705 in Stat3 in the absence and presence of GH stimulation.  SSG1 also appears to 
stimulate the phosphorylation of a novel residue on Stat3.  SSG1 contains a functional signal peptide 
resulting in SSG1 secretion.  JAK2 enhances the secretion and proteolytic processing of SSG1. 
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secretion is enhanced as is the detection of proteolytic cleavage products.  SSG1 does not 
appear to be cleaved into products that function in different parts of the cell.  Because 
SSG1 is highly expressed in adipose tissue and downregulated in obesity, secreted SSG1 
may play a role in maintaining energy balance.  Taken together, with published results, 
these results support the hypothesis that SSG1 is a multi-functional protein.  SSG1 
interacts with JAK2.  Conversely, JAK2 regulates the function of and cellular trafficking 
of SSG1.  It will be interesting to determine if the SRPX5 domain is a novel 
phosphotyrosine binding domain and the physiological function of SSG1; and if, in fact, 
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